var title_f11_12_11456="Fibroid embolization 4c";
var content_f11_12_11456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left uterine angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left uterine angiogram after uterine artery embolization demonstrates successful occlusions of the left uterine artery and its branches (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11456=[""].join("\n");
var outline_f11_12_11456=null;
var title_f11_12_11457="Patient information: Deviated septum (The Basics)";
var content_f11_12_11457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/58/42915\">",
"         Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Deviated septum (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/deviated-septum-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23424459\">",
"      <span class=\"h1\">",
"       What is deviated septum?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The nose is divided into 2 nostrils by a wall called the &ldquo;septum.&rdquo; The septum is made up of bone and a rubbery material called &ldquo;cartilage.&rdquo; When the septum is crooked, it is called a &ldquo;deviated septum.&rdquo;",
"     </p>",
"     <p>",
"      The septum is fragile. Even a slight bump or injury to the nose can make the septum crooked. In babies, the septum can get damaged during birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424474\">",
"      <span class=\"h1\">",
"       What are the symptoms of a deviated septum?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a deviated septum include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stuffy nose, especially on one side",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Trouble breathing through the nose",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Many people have a slightly crooked septum that causes no problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424489\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your nose always feels stuffy and you have trouble breathing, you should see your doctor or nurse. There are many things that can cause these symptoms and it is important to find out what the cause is.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424504\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will talk to you about your symptoms and do an exam. He or she will look into your nose using a tool with a light on it.",
"     </p>",
"     <p>",
"      Your doctor or nurse might also suggest that you have tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Nasal endoscopy &ndash; During a nasal endoscopy, the doctor uses a flexible tube called an &ldquo;endoscope&rdquo; to look deep into your nose to see if there are any problems.",
"       </li>",
"       <li>",
"        CT scan &ndash; A CT scan is an imaging test that takes a picture of the inside of your nose and sinuses. The sinuses are hollow areas in the bones of the face, near the nose.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424519\">",
"      <span class=\"h1\">",
"       How is a deviated septum treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with a deviated septum do not need treatment. But if you have a badly deviated septum, your doctor or nurse might suggest surgery. The surgery, called a &ldquo;septoplasty,&rdquo; straightens the crooked septum.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23424534\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"       Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/12/11457?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83312 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11457=[""].join("\n");
var outline_f11_12_11457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424459\">",
"      What is deviated septum?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424474\">",
"      What are the symptoms of a deviated septum?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424489\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424504\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424519\">",
"      How is a deviated septum treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23424534\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11458="Acral erythema on the hands";
var content_f11_12_11458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Acral erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 308px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE0AdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDidJg2qvArWAHIqvaR7IhU/es0d6FwMU1kB+tOoI9RxQFiIpg8GlUuOKfigk46Zpp2DlTFWVhjNTLcnrkVBkEZIxSFQW7Yq1NoydMluLklMZ/KuN8Q3aeW6ux/OujuwVU89RXEeJBhWLcim53M+SzOSuFBmO05ya2rBIBABMPmrJtSDcDP4VqBW3DHelewJFuytg12CgJXNem+GrELGpYY4ya5Lw9ahtnALd69I0+3H2dYhwZCF/DvWkGopyZKi5yUEaEN8kSEQW80wH8QwB+tPTV4dyrcRyQA9Gblc/WtyCwQRqoCgDjmszWdOQRsMA59uDXNLF1E79D2VldKUbXdycAH5hjB7iggetYehTtb3LWEjEx7S0WTyPUVuHGOK76VRVY8yPEr0nRm4SGEUh4pxpDg1oZCZz1pDjPIOKdSdTx1pAJ6dDQQOw5pcGk9aAAmkH3RS9umKSgAIH40np6Gg9aTj8qEIO9JS45pG60xEF02I6y2OWq/etgYrO6n3zT6DL9gvJNXT71XslwgqxjFIY1zgetQPk1NIKipACLlh7VNgeuKZEMU5zhGPTANAFCBft945YbkThF/rW5Fp6qmdox71h6GfKYN1rtYsSwjCcEZ+leNdzk29z7KhSVKlGMVoc1qtmYwJY12uhypHaoonEsauvRhXQX8O63bPUcYrmLYmG5mtm6D94o9j1/WurCz5ZcrPKzSjeCqrdFg9OhpDTu/tTfavSPCGOQFJ449axbuOW+LLAuV/vGtW5UyMkQP3jz9K2NLs1xjGGx0rhxVeUXyQPXy/AxrRdSpsedXGh3UJ8wgMvfArX0iPCg+1dnc2q7CAvFc9PbraXSbcCOU49gazw9d81pGmNwEYQc6X3D5PuHGBgVyHiNyqNg84rq7p9qnmuE8UXGI3wegruqOyPFS1PLNcZnvXLNnnijQiVvo8dc1BfOZZ3PvVnQo99/GR2NcvU2PX/D33VNb97JthyDWBoa7YlNXdWmxAa6ou0THqcb4uugIJTkBue9ebgNLNnkkmuk8V3W+Up6GszRoPOulwMjNc8ndmiVjuvCdmFgQhee9egWI2qOMVzXhy12xpxxXXQoFXNdFJWRnIfmikyOh6iitSbmEvAAxmlpM89KP8ivLPUHZpDSUUgD1xRSikNAw/CmuwX6ntTzXS6Po6tCsrDLdT/8AWqJS5djahR9rKz2OH1G2vJYS0MMmK8516S5ErRTh1I6hhivpG605I48qufqK8/8AH2gQ3+kSzIqi5hy6n+YrKNRp6m9fApQ5oM8WRGyCufwrR0/zDICckCrFlbjy8basiMJjAA962cjzY07bnX+GQMKxPNegaTKPtluGIwMk4ryvRrsRHG7Ar0bwc7XU4k687QaU6jULHRhaSdZPselWYEjKGU4PSo/EaiK3XC9cjp1q/pEBIlkdD8qgrmsrxDcF48ZwVbkVDVoHsU/eqWXQ4UNs161I4+cjH4GulLD171yV05i1eBjx8/H5GtaK945aunBStB+p4ua0/wB/dGsaSqcd2OOalWcMM13JpnluLJj60U0SA04c8jpTEIaD7UuOMmkoAQmloPsaSgA96Ttn1ozRQIQ8npSUpOAajkbZGTQBQvnyxqpGCXFLcPukp9mpaUHrTbA1YABGKkpOw4oFIYyU84qIZzT3PJpo60ASLwuaXqMGgDgUHNAGbYhl3KB9xiM12eiO0tuIh1HIJ9K5AZS+kQDhsMPeup0RvLbBJAxnP9K8aS5KjR9jh6nPh4s0tStygG5eCK4fXI2tryK4XJ2HB91PUV6m8cVxakBg2F9K4XxHChglTGCPzqpe6+ZHO5KpFwZnEZ5yKaxAGenvUNnJvtIy3VflP4VDeXQjQ4IxXrxldXPl5RcXYY8w+1xYPeuk0ucxupYA/WvM7rWFiv4dzADeBXoWnOrxq3XI9a8vFfxLn0eUyUqTi+hv3iEk7ACrDdxXJ63F5tq6rnzFOVA9e1dSjFlA6Ac4rI1CMSI2BhsVi31PR5fdszjr27D2qyAjJHI9+9eZ+LtQIBAOS1dpr8j2Tyowwjjevse9eT65ctcXTeg6V3e154pnylSl7KpKPYynyTmuo8I2BeUSEVz1vCZZlQDrXpnhWw8uFeO1KCuRLQ6axjEUAzjOPSsXxBqHkowyMD3rdlYQxckCvPfF90ADtbknpXRN2VjJLmZyGpzm5u2fA610Pg+1xISwB9M1zVshmuVX1Nel+GtN8tEI5rGKuzSWiOt0yEJGorYB+UetVbGILGMjmrZGK7Y6IwYh69M0UlFMDBpaTtSCvLPUFPWjNHH40d6AClHSm96d+NJjHRAeam7pkV6FpygRKf4V9O1eexruliUHqwr0bSESSARn5QACeaylrKx6ODVotmhOiyWE7tjIxgCuB1xM2lxyMFSPrXpl/EsNvHENo3ZbeORg9BXA+IYCqSA8DaT9azqxs7nZFqUGjxq1tVEZ4qhqIMYIXjFdNFaFVYjuSaxdZgXOCa0R4LMS0kkLdSK93+HUBj0y2LDLFd5z714nYwjzAoxzxXvvhtRbw26joihTU1HsdeCi+Zs9Q0qJV0lpJWCM5x+Fcl4gQGViuCoJ7+9dMlwo0/CkjH8LVz2rIpTJC+lFWWiSOzDycZt9zzbxEdt9BtPO7P6VXW5YYFTeIv8AkKqBztBOKo/y9KdFtI48baVUvx3mOpxVqO9J6fhk1jdOlOTcWG3qeB9a3VVo4vZKTsjoIXnu32QOVA4ZsZ/KrM+n3ITet3MG7HdWx4d01IFQyDJ25OPU1o6pa+Qq/KAecgc1hKUpPmuezSw1KEVBrU5bT7+VzJBdKFnj5JHRl9RV4TA1i6xiCeOZeCDtPuDTY7seortoV+aNmeJjMKqVS0djeVl9qX8vpWSl5wOaspdDArpUkcLg0XCM9aKhWdT1p/mL61SsTaw4jNVL6XapA+lWmYKhJrFvJdzn0qkgK7nJrS06LjJrOhXfIABW5bxhUAqQJvakyPYn61QuJJbqdoYGZIxwzKeSagGjBUZ1eQEdGVjmuSeLjGVkrnq4fKqtaHO3bsaDfe6ikXORxVa1lkDeRcHMqjhj/GP8atx8810Qmpx5kefWoyozcJ7j+/SkzjtS45oIz1qzMpX5MTRTgdDhvoa6CxPmIshIKkdM1kTRrNFJE3RxjNR+HJ55EMLceWxU7j3FebjIcslLue9lVa8XTfQ9AtrpVi2yEjHQDpWBryGZSYoywPBIq3ChZQJSWbqo7CrRiaeIIcDHHSsL8ysehKKi+Y83ug2muVckpKM5PZq5TXdXEQb58AV6T4l03zrZoiozgkMOxrwDxW88V/JBNkMhwfcetdFKs1HkPFxlD3/aLZlTUdVe4myrdDkGvcvBN+t7pFtKMElASfQ96+dxkNXqHwl1YKJbKU/dIZOex61lXV1c3y2qoVOV9T2RHZiW7Gi9iUpxn60+ylQop3cg8VYuEkmhYxxuyngsB0rJanszmeWfEOxf+zXnU5aM7vwrw25+aVia+ldbsZZ4pI5VYR9Oe9fPOuWTWOpz27DBRiB9O1aUpW0PGzCHvcyJPD1qZblTjpXqmlRCKFSRiuH8JW/RiOten6DbrLOu4DCjOPeupS5IuRwUqXtqipkTafNckb7bMR4wWINcD8QvD62kCXdt5wQna8cnO33B9K+hbWCE2hJQE449q5jxDpsVykkU6q0EikEYrldWe7dz2pZfSnG0FZo+eNCtDJcKccA9a9V0KHbEtYGn6Sun6jLbEZVW+U+1dpYRKiDFd9D3tT5+snGTi+hfiXaop2cdaaxxjP04pT3rqMBG5NFJmimMxDzSGlA9aTGTXlnph35oopfekMTtRSjmkbgZpATWXzX8K+rV6T4ftfMlTcMBiDn6V5npLB9YhGc4zXrvhsIoQOAR6Gst5ndh5ctN2NLxBEscSqmME5YY4A7VwGu7/KKMQcL1Nd3rk6PtwcnP6Vw/iF0MMzdMA81NV3Z00W+TU8xdgI2+prldalw59a6e/wDkjPXoDXE6q5kkP1q0ePJl7wpE99rtpAoyC+Wx6Dmvo3RbKNo0Migkeorxj4Qab5+qzXJB2xKFBx3NfQGmRjKYx9TUvWR2Ye8ad+5ZvYongRFj2y9iCea5/VI51jYM3yj2rorrar7v4RnBz1NYutOTCyjGCMk1E1zanXTlZHlVyzPqNy0hzjAFNpZT/pNwx5y5GaTFaw0ijzqz5pthV/RoPP1CMYyF+Y1RrovCkO53kxznFE3ZF4aPNUVzv9FhGzLn5jz1/pSeJpFVYSnJZNxHoav6XbgQK78HaQRjk1z/AIkut90VU/Koxx0oekD06fv1NDi/E7Zt8jruGKxBIVJwa1PEM3yRoerOBisk9amk3qcWYK1RInS4ZehNTx3h7mqNAGTXQps85wTNeO76c1ftpt5z0rnYkZn+XNa0beTF74ropTcjCpFIvXt1iPGcisaScZ6ke1Q3t0ectWZDP5s3B4FazqqJjGF9jq9MAJDGtfcAhIIyBXPWk4RAParsd2CME4B4ojNND9m0ybTDmIFTlm6muosLdXsmUgF/WuP0SQB3jbqjEV2vh4idnjYhfl+UmvJiry1PsYyXsU15GLq+n7k3L8sg5UjsapWUvmo24YmQ4ZfT3rrL60JRlGDnkVyWowvayrcIDxxIo7r/APWrelU9jLXY8/HYZYmnzR+JFnrTT6UoIZQVwVIyDRivTWp8ywPTAqGxIh1Vgfuvh6mzwarXWI5oJv7rbSfY1hiYXgzswNT2dVX66HaQYIXoc8Cr8cZAbBwe9ZmmSDylPLetasjqFGfvHpXmx0PdnJvQxtQgLMS2SK8b+LGgh1GoW6/OnEgHcV7lcJvByc5rlNesUuLWRHj3DnOR1FJuzujKcOePKz5jYYOOK3PBd2LTX7Uv91m2HHvUPiTTH0rVJYCuEzuQ+orLtpDFOjj7ysGFbP3onlxvSqeh9TaUkccUcijcDjOea6aOdkh2qcKf4a4zwjfJdafbyEfK6A/pXUDcGTGWGe1YQ0Pdk1NamfrUJMYUAc814R8U9I8q/ivY1GyT5Gx617/fkPnpkccdq4PxrpS6hpcsRX5sZU+9U3aVzlq0+eDR5r4aVY4AT1rvfC0wa6IBHArz3TZBACknyleCPeuo8J3Y/tXywR868D1xXTUf7pnnYN8uIiz16xkxHsGMkHGRWdqUe6MnAz6ZpkUhUK3OSOgqe6jEsKtkhvrXItj6ZR5Xc4PUbQDUUcjBbgYq/AgVBgUeI4nA3KPnjYMCO9SxkGNWXowBFd+DldOPY+bzWlyVedbMCcmkPtSnikFd55Q08dRRS8HqKKAuYZzRzQaWvKPUEFW7Gye7ZtkbMB6cD8TVUcsAO9eieHLFbaxRSmSRlv61EnY3o0vaO72OPm04JGcwyKwGQVfd+YrHmbCHpkV6jrVtGyKVG0Yxnua8w8UAQzkrwHH61mqjUrM6K+GjGHPAb4SBufEJUc4jJ/WvY9Ht1WPJ3ggdmrx/4X5m167kJ4RAM/jXtNkB5fLf0zQtyKLapiXMEQ52n6k5rjfEsaLC/GQAxP5V2dy23K5wO2a4/wASAfYbknPKkVEjqjKyPKdUbMfHHFcNfk+eR711+tyFUJGR+NcrbwNfahFboMtM4QfjWsTyHqex/CSw+zaFHK42vOxkP07V6la/JGpBGBXMeH7ZbeGGCL7qKFA+grqAVGEAOR6Vmnrc9OMeVKIXEyuNo5z19qwNdkAtXxkYrckhCoxGRnnpXK+JLgx2Ux3AnBqXruaR0RwUZ3KXPViT+tO78UyI4iQHrilJrdLQ8tu7Y8ZzXZeEF8q1G4YLHNcdap59xHEOrMBXp2h6dGfLJXGCBkDtUS1aR1Ya0byZtzzvDpe9GRiR7j2riL+6IPzA5J713utQ+QiQw7ZB1yRiuP1YRpkumGPqKiq3ex6eEqRSvY4XWpDLdw+gJNV6l1KVZdQOzG1Fxx6moc1dJWieXjanPWbQozSqCSAKaOcCr1pDzuNbwV3Y427IntYhGoY9aiu5sZx09qkuZgoxnHasLULrGVB5Ndl1CJySbk7EF7OXl2qcmpbOLauSear2sRY72rRAArilJydzphHlJA5Hc1JHOwqCihSaKaTLtjPtv8htvmD9RXb6ZdCMKxP1rzph8uVzkHIrodNvw1um7JrmqPllc97LZqpT9m+h6bbTpcQY4yOnvWDrdsEYhwcEEn2rPt9TliMbqNqr3xkf/XropLddTsvNZ2TcOA33m9/atOZVEa1aPsnfozhLSf7PK9q5+UfMjeo9KvLMGqfWNKBiURjDp0Nc8tyyOyPkOpwwrrw9f3eWW6PncbhVGfNDZm6rAjrTZUE0Lpn7w4rLjuxxnvVhLn1NdfMpaHn8rTudB4dvGngVX4dTtI+ldJnze33a4DSrkW+rkbjtmG7Hv3rs7aQAg7uD3ryZLlk0fQUpc8VI0PJMuBu46dKztQtvLQgkHAOM+laSwTP+8QkK3Ze9F7aF4dxxu7jvQldbFt2e54T8TtKW4sGnjX99BlhgdV7ivJ4VzKAO9fS/iTTkezlB+YkEHI5NfP8AJp7WurS27ZyrYHHaik9eVnFi6aupo9c+GF2G0lLaQ5aM7eTgY7V6PHc7UA6kcV5F4PkNndR8gLIMfiK9RhcSkSAfLjtUT92TR24eXtKaZcmIZd3TPWsTUYgyY5OK1pHVUwSASPWsy7YeUxBJB7U73RpbU8R8bWbabrDsnEc3zD696zPD+qNaa7aSsx2B9p+h4ruPijZb9FW5C/PC4/I15KrHzQR1B4rSL5o2PLqx9lVuj6asJllCbj9K0Jkdl2hQo67jzXE+DdV+2aRbySKd2wKfqK77Tw00IIDHPfArGOuh7qq6KaOd1e03WzZyGxgVkacxNminqmUP4Guo1m1naRlHH1rlrNfJnuoCTkNu5966sI+WpY8nNFz01IskZNJS85PNNr1DwhcUUce340UwKUln/s1Wa2I6V1b2oI6VVezGeAK5ZUex0xrHP20bfbYAQDlq9E0071GSfbnGBXHJAP7VVB1RQfzrq7SQqhA6mvOqO02j6HAwvR5u5e1GRRH8w4xgV5R8QX8nySBgNur0K6mZjgNkA5rzT4ozbFtV7ndWW8kaYqPJSaNL4Nx+Yb+4Izlwo969hjYiIc8jFeZfB22aLQRJgAysX57816hbpuxuPUdAKuO5xQVoIr3MoJKue+Qa5fxTuaxuST8uwkfWujuBum8sN83bisHxTETpdxj+4cmpaNeh4Zrdx8pXFHw7t1uPFETsMrEC/ToelVdaIJyDW98JYt+qXkg6qigfia0fwnn043qJHteiw7nLZB4AGDW5KqIp4Jc9TmqGkwgBV3Db3z2reSxRnDF+nX1pJPlO9ySepnqwaDJJAAx1/nXn/jefFrIqk5J29PWvQtWtDao4iIA68Hrn1ry3xhK8k0SP90uD+XNRK60C65XJGGw28dxxULuRmpJGxmqc7ZBA61tc846LwdbG71FpG5WMYH1r1jSIysf3eR0FcV4J082lqm5csRlvqa760Cxx7lxkDDZNZxd3c7VHlgkPuMtKpOfWud8R7GjYMB93vW7PLk9O1cn4onKwSuDgEE0pGsNNTzGV1W7mC9N5qRWBFZSSFnY5yCc1o2+XIAGa0jsedN3bZeto97DjitBmWNMDimQKIogapXtxjPNd1OHKrnJUldkF9c7QTmsiJTPLk8jNE7tcS7RnAq/bQhFBx2rnqT53YunC2pLEgQcU6jocUevpWZsLnikzQaUdaaAAeRU2myGK7CEFlY5GOxqCnRuY5FcDJU5qZxTRth6rpVFJHoulQCVE3KCCM49K6KJBtC9AOhrmtDuA8SbCDkZFdNGx27umeuazjoexUqcyK2pxBgFQcY+auI8TaU4DXEC4dfvAdxXo7KrKSRhj0OKxL+yGG64PGD3pvujmklOPKzyxbg4zmp1uz3qbxBp/2K6ZowRGxyR6VmjrmtYVGzzKlHldmaP2r5433YKsDkeneu/0KRJI0Z3LggHk15a5xxXVeELmaQKgIO35etRUd3zHThH9g9ZE5S1AtwDjmoSwKESOCxGQfSqNq26Hy2fk9cVbGxW3ctjgbqSfU6eTSxz+s2hlycEDk49q8l8ZaUseopdKgXna3Fe46l86l1rgfFFot3bybQMn+dRfllcU6ftKbiziLRvLSIggFSCPavRdCuvMCoS53dMHpXkc94YG2scFGwfwr0bwvKJrVGQkOQDnNXXaclI58uvaVNnax2yM5EmAQcjNVdRCxSMqKuGGc461aSM3MMR3Dcncd6mu4oxa7WwWHQ5zzSSujsldPU858UWzXejX0DLyyEgn2rwqBP3+G7HFfR2trhGyDhhyPWvA9QtDb6zcxAY2yHH060U92jixsXpI9T+F+BYvC2PkfcOPWvT4QUiAj4wcnFeS/DiUxzyLnGQK9cglwgYKcHvQ1aRvh5t0kQX7AgsWzkciuHuiI9ZViMeYpTH8q7e9IZMdCfwrhvESmJ/MBwyOG/AGqhPlkpCxEOam0W40eV9saM7cnCjPA6mnrCos3mlWYBjthZVyjnuCe3FW9HniWO8he4Fq1zEFSY5wOc7SR0BFSv5VjpV3bNew3Lz7fLhhfcEIOS+egOOK9e/Q+cMY47sB9aKXNFWI6JjxgUijgdKhWYEVIsg/GkBnxxZ1a4I+9kKPwFdALbZaBlbJ9Md6ydKG67uHKFgZTgjmuilSeODKoAp5weT+VeLNXnJn1WFqONKMUYM+Qrk8YNeTfEu68y9ijPVUJ/WvX9VDxWuTGd714R46laTX5lY5KgCsoL3gx1Xmpntvw/hWHw5YhccRL+tdzZ7gm/04rz/wPuufCtkyyMqmED5ep+h7V3emMkdoFeJ2YqRy2cehPrWlPVmP2UQxTLJPKSg+U4Fc74unU2k6A4BU/wAq6q3hAZmwNntjFcl4xj32twYAQ4B54xipkaRSbPn7W0dH56Yrtfg1ES17IRkF1GPwrkvEB+6D1Ir0D4QW+3TGkHLSSn9KuorRODD+9UPXtPgbjyuOnWtH7SVd1cNuHTnGag0kEbh2C9fSnXcbBgyZznNLVRVjrVnKzKWuyuYWKMSrDuK8f8RXLtqmx+iA/jXreqTfuD5nJxnpXjHieT/icyfSo+0hVXam0RM+fYVLpcP2nUYEIyoO48Z6VnLJkda6XwbCXnklI4yFB9PWrk9DlpR5ppHpWiW+2OPIOTz9K6CeJVkAzyQD1xVDQ43lXeiqV7jOK0XSUuWniGDyMcYFNaROyT94o3hCR5wQSMV5742uzHZSkE9CK7+/ljRPrx9K8o+It5hPKjb7zYrORT0g2cZa5wBmui0yLauW61h6bHvIOOK3zIIo8DjiuujDqzxqkyxczhQRWBf3G5toNGo3wQHms2zbzpN7etaVallZGdOLbuzUsocDce/WtAcVTSVVTA7807zxXOdKLXGc0o9qrrID3qZWBoGB60poGCeuaD0ppAxO1IvJpT0oHTimJHQeF77y5BAx75Un+Vd9DcFVHoexryRJGikWRPvKciu98OakLmFSW4bj1NZSVmelh6nNGz6HUJcblxzjOAKtSQeZbnI+Ur1qlbSRvGVbrnArQslA+aRsgHjPQ+woj2NqlrHHa/pyzwOpHIFedSxmKVoz1B44r2rX7ZNzeUow45A7GvPvEOj/ALovD98HP1pP3WYzh7WF+pyTD1rQ8N3v2PUlBOFes8k8gggjqKgclGyvUciqeqOKEuSVz2TT7gPhieTWtDIp3bj06VwXhrUftFsoyd2cV2dqQUAZhuI61lF3PalHRNdSa9xnAOARXKaupKsAMiukuZAB8vLdhWNeIX3fLhRRIdOJ4b4zhe21Fm/hl/Q12Xw7vPN0pQT8y8Gqfj7TfOtJHQHeh3Dj8xWR8MbwLey2znAbDDmpveGvQ5qcFRxVujPbtIZpbd1wxIGeKvG3eSPqCB0/xqn4VJW5Me4iPJzkdjWnLCYsoG6HA9hmtkvdudGIsptHLa0hwcngDHTpXjHjK38nXhL/AM9Rk/UV7jq9uWjII4ySMmvJfiHblY4piPmR8ZrOLtM5cVBTpaEvgmYLfDjqtew6fMXtgAueBmvCPBd1s1eAHvkV7hpBJiCqx59O1XN+9Yxwi/dalq4kypDxYG3JY1xHiEGTzOmSDj6V3VzDvhZZGJ7Ak1yGt2ZRDg5AFD2NpJWZZ8Jo8tnPJbWy3F2kCmIOu4DkZ4PGcdM1NqLasbKT7XYpDb8bnFsqY545FZ+kSaOLCLN3qKSgYcIgwD378ipryXTjbOLe81CSXjasqgKee/NetB3SZ83NWbRncUUzzQOKK2My4JuPepUn561UAwKXO3J9s1LKtc1/DCZWSXJ+aQtjPvXTyuXi75wMZrnPDyeXbRbTywzXRyFliXB6+vavFe7Po6ekUZ+o7ntsSgfKMAV85+Kt0nii8B5/eYr6L1OYESJtyQnJ9K+ftZtt/im6B/v5pU/jMsX/AAz1v4cPs8O2sK9Vyv616Ppcn7pwyAjAAHpXmPgP91Yc9VcgV6bo2GTL4xjOc8inDSTRS1ppjpEijl4TO7HHpXOeJ/8Ajzk2qAMEYrpbnHnDjO3rk9a5fxC6/Y3Gc5xis5dTWmm2j548SSKZwo6rwa9X+F0QtvDtrI/XBbGPU9a8g14Y1GZfRj/OvaPDMRttG0+HphFzx7Vc5aJnPg6d6rR6V4eDTpKflDBd34VNcOM4dj1wMetV/DUT/YLidhhdpUD15onQsTlcEHg5o1UUdM4pVGjL1iQCCTkY6fhXjusoZtUnYnpwK9a10bYMHsvWvLlQSvI/XLk0UY807HPjGoUl6mX5BFd34NtDFZRt3OWI9a5zyNxVcdTXovh218uOPd2AxV1o8rSM8F715M6nRINiGTBwoyRjtirQu1dCGYc8VNajy7ZlBwccgd6pyjcoyACCelN6I1vzN3MTxCwGSHx8u3IrxPxi7SaqsO8vgZr1rxHjyJDkhhz1rxySMz6tNKSW+brWUVzTHiZ8lK3cu2EYjiB70y9uNqnnFSSPsTHbFc/q9ycFVPNehdRieN8bsUby5aebaDxV21kES1nQRkfMcU6aXHANcjd2dSjZWNX7ZnvT0uc45rA87nrVq2kyRmkFjoYZc96vQtWNat0rUgOaaBF1O9BH4+9Cfdpx61aEyPHIpxpepxSUFLYQcVoaHfiyugGYiNj+RrOJ61XkcrypweuaiSujSnNwkmj1TTLtblwyEqB/ETXTxSGaAJEMqOprzLwpc/alVpZC23qvpXo1nPtQCMfLisoPuerJqSTRfMWYJAQrM3A+lcvqkKqHQjn2FdE8+3Dqc7hWZqKB0Z2A3HpirnsKmtdep5b4gshBMZ4x8jferEfnNd7q9nvib5eDng1w97AbWcr/AAnp/hWcJ9GY4zDcn7yJe8MXn2e88pz8jnI5716NY3GY/mPQcc15CrmOZHBwQ2a9F0a58xE3YbIqZe6zfB1OeHK90dXFH5gyxBPUCoL2C4VSqxscjIJ9KuafcBbdyDs28kYqSG9E8hKMMnsec1dvM0bldtI4fWLFmgkWVScDIyMCvKtEs5bDxpFFGGCMxI47YzX0FfWKysxdgx9uhrDm0a2EgkMaq6nggcis2nG9iZJVHGXVMv6E0iMrOdq452jmt9cYZzuJbu2K563Ei4jjfC98itBHlhQlpF/Kri7KxVWLm7lbU1mCkvHyD0PTFee+OLQXWjzhF3OBuGPUV6LesZowruXB7CuY1Kx85JUTJGMUPXYycHZpnjHhiYxa3aE9C+DmvofR1BiQg8Y5rwe60O+0/XUKW7mPzAysBwBmvbtCuV+xxq2A/vSk7tMyw8WotG8+3PJAJHGe9YGtW37ptwz6e1bsC70IJye1UtTiJix1HvWttAl7rPLBcG1nmiY4G7cPpVyyd7tZTHLboIwCxllCZycDGetSatpm8alPFaSXl1FCFggQkfMzbd/HJ25ziqWuLZ2+m6rBHZxxx6UsMS3/ADumuCQJEJ6HqeO2K6aVZxikeLXpe+7D/tiqSG6g4PNFcYupccNRW3tjH2R6f7UNyjD1BpfrSdM5HFdTM0dLoKqbKA98CtqZQVBcjr0Fctodwy2Uag4IbGcZwM11hO9AXaN9w5JBWvHa3R79N6JmTejNnNIEI9Se49xXjWp2Z/4SBnbjcAcV7rcR5sWjYjBOcAdK8v1uz2632+73+tKl/ESJxWtFmz4QjZYZVxyCCPyr0HSZB8inJOOD6e1cFoRWIujfxAd67vTkUeUwP3fl6UTVqrRVH+BG5enXMbEHkjqawdXtA1lISRjIPTmtjU2EcTCORQw44bpWXLG8kbOzMQR8ozUTVtDWle3MfNOsxeb4nuIl/iuNv617jpcTlYkUAomADXC674TuYvF0V5bRBrcyb3GfukV6HoEMsYUyj5vQVLldJCoxdOcpHdabIieH9hZQ7yfMAckr9PrSPAAoRCxOBkketZqXCQ4JiII7qOv1qaTVGCBgSdoypY4rTnTVmJwk3zLqc34xl+z21x/cC8YrziyO2FPpXe+MN9zps0nUlScCvN7eYBF7YFaYb42zmzDWEUb+mRPdXqKvReSa9L0qMBkQdB1x2rh/C8bLErquWc967zTysaqOmCM+9Y1KnPNs6aFL2dFI3IztjPfbwM9D9azLi5MfOcHPA61blO6PKnjt9awNQYqRg4B/nVSloOnBN6nM+LL8eVL2PrXBW0WxCxwSea6LxZMDIsQxnd2rDlYKuBW2EjduTOLMppOMEUbts5rFa1M82TzitiYbyBVy2tBtyRziuiUOY82MrHOzWvlpxWLcKysc+tdjqMIwcDiucvocnpWMqdjaFQyQ3NXrQnI96jS23HkcVo2tp0wKz5TXnRetelatvz1qnb2xGOK0YYWXnrQkwUkyyh4FKTxmm4KjJpDmrDcXrR25oFApFDHHBqpNnkVcbv61UmGcVIC6JqJ0/UEJb923DV67ot/uVQCCpFeHXK4z2rsfA+uNg20jjzF+7nuKxl3O3C1fsM9YRzIDz05FJOqODuwvt6VQsrgyJuBwc9KuqqkfMTu9Kpands9TJ1KHdGwI+YdDXK6vozXFtvCgMec16M1l542jjAyzHoBVN7IM20LhF4Hv71nKDvcp1VKPKzw24ieF2jlXDD1Fdx4JaSa3XcvyqMZNdBceH7a5mzPGpCn86v2ttDb4jjjUgDoB0obcjClRVKTaYx2coV/hPXFSWMDQyhtznPY9Kti1LP8AN1PIHpSiKZWCnCgjg1SXU7o1Fy2LF0xTaRH8vc45NUrlXkB4AQ+1aixu0K7imdpJ56Cnm1MvQ7vcVcoNnNzqLMNIX4wOMdRVhUJj2uuSP1rVSxmQZCjYfQ1KLZTkFdvfmiNIbrI5m5iaPnop/OqAjcyu5BK9Miujv4TIwCH5ckdKrpp0gX50IX2qHDXQ1VSLWpz88KOTlBioktnUDyG24rakthuYYwPSnxWmyMNjcD2JqOW4JxWxmwzSxA+aWP0OKLi53sD5mM9sVeurYBAy9fTNUpUUIwcZyO9UtNDOcVJXRha3Ywz2V7ezm6C2kYcLbyeW8hJwAGHQeprzXXtMtEXxJbWjXUR0qWO4RHmLxmN9qkHP8eTnd3r1/T7O4d7k208EQWMmRbjmNk9CK8/8YabqepLdp/anh23spJ0MvkFozLIeEEjEZ+meK1ieRiFaVzy8SEdCaKL22msbye0u4zFcQOY5EPYiiq1MbHuvqP1qC6kKoe3FT55I9BWTq0wRGwTXrN2R5x0PhOfzIZF3End0rs7ZvM3FiMbema8y8BXRd5EHJ8zH0r1DT41Eb7sEFT1ryJfEz3KDXs1cbO/yOgGeM8Vw3iGEJqMDEcMSuf1rs3AhklDH8K5vxNbvJDG8KbpVfcPpWSlyzTOidPmpuK6mZYOqXq55wK7Ozuj5AJAb2zXEaVBNdaifLUrGAMlu59K7mKPy4VUkDjGPWqqSUqraJoQcaUYy3G3E6uzAxYZhnJNNjaRYdm8BfX2pwgabIBHHAHp71VvxIkYjZhkdSO9ZS7s76dJO0Rx8ncefx9aWORYeUGRVWJ1dBEvPH3qtfZzHbqT26GkrsqVGKdmXo5llUHB4HNUrq88uUKFyp61kC8mhuJIy2FfqKSGaSe4YEnIHSocr6G8cIlq9jXmhinhIZBz6cVx2peFVM/mWjFQTkoea63f5Ue4knHUetSx5mj3YwSelXGTvocNTDKXxK6KWg2ixxKpQgDAIJxXUWkayDy0Pzg+md30rLTK/Mw56cVq6cRKwYZBX0/pVQiTNWWhNch4VKHnHcVzWtzCKJ2I+YD9K6DUJnCMM7mPTjn6VxWuXOTIj574B7U5kU7vVnC390bm83ntnj0qnK+SaLqUG4lZeAW4qjPNgV3YdclNI8PGT9pVky1bKJJfpWxkLGKxdNbGTV6acbeTXRHRHM0Vr9uDWBdYJNaN9cA55rHkkDNx0rKbHFMmt4QzVtWVtkcCs2yG4j0ro7BQMUQjcJNont7PgcVfSzAGcVNaoMDgVpIg2+9bKmhc7Md7T2qB7X0FdA0QOKZ9myamVJMuNQ5x7dhULRsvUGulktfTmq0lpweKzdE1Vbuc+wOTUEwyK3ZbT2/SqU9nwTWUqTRoqiZz1yvBqhFPJZ3aTREhlP5it26tCAcA1jXcDAEkVhKD2ZUZ2d0eq+FdaW6tI3DjBHOexrq7e5BdcMPWvC/Cmptp2oCGTPlSH9a9ZsJxK8TDIUDisdYux7NGaqxud1ZyEp5YGFYclup+tSTDcWZMbcY96w7W8GTGM5PGa1LSePOGOcdiK2i1sRKDizOudqtjHfrRDHgZIPPoOa0XhSZhtGSeeKniRVXAGM+1NRL57IzY44fk3M6uT3yKszWa7WMbleeCWzU3ALDt/Kqkyhg/lsUI9OP0p7CTuyC5EkIDgbip5OM5rQsbtkUEgAMOazNzlNkoygPDD19KecgAqxX2zmpUuxpKKkrM2/tiE5wF+tUZbgO6gHgnAqkQ+GyQWpkIYvlyNuc1Tm2RGnFGx5cPlIrcuo6LzihYJTuAzszn5u5qFLtoWQRcex9KuR3i+YFJ56n6+1UmnuYS5kUZrHID43k+lFxaE26eWuDj7pq1LdSucKmwA9+tKhWTLNIST2J4oshqUkrs5+7TZGckArz15rn76f58lSD716FPZw+QSoUOBycc1yGoRRmRlj2H14rKpBo6qFWMtLFLRpUuBcW8kEk6ToAyxfeGDkEVw3xG0+DTbaVk0zUzY3LRLf3bqFKQq4IVB03Fscmu+sXEFrfxLKsDPH8j9MkHO3PbNcv8AE8QXnhbVJnvFlSVIXgg3kuk643EjsMZ/OlHQ4MWrybR4l4g1D+1tbvb8xmITybljznauMAE9zgCiqB680Vrc8896mYKpJNcj4gu9qNzXQanMEQ8815z4nviMqD1r0KsrHFFXOt+FN35l/eqT0YMK9mhlOwDPyn3r55+FE5GuzJkjfHn9a9waZjsSDr615ctJNnt4dc0Eac8sRYtvA9eelZcp8w/KTt7tj+VTx2wOTKxZjxSRwjzPm5A6CsZ6np0oKwtmsVupKr+OKuxSJIpZT8w6+1RhQVCr0PHSgQtCDjr3x3ppD5I/MfKxQsqH7w4qm0TyPtdSRnGf71WVxcdeHXseKs28KbATuCHjOePr+dO3NoWp+zKtlp6quQnDEgbh0xVq8jwhw2ABWq6+XbLHHzzyM/54rF1KUIrA8EcAZrRxUUZxm6kjCu4d1zJ820ADp/jUlrFGnEQMjkYLA8fnToEWWQ+c2985AIwPxAq4YHktmSL5B0Y4xt9cetYKN3c9KU0kkxlpZSvkvhmJwMdAKtC2lQbMHn0rU0tY47OOIfNt4znqavbo3XAGCOvfmtlSSR51Wu1J6GDHHsjCOSTn73c1difyYRkDeD1FRXzL5jFflboayrm4McZLnC/rUN8pKi6henvMk5x6Vx3ii6Xy2JA6Grj3byNhgdmODXKeK7srE6sefuio5uYVaCoq5zEj8ZJqhPJumCg5FSyy4U1UtyXk3V6fRI+YerbNa1fZGKbcXGByaYX2riqF3LhTzTuJK7Kt7dcnmqUc+XHNV7ubLNUducvxWTeppY6jTnyVrpbB8Yrk9OJABxXR2LEbc1tBmUlqdRZuOK01cYArBtHNaKTc/wCNdCaM7MvqQT9Kf5scYy8ir9TWbvkuHMcTbVHDEdfpVqDT4VXJGWz1PNctTFqL5Yq56eHyudWPNN2JvtNuxwJo/wA6eY1YZwCD3qq1nGXzsU00220lrdnQ+xqI42796JrPJ3Fe5IlkgB6c1Xkts077RcQnE6CRf7yDBH4VYgminUtG4b1HcfUV0wq06mzPPq4erQfvoxriyGMAcVi3tj14rsJUByCM1nXcAwacqaZkqjOCvbMq2QMEcgiuy8K6w0sSI/MicEetZ17bA5OOKy4GazulkQnHQiuOtRsro7cJiOSeux65ZSOTu4CN781r20qlwoy/rzXF6Tfl4EZWwCOhrp9NKqoZW4J5FcSep9HK1rnQmTyiNgzIRwP600NI6DCgDOc561Vt7kqHYcseM98elSeb8mdxQ54A/lWykczVhxlcM67m3tzULzYxyff3pjOQSSSx7gcVGwyQdvGPrSbKVkPkKuMBWI9PWqpLxAgBmQ/TimzSSswCAFe/sPao7qUTRKsZYHOM5qHrqWo3ZImoJuCZwRxyOlOkvSSxVsDGAKzTM6zqsi8Zyff3qd5gmMKm3/dov5jcLPQsfaAWLO4YnoM1YS+QY8tij9+eazS+84XZgdPlxmmGAGQB02tnPWjXoVOmpG8t7GSfnJ7GpftS7cevGPSsOe0V3Z1yB0GDjH4UQ2LsQGmdR2XdVKUiPZQte50drI0oKIC5YYznGPxrC1K12zbix3Dg1r2FsI48NPKOwy3T0+tYviK0uopldZ2cdGVhyfxrWV+S7RlSa53FMbYw+Ybry7VbmcJmKNuVPPzceuK5nxlDfN4fulm0eG3iIw03kbSvPrnvXQWMyxQ3UN3M1tFLGAGUFmJBz2rm/E8VmNOnMeqPLJgBYjG438+p496yb0uYV4u7X+Z4AwAYjjgkc0Ul2NtzKM9GP86K2T0PLuj1PXrgKhwa8v1m6M10wPQV2nii6Ko+DXnTuZJST3NdVV3ZywWh2fw0cxa/CwzhlKmvoK2SOC2TBy7DJxXgngaIxXltJz98V7HJcTSgCLEWOMsM5rhre7qezl8edWNhJ0aQlj8o/SrtuFmTzFYE52gAVhWNs6uZBKDIT3APH9K7Hw/okzIrvOGZjuIYD+dZ005dD2KrhSjuPtbQRRhzjOcnvVHVGMYLpyDzjGK3r+KNF2bug5PTmsW4lURnB3AcDI7VrPRWOOE3J8xzKTzRy7yu0d8n+lalneMTjjAA7989agn8k7lxgk5qrbIscp+cHJ49vauZNxZ2ScaivY3DcMT+9f8Ad7iAw/rVS6ZdxKkEDvUEmoBYyS2BnBFZ07+eT5Sd8jnFW5oyhG0jQgKouRhpTwoHTNXr5s28cMP7tRgYHOfqaxbDjbGqlpAPmZuRn2rSMxEWAEGBzlacHoaz+JMnhk6oWCqoxgt1q0t8fNCqhYsMDaOc1mWqMW8wgD2Axmre5QflBJ6D2puTMp8smWJ42ZGOAHPbOTWPNblmOQdvc1rJ+6j/AHjgnHOehrOu2GMJ8wBycdqmViKc7aGVfQGNGUEDPXnpXm/it8XKLkk5OSe+K73WZjHGSWGOvFeYa9MXvcscnHOaVJJzSMMdN+yZlXcmFx6mn2QwmapSvvmx2FX4jtX8K9BM+fasTu9Zd/J8p4q5I3y5rHv5MgiiTBGbO+XNWLJSSKpnlhWxo1pLc3KRQrudjwOwqL23NEm3ZG1p6HCgDrXT2VjcugKxEE9M1o6FoSWqglQ8mPmY+vtXTRWgOGb5R7VhLEPaJ6uHy1Nc1X7jBtdNkABmYk+g6VbFimz5VyTwM9a2ljVsc8VDOFDccYNYucnuz0IYWC0UTO0JAgKSfLKhIINdBEkQXPDMT0rL1AKwW4h2rP0P+17Gl0fUUuAWUgspIKn1qY6Ox07qzLMy/PypXvUSq/mIqgFTnOa2BEk6KVKq7cEVK+lyKyjABbJ+lX7NvUPaRSsY00BCEjk1lXVuRKJoT5cvqK3723kTg5+Xjise7V3GE60pNxeg40o1laWqI7a6MmUkXbKOo9fcU2bBzUE1tMwjdPvjow7UM7gbZVKv+n4V6WGxPtFyy3Pmcwy94eXNHWJTukB6d6xLyLk1uTkYrLugCTW8jzFoSaBcSNmHIBByCfSu/wBJSVgo6AjjmvM9Pl8m8B7V6Lo1yzxrtzj+dePUjyTaPpsJVdSin2N1Y5oh84PTjv8AnViNCASxOcZx2/Clt5d20csw7ev1q25UqWBAJ7etUkrFymyrKm6PKsgfP3SeT71TeSaFiANx6ZUcGpJWidpQVZen4fSo7TiRt43Z6GjyGtCF7kKxOPmxg8dKit5GPLfdJ4ArT8hWiwI8ZyBnue9I1pG0SnZh/Reop8j6DjVV7WKVzBuIwV3dvaonhmbJQBsDlavx2jtMoU5jPH4+lSFZ4HYOgxj5sDoB7UuVtalSnbZmdAu3GQMn1qQ48wNyBVuVQUUuFKjuP5VQYrvY5JA6cdqm3KaRfMToR5uAc9yfSpGkz1PXiseW5ZbgFQRu7YqxbPJI3zfLg0J66F+z0uzp9PmcLsOOR3qtrVyjPhVZsDG49zUFpPIj7E2FWGct1qPWA3kMQWfaerdzXV9k5ORe01M681nUIYVWKZNqjA/drkfpXL+Jtbvryxltp5FMTjJxGoPHPUCuktfIuXWOLSJJ5VXLFZz+J9qx/FunrDpU9ydGe124Ama53BcnoF71zu9iaygtLa/I+eb4EXs/++aKfrSlNTnH+1RWy2PFcdTV8V3TcrnrXNWke+dQOea6nxBol3LLuX5vw6VS0zRbhJwzrjFdUou5zxaOy8Kw+W0DAYbcMV6HG7M6owIHcDua4vSozBFE2PmV1/nXYwJI00bgnA61x4lWaPYymW50mgqgdS8ZOTnc1d4jmyhWckSEDA+lcNp7rDOskshVV5HtXQ6pqNxcwlraMLGADmUYBPpx1opySTO/ExlUkuxU1HUvNlbYoOec1iXFwcNhiCf0pLq2uZpt4lVT1YqMZ/Os6/t7hlIZjsHJx1Nc85Ns66dOCSSJpboMvlnG7HQdaoJHK15hTtQck5ptuoDNvIyemKuqPLGduM9/Ws7c25TXI7IGiVZSyqGB6AnOT60/LblXBPPAFCZLAL1HXFX7eMABhwF+8fWrsZN2IbdZWlwFCqvTH61O/wDrCCcOTTmn8z5YI8L03N/T1qf+y2CZuvv5yV3DIHqQKuMW9jKpU1u9Co1yyllTLEcYWmxfaXuFAQAHpk8itkxrbkoF+bbgFRxj6UqEMAmMJj7xp8r6mPtbbIBZI6Lucsq9SehP+FQXtqqLsifjrx6VoMQ0KgEAD5RjvWXqSOFJTkr2HHNVKyRhH3nuc1rkMaxMc5wOleUeJZlOoMygDC4Ir1C+n85HUdVPINeVeM4vJ1IkDhl4qKb99CxkX7KxjwHdLnNXw2BWda8c/jVjeOea7keNJD53wOtY14+c1dnk7ZrNlO5qUmNKyG2sTSzKqIWZjgKO59K9e8HaAljZbpB/pbjLE/wj0rN+HPhVgUvrpP3hH7tCPuj1r1VNMjWDLAZ9a5Ks+bRHrYOgqbU5mVZR+SuPvNV3G9MYOPpSwRMGxzt6DjmtaOzMdsHk4B6GojF2PWnWje5hFGCnHB7VSuGGMk4Jq9qMyqSiZOeetc/q1y7FIYiPOfv/AHR60rXdkOdeNOPNIhmuXmlaKNuB95vQelCJ5QUwfIy9D/jSQxrDEETp3PqfWnnPWvUo4eMIWlq2fL4nGzrVOdPbY2NI1cStslGyVTyK6y2vS6Zc4x0zXmtxEzhZIW2zqPlPr7GtbSdZd4vLkysicMrHpXHVhKi/I9jC4qOKjZ6SPQJLVLyASKecHnsK569thAVUJ8+am07UShynTuDWrbi2usyzOAx+6v8AWpupm3NKk/Ix1sYwgYcA8ke9Z2p6erxsMcjofSukm2IAVkyOmMVFcxRug2gEsORU8vLsHtPaL3tjzi5R4XKSDr0bsazbkEZ4rvbjTomQxyR/KfWuU1LTJYJfLjBkUjI9RXTTxP2ah5OKy9xfNS1RzgG2dcDvXeadd+VBGIhln4U1xNxGUkAKlWz0NdNpE26dDxtjXGPQVjiLc10b5d7t4SOvtZJYFBZiSPvD0qc6ijkAhgfft71ziar5zAqu5fQHrUklxNKpwAMcj2rDm7HtLD31aN2SVcFy25j1pbe4VMMFPXGCelc+XJXczEnPIp63LhirMdp64oUxSw9kdbaS7njhXPzHAI647g10h0uCaxMkhWOVFZQ3fI6H8a4jSpFKAbyoPTH8s11uj3e828HLjdgEAE/Q11Un3PLxMHHVdBlkSPKdEKKqjLnqW9vSpru3Z7OaUuFViMgcswz6VrxQF47hcIuSMEpweO3vUVhJFbyzmSMNGR5bbhnPtW/Loc7q3u0cveadmNRabgjNkB/T1rmbkyQztCxx83BPeu01N9l4HaULHu2snQqwHTHfI71z2twbJ3EqYZm+XPGB1xXNUgejhar2fUyGcNcL6fyq8XRIycjHb3NZgbypRvAZs9fXNW43ZWww3ADt2rGOh3SjfY2dNljRd3mKrEfxVHqMqurfvlPuD/Ko7eY7BuwBjgY5rP1V5SrFCoGM8CujaJzqnzTuQC5XyL61y0TTxZR1Utypzg47HFZfiC8tZdKvLlpy/wBvSJY7cq3yTJjc2enTPTrmp9MncLfQSXa28lzFtjmfgDnlSe2R3rP1BE0/Qb2zury2maYr5FtDJ5mwhsmTI4HHH41zNtk16ai2eH+I0b+1ZCgyCAc0Vc8TRrHqrDn7oNFap6HhSjqz2qTRVfqoqo2hIh4UV1K53c4x2p+wHrgiveaR5CbOQutP8u0mIHRc/lV3TpwbeMAjGAeea2NStY5LG4VlDL5bHB9QK5XSZPMgj6g4+97V5ePXK00e1lDu2dRpyCSZS+XyTx2rsoFCwLu+YjHNcxoYBxghgegArp2dRECMDtgVy01oz2K87uxSnCtMTwOaqXKKRzjjvU80gALZOe1VXPmRlgwz6YrOW5Ue5i3ColzhOMnOKsFC7kM33Rmo3j/0oMxySOmKinu0WTgnI61ltubu7aSERGWQ4YhfX1re0618yDfOCoJ4X+9WXBGz7JF3CNj85A+6O9dQqFNPidm2srfKV6ke30Fa04mVeWyKVnbS3Afy1ZdsgXd0wPatWC3tbZEOGZSN0z84bn7oPTPvRpInMIy6kxnMcTLx83GWPrVrWD5kCWUbpDFb43L1BbHr3rohFJXOGpOU5qPQxvtYubp5NvkovKA5yPQfSnK0lw2yIBi3c8AUkiFLdSUCs/U8n8fpUafuwiqcZ9v5VDv1Ldnoh7SiIfvCB2I9TVC4meQks2VHbGRU8qmVsAZJ5J9qZ8jCRQuwpwWPINZu7NIxjHc53VbMThm8wBx0YDB+leZeN4z5B81f3sbZVvUV6rqAEZcjIyMsPSuS8TW0F9YNFIjbT0cDkH1qE+WSYYilzU2eUxPhacZetTXOkX0NyYY7eWYfwsiEgirVj4Y1a7lCfZWiXu8nAFdftFY8P2cm7WMiZ8j/AArt/BXg95Zo7zUV44aOM/zNa3hzwZHp94s12ftD44O3hTXodpGqOAFBUd6xnVu7I78PhLe/MtadbJbxKXXGOK05YwUG3+Lt0zUKurqc4wOxp0E67sfw9F9qlI6ZN7omggiEZ80YAHUVn6nfNtMQ/gHHpilvrwhWIbpn8q5PVtWjghZyxLtwF7mnJ9EKD5fekRarfBBvLDceAo7ms2AHc0knMjdT6e1ZvmvNOZpfvnoB/DWjbNla7cNQ5PelueVjcY6z5Y7E5PFFJ1FB6V2nnhmopo95Dqdso6N6/WpM0ZzxUyipKzKjNwfNHctaZqO19kx8uUdVJ6/SumsryN8YbBI6VxkkayAK3P06ipLe7e2wkw3x9pB2+tebVwzp6x1R7WHx/tPdqbnosSiRcnBJ6D0+tKkbHcCQT/KsbS9QMkYy3bFbEcqswUHDHqazTudibWxHNz8oGT6mqZtUlm3MoyOK0pFIkjlXG1eDUQiIk3g8tzj0pShc0jMwNS0q3ld96KfqK5+XS1iDtbSMjYwVzwR6V21zCsvJyD2rIu4B+8wAAq4FYyTR1UoQluUtLtoyilBt29gKnulfflWzkbcHsaXSN0EW4rlWHA9DU1ycoQUwffrTivdOyTtK3QyN7JI29iFzyMcVZEiLHkDIPah1GGLAAY4A71WH3cngenpUbBLVGjaXBRtrYGTkY/Suj07UBiPz8q2egOMVyCyM7LgjA4zWg0xZIieGTqRW1ORx1qXNoeqaFeR6pDc2zuVvEUYyTh/ce9Z1/cyJIlpa/wCuckF2PyqO/wCNcroviOXSb6C5ixhD+8UgHcp4IzXVXU0NykN3bRFoQXKj1GeprqhPmR5UqEqVS7Wj2GSabHHFGbhma4LEmTgKNvQD+dYOsySStGZn+cZVj6E9/wAq2by/+0WqDaEwmCB7Hiud8S3Kw3FoUDNbiLcyepz/AFNKdkjWipcyvuZl1CxlRcgsox9KkjiljfBIYEc05GUyfKQdigbhyMnk1aHCZJBzWFj0FNpWGFzGfnB24xn0NOljWaJgsjHjgY4p1tu3bP4XGMHvT5FWMGMEru6HtWsdiZMyLeS4uriZYY9OUQxAMblBt2g9fr6mqt9Y3N7YSbJfD4iZlTzIgEIbPAzjgmlkZDd3VhNBPPHdKFK24zIpByGA7j2rH1trbQLGS1ks9UEF46edcTRquEU52oASC31NYSdmZV1p5nlHi1ZYNcnhuUMc0R2Oh7EGin+Mrr+1vEFzfhDEs+HVDyVHQA++BRTsjwpNptWPoCThs96ar89qkmXJzUSJX0J46HXODZXHr5TfyNeeeGZmZfm/h4r0aQf6NN/1zb+VcNosKZVgOMYz615eZK/Ke1k8kpSudxowURgEkZ5GDW0CxjwqgL/ebIzWRpREaqcgmtzaXiVjkLjjBz+dckNj2Km5mXB2MQTnnk1kXl+6XCpGCSOvpWteIPLLEt9DXNah9/AyF7nv+FZVNDtw0VLctLITMoZsuf5VQ2FriRuuCRUNu/lXBkAO0YHPerrnfeZTo/zcdMVlujocfZvQ3rL93YmPnZOA3X+EdAfxrWhfNqIgvyqeH6ke1VNKRViaN1Voc7hnqpq1cqI4nk5CrwQDyfeuqKsrnlyld2JrG6AO2IMhUZyPmxUc0c8l2k0yBUbjfE33sd2U96z7SW4jleO0lSOZsKwZchgOnNOa4mjmIu0QE48t06Men4VXN0B0uVtouySsZMK7k8/KcfpUcroYmKqRxxnjFCruYkgDZx8rdfc1FNJhFx2OeOpokZKOpZtpNkfVWx1zw3/1xVfVHOwFYn5HDY21EtyDuLMpC8jNN82B0V7jeyjHfg5qL6GsYWlcwj5kE5D5LkZ2lciqd3F5hVgi7c8gVtXjQsD5R49CentWcGSJsM/BOTz92spKz0Om3OhYYpTFiJYwemcVatrAAAzH5j14p8cu0fIFzjqOc1aZA6KSSM9KauzllBRGMq7SNuF/nTrVMr5gIwentUVwGEeFOc+lJEGggAyW+bpTUbMXQub9xwvA74qCNtjvu6USyeUpbbgEdawte1SO3gAV+T+pptmcnZaia9qawqqI2TnAUd65aZXmlMkvLn9KasjXExlm5Y9B6VdiUEdK7qFDl96W54uKxLm+WOxUSLmr0Ix9aUIMU8DHauxKxxjs0hNJSZ9aYhc0hPNBHHtRmgBWOaQ9COD7GkzSFgPrSAls7qSxk3Kd0XcdcV1FlqEc5R0PBH4VyHmAZwRSwXJtJhIhJi/iXPT3FcNeh9qB6mExlny1D0uG5V4FTHJ4qVCsg2nj6Vzun6nG0CuhBBGauR3Rfc2cN1GK5Yy7nqcnNqjVlhMhAXgkHrWebZmE+5AWXhh61cjv1AIdeOOakW4hWQFGBEjYbHPatVFSBVJQ2MaKHyoDGyhW6AY4NVri3fBYY7cYravI4/NBZowzZOc5z9ao/u9iFmwenB4qXA6oVnLUwJYpcE7VY9apo5BHmLgE+tdBJEHdv9pCRj1rIvbZlhidfuzJuU9eR1FYyhbU7ITT0ZWcIDweD6dqmiuckI4yTwM1BEDJYTHBV4GDdOqt/wDXqW3AfzWkIJVdw9eeKiN7lSW6J2aTzMSDBPGMdK3PDOrSxyvaSS9FP3uhHpWFeuZbaKRmAkU7CB3qC2vJbK+hnj+Yk7ZE7MD2NWpOErmLh7SDizsBPI5NqseS0u8NnohqO+YyXMYuQrJayDPP3gegAp9tcRi72uqomPklxwns3t79qNSv/Msr2cbCxlGXQhsKO34+tdFtDld09EUwPIMkpUeVIxbaB93JpfN899sJGwCqut3gFvFZ2q5ZgJGb2PQflSac8VpAkmPMLDpjofSs3rKxtGLceZrU14QAuH6jkCqd1ebleNnCMAcZGR+FVLvUWY5jQxt9c1ntPcyuNxU+h280Ooloio0W/eZHYyyMdRgmuha3FzEEimYkDg5Klu2R3rNvLf8As/RNQtLy9gnlu9gjt4pvN2ENkyE9F44981sXWg6pdRq4sLjYwzuUDkH0rMfSL3T9C11ryxkhQxxhJJFALHzB0rFpmFaUXe0u2h5Xrrql+UReEUL0ordj0wSgyTY3ucmirR4krXPaJOtNjAIyAee1Pl4zUa9OK+iPDQ9hujYeoI/SuJ0ZQU2E8qxB9gDXaglcDOa4jSGP2yZVXKrI4/HNefmC0ierlbaqM6+wKmQIuQc84rpIF8xBHGwUZwzv0Ark9OKkF5CVweMda6aK7DxpHHDknhQ4GCfX6VwQPdq3exBqKiIhY/3gJ++e59q5m9TzZznC5/WunngZomknYMxyuQOOOw9vesloA8pbaAe9RUidWGkooyorYeYCclfSpYYikalmH3sEe1WjjILDPX8aarExzqOSrBsjnPY1CijWc2zYs22uzLweCV7VNq92pgbytvTbIpPbsRWMs7BshxtJwMGmai7Q2MgHLHoOpPsK059LGLoa8zJ5SVRSd7yYAPYk1HbSu96vDEgZw570jyv5ceVilAGAGbaw46VDFKyXBIxGpAG3ril1NWvdNoSnsAGxg88VBJcLFEQWGc4BPWo1uf3ZAJLD24z7Vl3ZaYc9ByQO1OTOenS5nqX0O4cNn27UCHfIcW4PYFueadp0LKqokTBzzvf09s1qpb+bblyZnxnlWwv5DrTjG46klBmPPGBgA5wOijHNVXtp3GCnDcnJ6V001ikMaGMSrxxgcMO9UVihSTDYGRwD15punfcmNfTQZY2/7sdM7R17VcNm2xeyZxzxTFkRUQ7sE8Yx0pLjUysI2YdtwyR696tRSRx1JSctCO5iEIyTlvWqUruZMkHB4xjpR9s+0y/PnHvVbUZwvTAHPNZTa6FwulqU9dvxBbn5gADz7Vwc9295dGRuUHCj0FO8R6i1xOLcHhSdwBqC0XgZrbD0rvmZ5eNxF/ciaduOBV+IcVTgFXk4r0keWx3ajNHfjpSMQKoQUhNNZwB1qvJPjPt70gLBbio2lAHvVGa8AB+YVmXOohc8/rUuVh2NiW6CjrVWW/C9SK5q91hVyN/Ssa51vrtbis3UK5TtZNSUHqKZ/ai56155Jq7knDGo11WTd1P41HtGVyo9V0nWhbzgMQYX4I7LXaWbGZNyyAAjg5rwK11ZsjLGu98G+J1Vltrl/lJwjH+VcdWnrzI9TCYpx9yR6Q1y8ceyXcpPcVW+2+W6NG/U85pZnae2Vt2OepqndoVETQAP3wOKx5mj2I2aL73xaYM7Hpx7U63mMdqNxL4IAyegzWHLculwhmB56d6spdoVIVwEIGQTxQqjudao2SsdFFJEU+8Mv1B9u1ZkhQwyoDkxyCVfTB4P60Wl75RwChxnaQcZzVcZkusBAqupU4bP0/WtG7oIxs9SxFCft1xCFyGt2B7DjnNU7W2Z7lIsfejbt1GM1dgcrqcbqQS0B3HPX5cU62OwWzK5DQyMpyM/KRUpJjcml8iDU7NILe0khdZEljVsjs3Qg1SnUSwqvAIGOOK09oltIw74iilZRjk5PT+VUJI8SMD8uDSkuxnF9Hua1hIL3TYULEBcCT1NTQWrGRECAQtJyoPQDjFZvhzPnyxjLcElR/d71u2JV73Zu/dsu4MT1x/Ca1haSTZhUk4N2Myxj2ao73OSYm9Oq9jU4JtL5mxm2diRn+lT6hDFK813ablVW2sd2QT3xT9Omivbby5zwecjqD60uXoWpXXMaccFre2wIiQk87sdqjuLC1hQtHGSP4s9qEt5bSPYWzGw+VvSmXPEcgdvmI5zWratqjn1T0Zw/iCW5a6ISWVIhwB5hrCkaQK3mSyMvdWcnNd7cRaQ9kbh7Sd5UYJKn2jaeejAY5B/SsHUDpJtJDBYXEU/8Lvcbh19MVwzXvXudXMpR5bM425ugkuCMccUU28tVmnLzNtY9BnGBRVcsux5UlFPc9gfBNNXA6UjDnvSZxX0x8yLuAIrh9PLQ6vfxZwPOYj6Zrs2PPFcbe/uPEd0Om8hgPYiuDHr3E/M9DLpWqnSxsQ0YUAA9K6DTL+C3KifI3DnBzzXMwTE4IUYHQmtWFpos4jXeejEYrzISsz6fkU1ZnRajc20sMbKWdGG4DGOc/yrFnkBjeTBwox/hUDyzFiXdWZj0HWmJcMHySsjKchT0B9aJz5jSnR5URXI8iISy/LKy/Ip6AHvUWmgqqyZIw2CPXNNuJ5riQmYKwHJJ706SVRAxdiX+9gAHms76m7i+W1iwUi8wkIUITBXHDNWfqUwSJDsPBH5/WteCRxGSjB42G4KRmse8H2lpAM7UQnHbNVLbQmm9dS158rWwCRW74HDSLlqhjcsxLcc8gDFRWW+W1V1OBjk1NYRSSySbBuPUGkm3YuUUk7lq0ZxIyrzGT3q9DakwBmTbIWySx4xnjApLCMfapS3zEkAfXHPFbdpb5YEkgl8ZI561vCDZw1KvKVbe2G9ZI1uZWxwQvAb157VYTEUauw2sx+ZWONvPXFaUeYbcqAQS2QhyMH6VSvWieaFXiWNgSWLdv8AEVtyqK0OP2jm7CXl0hiUBztyTtzuAORxmsi6uVVCvljjlSTjIpdQujbtMm5Wj4ICDj3x6VjSXieQC+0hC2N5zwegFZzlrqb06TtckvLwIY4gxXd37D2qpcXwt7Taw5zjjvWFcXjTSRssnQ8g9a0JEMkDZHzda5nU5m7G1SnGmlcvabKhhLEZJ9awvFWorbRER58w8AU7UNSh0y0AZyZeTgVx8tw97cNLM2WPI54FaUoOo9TzcZilT0j1KsaNJIXcncTk1qWykYqOGMCrSkKK9SELHgylcv2+KuLjAzWQk4Xqasx3a4+9WiJLzEZqGSUAVC1ypHWqc84APNDYySa4Cg9Kybu8xk5qK9usZ5rm9Tv8AgHmsZSKirly/wBV2Z+auevNWZ8jdWdd3TSHkmqTMTWTZaVizPdSOxyTUDOSaRVJp4iJ6UhjM0ZqTyWoMRFFgERiDxV+0u2RuprPKkd6ASO9JoafU9c8G+KxIEs9QfPaOQ9/Y13KS72xGvX36V87WtyY24NegeF/FjwGOO7bcg4VyensawnTPRwuL5fdkdpqVnIZ9zOcD1ohQRIzM/y5ABzkGpHvEu4wQw+ccEGqcUTxk88d643FJ3R9JQxCnGzZpwxFs/NGcHPymlGFbBBODxisyNgZCu5dvXk8VZ3RsBiQpjn5TxVJlvfcu28sKABjICODtPb0qaKSBpXLiYoCGwD1qlAEDbfMjZjg5ZsAZp6lDPta4QKPvNGM8e1aJmcyxLcYtblUARTKCo9MCn20Mt1IpUrGj/xtwBVZm2PL8jBQ2AXHP1NJFPJEgViy45APp9KNL6kOVloadoUtdbRYiZFBw7Y6e9bOtW8drC5tHLICCD3B71zmluVkuHlXhj8rNnhhzj8av6lerLbuFyGYjjPvWsGlE52m5pkkF29tK1vjEe4sQepz61Y8pBMZbZtqE5K/3T/hWNPKJi5DbJ4zxnv7VNaXLEBujdCM1nz9GdfJZXR0izvsCSYI7DPSqWpTfIDg5H61WN2FjwT8xOetUri9zkkngdapzuc3Kk7lqTS0ls4rmTVLaOJ+OUc7W7qcdDXP69HZ6fp8lx/atrO64CwojhnPoM1r3Vk1npP2nU9RFja3AEiptLbh2ZgOPp3rg/ENot3aS3mk6gl9DHgTLsaOaMMcA7T0QnjIrpo4Pm96povzPNxWY8t4U3d/kclqF3Jc3TyMJWPTCHhfairsejSFAWkZD/dTIAor01WoxVuZHhunUk7tM91brzmmHpnNOYc9+ahlLbflOOec1ZzjWb5sVx+vyhPFsYHa3GfzNdaT8/0rhfEMu/xXLgnIQJn6Vx47+EdmBX75HR28oLLgZGO3St/SrhkBJAcL/C3P5Vy2mtwu7qK39LkXJL9M546g148HqfY8i5TqUSO9iRYlSNpAd7BcbR/jUNxoyxKxj+4gHztwMnvVmzimnVDFcgKRnPVhVqPTRKHabzZkzn5zxn1xXVy3WxxqpyO19Dk5rfdcJGfLfJ6p0xVC6+Sbjlc5xXSvBi5uplj/AHcS7M5xhjXO3GGUsWyAc7u9c842R6FGpzluEb7ZYySGjOOeMjqPwqnY/OJ2wu0tg5qVJSbcSjqCUIz/AA9qtaLZE2+CxyQWOfXNOOrSRErQTbM3w8iypPExIVHIOPSurtbO3hRTGkkUaAMWbgse31rl7CI2uv3NqzBVkxIufTv+FdLfauBHbJtcsjksW5UgA1dJWjr0MsTzSklHZkdom/7K0IHnmR1Yr9c8Voxy/Z5riP7TseKRWXHQkn+Vc7Z6l5Qfy32GOdmBHbIGKBds+orI0xRXBBZQOlaRmraHNOjJvU6PUdcgkFtFLvEiOTKG6EY6j1rF1DVUuZE2gIhDKDtxn6VnaxdgTIDMzYypZgCW965y7un85NrSMqnbknpUVKttDWjhYpKRqahqe6dkHIK4JPasS5uVkUqm7oOtXTGJVBcnf1/Cs9YGLsGLBDzXNLmkbwqRgR2cQBaRsgDn61Yu9ThtLF5Z3CqBk5NVnmS0hkaY/KoJO48V5d4l159RnZUYi3U/KPWqpwb0PLxmLV2aGp662oXzSE4jBwi+1S29+vdhXGCcg4Bp63br3rth7miPEqPnd2d9FqAx94U9tQGOtcGl++OpxUovnJ+8a19ozLkOtl1AZOG/WoRq23ucVzJuWY/epplOMZpc7Goo69dWVv4uaH1AP3zXJKzEjGa0LNZGIHNPmbFyovXk5ZTgmuX1EybjnOK7CKyMi9M1XutF3gkrT5WCaWhwb5zToY9xHBrorjQSvQGkttJZW+6aVh3RVtNPLgEitWLSgQOK1LG02gccVrwWgx0pqNxORzP9kDH3ahl0zAPy12ptRjpVa4tAe1NwsTzHnt5ZbM4FZcqFeK72/s8g5HauXv7IgnC1DRaZjhiOlW7a4KEYNVpUKtjFMzg1I7nbaD4ge0wrnfDnlSen0rtrPV47iHfEwcdxivGIpmQ5BrU0/WJrSUPE+CD07GsKlLm1W53YfGSp6PY9bLIQSgHNS+ZB5YyX80HAH8OK5fRvEdvfqI2YRT/3T3rWmmd9rEAEdTXHKLjue7QxUaq3NJpEMhODgDpUiNvZiABjHyg4rLtZQ8gEm4BuM1ZnzG4CAnjrUp9TsvdWNFbuSKcvGQWXBBPNEt1I0nnzSbpW4yazY5iOoxkcgVPaqZ5Msnyjpn+dXzMxSu7Mv29ywhYMTlm3c9zUqzhh0J5zUckWQB2FTQRYOEXk9atXFeKIY43lneT5gzHp61ZZniUHGB0JqzHCQV+bb61laxqMNuJIoZBM6/ffdhI/qfX2rSlh51HaKMa2MhSjeTJLi/jiiLytx2HXJpYLgeSbq9Qsq48q1U/M3u57CuesIZtTv4EBmzK22PauZZT6Rr2+tbmqWss2NNigNpBEP3yMcHPcyt6+1e1h8JToR556s+fxWPqYl8kNEXL2+vPF0UM2o6Fd3kMH7uKawfZCqj0U/eI/vDir1p4fgs9FujpenyqbgqtxPPL5jsM5256YzgnFX72T/hHNC0XXitxDaOqWcb42bSoPKj+43r3rqIRDqumPcefHZy3USRrbAjanzZLKfQ9TXNVqOpotiKMI09d2eXSwRQOY1i83HVsd6K7S6treCZorWITRrx5mPvHuaK5vZs7faRHv3xVWZuoAyKsSMMVQmfJOCa9g8EFyWHvXA6gd/iGZ+pLt1+td5GQq7mPQZNcHMoe7SVs/OSc/jXn5g/cSO/L1eqbtvuVMnmrtvdBR8nytnmoLFP3QwQ3HRqne2Ung7TXjO/Q+3w7i42Z1ugahGzKrSY4wSBXVWd5mwzHh4sEkN1B9M15XYyNBKcZyOBiujt9TKp3j4AcD+P3rqpVtNTlxWE5nzI2NTuNlksaptLku+D94muR1AhFEYPB5PpWhd327lufxrGvZlaPr8xOamrO5rhqfJuNiuMF1bIjwTx39BW5pt55SwyY5K4IHrXPwZMTADLnoetSXt0ttPI0GdpAwvvjFZQny6lVoxm+Uu6zdFb62vo8GRco6kcbTVW81VpkYyHIUEADgcjmsu5v90JUnqNpHtWS05KumSQSdpz+lKdbXQcKSVk+hvWl2EaYOcI6q31xxSS33zAKA2PQ9aw0ncBcfdHBFWbcM4JjHzMec1KqO1kTJJO7LUkwnYCMOTmkgtHWQmRs7TnFQWtvKZxnIA5JzWzhIkJZt+BxTj725hWr8qtEkdVC7hn6Vm6jOtvC0jsFVaTUNWjtkZ3YKi+teTeLvFUups1vbOVt8/Me7e1bpczsjyK9fkQvi/wATNqE729s2LcH5iD97/wCtXJl89TUbEk8U3muiMeVWPJnNzd2PL0B81F3pe9WQWEapVbFVVB9c0/De9FwLSuaswKXI9KpW6Mzjg810+lWDMASKpaivYZaWZbHFdBp9jyvHFWbOwwB8vStiztdhHFdEKZlKYtrYjAO3NWJbEBela1lF8tWJ4QVrpUEjO5xl1YjnIGaom0APSumvoeTWW8fPNZzhYaZUt4MHNaECDFMCYNTLxjFSo2Hcn2AjioJYgc1LuIFNYg07Bcyrq2BBrDvrIMG4rqZFyDmqVxED1FZyiUmee6hYEEkDFYs0ZQkV6Le2isORxXN6jp5yxA4+lYtWNE7nMZxShuanuYGQ1VPFRYNiVZGU5XIxyDnoa6PSPFVzaBUuP38XTnqK5XNO3YqJQUtGXCrKDvFnrGmeIrS9CiJ0D5+4/BrdjuAww+fbFeGrIQwIODXS6F4pubLbFcjz4Bxk/eA/rWMqNtj0KWYS2Z6pGC7LtANatrFtGFByayND1G01G0EtrLvXvzyK3IZAFG1t3tU+zsdscS3qOaFhkAfWk82OzjMtw/lxDnPrVfUddg05dmFkmxnaDwPqewrjtR1WTUJPOabEY4EhGQPaNe/1rtw+Cc9ZaI5MTmChpHc2tZ1t7l1htfMjU9I0/wBY/wBT/CKx4gzsoRUmkQ8KATDEf/ZmqTR9JuL5tkcbrG3LDPzMPV2/pXouiaHbabGsrqryr/ERgL9BXfKpTw65Yo8+FOpiHzTZj+GfDN2J47+a5mtZEIkWUHEuR6H+EewrudAt9CWy/wCEh8SXcd3E0haDT43DvM+fvze+RnB47nNVxci6PkWz8kEnjjH1rzLxRoeo22oSjT7gJbXGQyk/KG9M1xTqSqPmlsaVYKC5YHd/EPW4/Euj3cmtTFbd0BtbaBfMEUe7BdV4zzxuJHtXJ+HNZHh+yaPVbo3NhFgR3EkZjkjyMqkiH1H3SMg1q2sEH9io2oXn2WxZYi80i5RNibGhOOQc/MB3zWN48u4LXQlMitOHtltLOGdCr3D+ZvEjA8hEA4HvSlZq+xhCTg7I43xD411a+1N57W4NjbkARxE4O3sT7mitDRPh1f6vYi9uSoklYkmQcn3orlc9djsVGb15j1mZjWeWJkK5460UV7h5I2/cpplyynB2VzcsaYt/lHXFFFebj9kehgPiNKzUE4PYVoxfN15oory1sfXU9h5hTDEDBHpQGK7cc/Wiil1OmT0K1xK+489OlUJ2OVJJOetFFRMqJeg5Cr0GO1ZmoOysoB6Niiik9jH7ZTjUNdYOSKbNGoVQBxn+tFFZhNu5HEoYMpHGe1acY2pGBkfNRRW0TiqN2J1YrM5BPXFR3s7rEMY70UVojhqM8g8c6vdyXLwFwIl52gVzBPAoorqpL3Txa7bqDSeRQe9FFamYDrTlUGiigDQtYkYcirfkR/3RRRWT3NUSxRqrjArrdEAO0HpRRW9HcisdTbxIB0q7Gig8CiivShscXU0bQDH41ccAqc0UVYdTHv0HPFZDgb6KKiQwVQeop+ABRRUDEIGBSYGaKKfQRG4qCVQe1FFRIZQnUelZN5GpByKKKwkXE5rU4k9K564UL0oorJmjIO9Jk5ooqSRwPNSIeDRRS6lI7TwvNJbaMlxC5SVJiuR3HofWuw1LVbpIIFjcJ5iZYqMH86KK7YxVo6CUmr2ZzcEjXK3cs53+SeEP3SfU+tdR4Y0u3vHSW4DM5Gc56ew9BRRW9Z2i7CopOaud4riyswLeONQB6ViDULm8kxNKdufujgUUV47d1dntS0dkbmnM0MDCNiuV5wat6o4TRrhmjjkxExw4yCQOtFFb0XocuJPILfxDqtn4Zl12C9lF+8/kKSfkjX1Vem73OTWx8MtPTxFrUt/rk1xfXSDcHnkLE/XPb2ooqavRGOH1m7nt8cSKgCqAAOAKKKKybO1I/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral erythema is present on the hands in this patient with acral erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11458=[""].join("\n");
var outline_f11_12_11458=null;
var title_f11_12_11459="Diaper dermatitis candidiasis";
var content_f11_12_11459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaper dermatitis complicated by Candida infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diaper dermatitis with superimposed candidiasis. The skin folds are involved and satellite lesions are typically present at the perifery of the involved area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11459=[""].join("\n");
var outline_f11_12_11459=null;
var title_f11_12_11460="Zinc acetate: Drug information";
var content_f11_12_11460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zinc acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/19/36147?source=see_link\">",
"    see \"Zinc acetate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/56/38787?source=see_link\">",
"    see \"Zinc acetate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9831430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Galzin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9850296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Trace Element",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9850339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Wilson's disease:",
"     </b>",
"     Oral: Dose expressed in mg elemental zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Males and nonpregnant females:",
"     </i>",
"     150 mg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Pregnant  females:",
"     </i>",
"     75 mg/day in 3 divided doses; may increase to 150 mg/day in 3 divided doses if inadequate response to lower dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9850338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/56/38787?source=see_link\">",
"      see \"Zinc acetate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Wilson's disease:",
"     </b>",
"     Oral: Dose expressed in mg elemental zinc:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;10 years: 75 mg/day in 3 divided doses; may increase to 150 mg/day in 3 divided doses if inadequate response to lower dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) practice guideline recommendations (Roberts, 2008):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;50 kg and &gt;5 years: 75 mg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;50 kg: 150 mg/day in 3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9850340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9850352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Galzin&reg;: Elemental zinc 25 mg, Elemental zinc 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9882124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9850347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on empty stomach at least 1 hour before or 2-3 hours after meals, and 1 hour away from beverages other than water. Gastric irritation most commonly associated with morning dose; may administer 1 hour after breakfast if gastric irritation occurs. Swallow capsule whole; do not chew or open.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9850297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of Wilson&rsquo;s disease following initial chelation therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9850327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Neurologic deterioration (uncommon)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Amylase increased, lipase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Gastric irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Alkaline phosphatase increased, hepatic function decreased (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9850302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zinc salts or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9850324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Central nervous system: Neurological deterioration may occur with initial therapy as copper stores are mobilized; effects are less common when compared to chelation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; GI effects: Gastric irritation/upset may occur with use and particularly with the  morning dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use in hepatic impairment has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use in renal impairment has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not recommended for initial treatment of Wilson&rsquo;s disease in symptomatic patients; may be used as maintenance therapy after patient has been stabilized on initial chelation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Therapy management: Hepatic copper levels should not be used to manage therapy  as they do not differentiate between potentially toxic free copper and safely bound copper.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9922728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ceftibuten: Zinc Salts may decrease the serum concentration of Ceftibuten.  Management: Consider administering oral zinc salts at least 3 hours after ceftibuten.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: Zinc Salts may decrease the absorption of Cephalexin.  Management: Consider administering oral zinc salts at least 3 hours after cephalexin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Zinc Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Zinc Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., zinc-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Zinc Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Zinc Salts may decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Zinc Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Zinc Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9850330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food and beverages other than water may interfere with zinc absorption. Management: Administer on empty stomach at least 1 hour before or 2-3 hours after meals and 1 hour away from beverages other than water. Can give 1 hour after breakfast if GI irritation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9850298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9850299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The risk of fetal harm appears remote with use of zinc acetate during pregnancy. An increased risk of fetal abnormalities has not been observed in pregnant women receiving zinc acetate (regardless of trimester).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9850300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters human breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9850301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women receiving zinc therapy should avoid nursing due to risks for zinc-induced copper deficiency in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Galzin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (250): $356.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (250): $593.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9850349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum non-ceruloplasmin bound copper, 24-hour urinary copper excretion, 24-hour urinary zinc levels, LFTs, iron and/or other trace minerals, neurologic evaluation including speech, periodic ophthalmic exam",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9850346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     24-hour urinary copper excretion: &le;75 mcg/24 hours (or 200-500 mcg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Non-ceruloplasmin plasma copper (free copper) : &lt;20 mcg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Galzin (AR);",
"     </li>",
"     <li>",
"      Wilzin (AT, BE, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR, TW);",
"     </li>",
"     <li>",
"      Zinca (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9850344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc induces production of the copper binding protein metallothionein in enterocytes. Copper binding within enterocytes results in an impairment of the intestinal absorption of dietary copper and reabsorption of endogenously secreted copper in saliva, bile, gastric acid.  Following enterocyte desquamation, bound copper is eliminated in the feces.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9850333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: pH dependent (enhanced at pH &le;3); impaired by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Inhibition of copper uptake: ~ 11 days following cessation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily in feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson LA, Hakojarvi SL, and Boudreaux SK, &ldquo;Zinc Acetate Treatment in Wilson's Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(1):78-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11460/abstract-text/9475826/pubmed\" id=\"9475826\" target=\"_blank\">",
"        9475826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill GM, Brewer GJ, Prasad AS, et al, &ldquo;Treatment of Wilson&rsquo;s Disease With Zinc. I. Oral Zinc Therapy Regimens,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 1987, 7(3):522-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11460/abstract-text/3570163/pubmed\" id=\"3570163\" target=\"_blank\">",
"        3570163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts EA and Schilsky ML, &ldquo;Diagnosis and Treatment of Wilson Disease: An Update. American Association for Study of Liver Diseases (AASLD),&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2008, 47(6):2089-111.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11460/abstract-text/18506894/pubmed\" id=\"18506894\" target=\"_blank\">",
"        18506894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9980 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11460=[""].join("\n");
var outline_f11_12_11460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9831430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850296\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850339\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850338\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850340\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850352\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9882124\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850347\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850297\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850327\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850302\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850330\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850298\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850300\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322803\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850349\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850346\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707705\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850344\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9850333\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/19/36147?source=related_link\">",
"      Zinc acetate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/56/38787?source=related_link\">",
"      Zinc acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11461="Nonislet cell tumor hypoglycemia";
var content_f11_12_11461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonislet cell tumor hypoglycemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11461/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11461/contributors\">",
"     F John Service, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11461/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11461/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11461/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11461/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/12/11461/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia can be caused by several tumors, including islet and nonislet tumors. Nonislet cell tumor hypoglycemia (NICTH) is an uncommon but serious complication of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common cause of this type of hypoglycemia is tumoral overproduction of incompletely processed insulin-like growth factor-II (IGF-II), which results in stimulation of the insulin receptors and increased glucose utilization. Other potential but less common causes include the production of autoantibodies against insulin or the insulin receptor and extensive tumor burden resulting in destruction of the liver or adrenal glands. NICTH occurs more commonly in patients with mesenchymal tumors, fibromas, carcinoid, myelomas, lymphomas, hepatocellular, and colorectal carcinomas (",
"    <a class=\"graphic graphic_table graphicRef69283 \" href=\"UTD.htm?24/36/25164\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology and evaluation of nonislet cell tumor hypoglycemia (NICTH) will be reviewed here. Islet cell tumors (insulinomas), other causes of hypoglycemia, and the diagnostic approach to hypoglycemic disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypoglycemia has been observed in a small percentage of patients with nonislet cell tumors, usually of mesenchymal, vascular (eg, hemangiopericytoma), or epithelial cell types (",
"    <a class=\"graphic graphic_table graphicRef69283 \" href=\"UTD.htm?24/36/25164\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. These tumors are usually large in size, weighing on average two to four kilograms; they are located in the chest in approximately one-third and in the retroperitoneal region in two-thirds of cases. There are no epidemiologic studies of the demographic features of NICTH.",
"   </p>",
"   <p>",
"    In the first case report of a patient with metastatic hepatocellular carcinoma and severe hypoglycemia, extensive postmortem examination found no abnormality in the pancreas, extracts from the liver tumor contained no insulin, and the glycogen content was low in the liver (in contrast to the abundant hepatic glycogen in patients with hyperinsulinism) and absent in the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, severe hypoglycemia was mediated by mechanisms other than excess insulin.",
"   </p>",
"   <p>",
"    No single pathogenetic mechanism explains all cases of NICTH. However, the major cause of NICTH appears to be increased glucose utilization, particularly in skeletal muscle, due to tumoral secretion of incompletely processed insulin-like growth factor-II (IGF-II), termed \"big\" IGF-II [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/7-11\">",
"     7-11",
"    </a>",
"    ], or rarely, IGF-I [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/12\">",
"     12",
"    </a>",
"    ]. In one series of 28 patients, for example, 25 had elevated serum big IGF-II concentrations; the concentration of normal IGF-II was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonislet tumors can secrete insulin, although it is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In one report of NICTH associated with a cervical cancer, in situ hybridization confirmed the presence of proinsulin messenger RNA (mRNA) in the tumor, providing evidence for tumoral insulin production [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential mechanisms include extensive replacement of hepatic tissue by tumor with or without glucocorticoid deficiency due to extensive replacement of the adrenal glands by tumor or hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/17\">",
"     17",
"    </a>",
"    ] and autoantibodies directed against insulin or the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the mechanism in any individual patient with NICTH, the identification of this disorder is not usually difficult. When a patient with known tumor burden is found to be hypoglycemic, a search for other causes of hypoglycemia is generally unwarranted and fruitless, especially if the tumor type is known to be associated with hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef69283 \" href=\"UTD.htm?24/36/25164\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with NICTH typically appear ill due to the underlying tumor. Symptoms of hypoglycemia more often occur in the fasting state and may include confusion, lethargy, diaphoresis, or progressive somnolence, with some patients presenting with coma as the initial manifestation of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A healthy-appearing person with episodes of hypoglycemia is less likely to have NICTH, although in some cases, hypoglycemia was the initial event that led to the diagnosis of a tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In such cases, an evaluation to determine the cause of hypoglycemia is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Approach to testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the biochemical findings in individuals with hyperinsulinemic hypoglycemia, patients with IGF-induced hypoglycemia have low serum insulin and C-peptide concentrations during hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, the beta hydroxybutyrate concentration is also low, consistent with insulin-like activity. The plasma glucose response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    administration is normal or near normal unless there has been extensive tumoral replacement of hepatic tissue, resulting in low hepatic glycogen stores [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Although not routinely performed, measurement of serum IGF-II and big IGF-II can establish the role of these hormones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Interpretation of data'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential causes of hypoglycemia in patients with tumors include extensive tumor infiltration, resulting in destruction of the liver or adrenal glands. Dynamic testing can be performed to establish the diagnosis of adrenal insufficiency in patients in whom hypoadrenalism is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'ACTH stimulation tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to endogenous insulin or to the insulin receptor. Symptoms can occur postprandially, fasting, or in both states. Insulin antibodies can be measured to distinguish insulin autoimmune hypoglycemia from other causes of hypoglycemia. Insulin antibodies do not need to be drawn during hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Approach to testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three components to therapy in patients with NICTH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate correction of hypoglycemia",
"     </li>",
"     <li>",
"      Treatment directed at the underlying malignancy",
"     </li>",
"     <li>",
"      Prevention of recurrent hypoglycemia if the tumor cannot be controlled",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The acute management of hypoglycemia is similar to the management of hypoglycemia during the treatment of diabetes. In brief, treatment of severe hypoglycemia, when the patient is unconscious or unable to ingest carbohydrate, requires a subcutaneous or intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (0.5 to 1.0 mg). Patients brought to the hospital can be treated more quickly by giving 25 g of 50 percent glucose (dextrose) intravenously. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H26#H26\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Treatment of hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a tumor is producing IGFs or insulin, complete removal of the tumor results in cure of hypoglycemia. In situations where the underlying malignancy cannot be treated, medical therapy is required to prevent recurrent hypoglycemia symptoms. In case series and reports, hypoglycemia was controlled with glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    40 mg daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/2,3,24,25\">",
"     2,3,24,25",
"    </a>",
"    ]. Patients with a glycemic response to glucagon (eg, due to big IGF-II) can be treated with a long-term intravenous glucagon infusion (0.06 to 0.30",
"    <span class=\"nowrap\">",
"     mg/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/24\">",
"     24",
"    </a>",
"    ]. Somatostatin analogues have not been effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11461/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"       \"Patient information: Low blood sugar in people with diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe hypoglycemia has been observed in a small percentage of patients with nonislet cell tumors, usually of mesenchymal or epithelial cell types (",
"      <a class=\"graphic graphic_table graphicRef69283 \" href=\"UTD.htm?24/36/25164\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of this type of hypoglycemia is tumoral overproduction of incompletely processed insulin-like growth factor-II (IGF-II), which results in stimulation of the insulin receptors and increased glucose utilization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with NICTH typically appear ill due to the underlying tumor and, therefore, the identification of this disorder is not usually difficult. Although a healthy-appearing person with episodes of hypoglycemia is less likely to have NICTH, the diagnosis should be considered if evaluation for other causes of hypoglycemia (factitious use of insulin or sulfonylureas, insulinoma) is negative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment involves immediate correction of hypoglycemia, treatment directed at the underlying malignancy, and prevention of recurrent hypoglycemia if the tumor cannot be controlled. In case reports, oral glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      were effective in controlling hypoglycemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/1\">",
"      Scott K. Non-islet cell tumor hypoglycemia. J Pain Symptom Manage 2009; 37:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/2\">",
"      de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer 2007; 14:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/3\">",
"      Marks, V, Teale, JD. Tumours producing hypoglycaemia. Endocr Relat Cancer 1998; 5:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/4\">",
"      Ma RC, Tong PC, Chan JC, et al. A 67-year-old woman with recurrent hypoglycemia: non-islet cell tumour hypoglycemia. CMAJ 2005; 173:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/5\">",
"      Pink D, Schoeler D, Lindner T, et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. J Clin Oncol 2005; 23:6809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/6\">",
"      Nadler, WH, Wolfer, JA. Hepatogenic hypoglycemic associated with primary liver cell carcinoma. Arch Intern Med 1929; 44:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/7\">",
"      Eastman RC, Carson RE, Orloff DG, et al. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest 1992; 89:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/8\">",
"      Gorden P, Hendricks CM, Kahn CR, et al. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med 1981; 305:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/9\">",
"      Shapiro ET, Bell GI, Polonsky KS, et al. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest 1990; 85:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/10\">",
"      Zapf J, Futo E, Peter M, Froesch ER. Can \"big\" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 1992; 90:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/11\">",
"      Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism 1993; 42:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/12\">",
"      Nauck MA, Reinecke M, Perren A, et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab 2007; 92:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/13\">",
"      Shetty MR, Boghossian HM, Duffell D, et al. Tumor-induced hypoglycemia: a result of ectopic insulin production. Cancer 1982; 49:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/14\">",
"      Shames JM, Dhurandhar NR, Blackard WG. Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med 1968; 44:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/15\">",
"      Kiang DT, Bauer GE, Kennedy BJ. Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia. Cancer 1973; 31:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/16\">",
"      Seckl MJ, Mulholland PJ, Bishop AE, et al. Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 1999; 341:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/17\">",
"      Frankton S, Baithun S, Husain E, et al. Phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension. Hormones (Athens) 2009; 8:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/18\">",
"      Redmon B, Pyzdrowski KL, Elson MK, et al. Hypoglycemia due to an insulin-binding monoclonal antibody in multiple myeloma. N Engl J Med 1992; 326:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/19\">",
"      Walters EG, Tavar&eacute; JM, Denton RM, Walters G. Hypoglycaemia due to an insulin-receptor antibody in Hodgkin's disease. Lancet 1987; 1:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/20\">",
"      Soares-Welch CV, Zeldenrust SR, Conover CA, et al. Hodgkin's lymphoma manifesting with hypoglycemia. Endocr Pract 2003; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/21\">",
"      Fukuda I, Hizuka N, Ishikawa Y, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 2006; 16:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/22\">",
"      Dyer PH, Chowdhury TA, Milles J. Recurrent hypoglycaemia. Postgrad Med J 1998; 74:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/23\">",
"      Pun KK, Young RT, Wang C, et al. The use of glucagon challenge tests in the diagnostic evaluation of hypoglycemia due to hepatoma and insulinoma. J Clin Endocrinol Metab 1988; 67:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/24\">",
"      Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998; 82:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/25\">",
"      Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf) 1998; 49:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/26\">",
"      Perros P, Simpson J, Innes JA, et al. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clin Endocrinol (Oxf) 1996; 44:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11461/abstract/27\">",
"      Morbois-Trabut L, Maillot F, De Widerspach-Thor A, et al. \"Big IGF-II\"-induced hypoglycemia secondary to gastric adenocarcinoma. Diabetes Metab 2004; 30:276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1780 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11461=[""].join("\n");
var outline_f11_12_11461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/36/25164\" title=\"table 1\">",
"      Tumors reported to cause NICTH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11462="Pericyazine: Drug information";
var content_f11_12_11462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pericyazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/57/18325?source=see_link\">",
"    see \"Pericyazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1963008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neuleptil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1963010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine, Piperidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1963056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Psychosis:",
"     </b>",
"     Oral: Initial: 5-20 mg in the morning, followed by 10-40 mg in the evening. Maintenance: Decrease dose to lowest effective dose.",
"     <b>",
"      Note:",
"     </b>",
"     Reduced doses (2.5-15 mg in the morning and 5-30 mg in the evening) may be considered. In general, lower dosage should be used on initiation and gradually increased based on effect and tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1963055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Psychosis:",
"     </b>",
"     Oral: Children &ge;5 years: Initial:  2.5-10 mg in the morning, followed by 5-30 mg in the evening.  In general, lower dosage should be used on initiation and gradually increased based on effect and tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1963057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Oral: Initial: ~5 mg/day; may increase dose gradually based on effect and tolerance. Doses &gt;30 mg/day are rarely needed. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuleptil&reg;: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuleptil&reg;: 10 mg/mL (100 mL) [contains ethanol and sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13382967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To minimize or avoid excessive drowsiness, administer in divided doses with larger dose in the evening.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1963011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in selected psychotic patients to control prevailing hostility, impulsivity, or aggression",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1963018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined; listing includes adverse reactions reported with other agents from the phenothiazine class.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Arrhythmias, AV block, cardiac arrest, ECG changes, edema, hypotension, orthostatic hypotension, paroxysmal tachycardia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, tachycardia, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Aggressive behavior, agitation, anxiety, bizarre dreams, cerebral edema, depression, dizziness, drowsiness, EEG changes, excitement; extrapyramidal symptoms (tremor, akathisia, dystonia, dyskinesia, oculogyric, opisthotonos, hyper-reflexia, pseudo-Parkinsonism, rigidity, sialorrhea); fatigue, fever, headache, insomnia, NMS, paradoxical psychosis, restlessness, seizure, sleep disturbance, tardive dyskinesia, temperature regulation impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioedema, dermatitis, eczema, epithelial keratopathy, erythema, exfoliative dermatitis, photosensitivity, pruritus, rash, seborrhea, skin pigmentation (prolonged therapy), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Delayed ovulation, galactorrhea, gynecomastia, hyperglycemia, libido changes, menstrual irregularities, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Adynamic ileus, anorexia, appetite increased, constipation, diarrhea, fecal impaction, nausea, paralytic ileus, salivation, vomiting, weight changes, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Bladder paralysis, ejaculation disturbance, impotence, incontinence, polyuria, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, leukopenia, neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Cholestasis, cholestatic jaundice, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, corneal deposits (prolonged therapy), glaucoma, lenticular deposits, pigmentary retinopathy (prolonged therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Asthma, laryngeal edema, nasal congestion, pneumonia, pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Diaphoresis increased, lupus-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1963013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to periciazine, phenothiazine derivatives, or any component of the formulation; altered states of consciousness or comatose states particularly when due to  intoxication with CNS depressant medications; hepatic dysfunction; circulatory collapse; blood dyscrasias; patients receiving spinal or regional anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1963014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines); QT prolongation has been reported rarely with periciazine. Use with caution in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), hypothyroidism, familial long QT syndrome, concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, glaucoma or other visual problems. Advise patients to report bothersome effects (eg, severe constipation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Check blood counts periodically and discontinue at first signs of blood dyscrasias; use is contraindicated in patients with blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, prolonged therapy, use of conventional antipsychotics, use in males, and younger patients. Risk of tardive dyskinesia may be increased in elderly patients; antipsychotics may also mask signs/symptoms of tardive dyskinesia. Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Patients experiencing hypersensitivity to phenothiazines in general should not be rechallenged unless deemed clinically necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia). Discontinue treatment immediately with onset of NMS; recurrence has been reported in patients rechallenged with antipsychotic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pigmentary retinopathy: Prolonged therapy with phenothiazines may cause pigmentary retinopathy, corneal deposits, and/or changes in skin pigmentation. Discontinue therapy if adverse effects are observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (including fatalities) has been reported in elderly patients with dementia-related psychosis. Periciazine is not approved for use in elderly patients with dementia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma; patients may be more likely to experience severe hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Avoid use in patients with untreated seizure disorders; use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol. Reduce dose of concomitant sedatives by one-half during initiation of periciazine therapy and monitor for excessive sedation. Ethanol consumption should be avoided during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; increased risk for developing tardive dyskinesia, particularly in elderly women.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1963044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1963043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1963047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid kava kava, valerian, St John's wort, gotu kola (may increase CNS depression). Avoid dong quai, St John's wort (may also cause photosensitization). Cigarette smoking may decrease the serum concentrations of periciazine.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1963012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal studies. Safety and efficacy have not been established in pregnant women. Use of antipsychotic agents during the third trimester may increase the risk of extrapyramidal and/or withdrawal symptoms (eg, hypertonia, tremor, agitation, respiratory distress) in newborns.  Reported adverse events have ranged from self-limiting to severe.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1963058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC (at baseline and then periodically thereafter), serum potassium and magnesium, lipid profile; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; waist circumference, BMI; mental status, abnormal involuntary movement scale (AIMS); periodic eye exam and evaluation of renal and liver function tests (long-term therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Based on experience with other piperidine phenothiazines: Consider baseline and periodic ECG",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Neulactil (AU, DK, FI, GB, HK, NO, NZ, ZA);",
"     </li>",
"     <li>",
"      Neuleptil (AR, AT, BG, BR, CN, GR, IL, IT, NL, PE, PT, PY, RU, UY, VE);",
"     </li>",
"     <li>",
"      Neuperil (FI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1963052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks postsynaptic mesolimbic dopaminergic receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Buckley NA, Whyte IM, and Dawson AH, \"Cardiotoxicity More Common in Thioridazine Overdose Than With Other Neuroleptics,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(3):199-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11462/abstract-text/7760442/pubmed\" id=\"7760442\" target=\"_blank\">",
"        7760442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaworowsky S and Zamir S, \"Cardiac Arrhythmia in a Child Receiving Periciazine,\"",
"      <i>",
"       Isr J Psychiatry Relat Sci",
"      </i>",
"      , 1995, 32(4):299-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11462/abstract-text/8641860/pubmed\" id=\"8641860\" target=\"_blank\">",
"        8641860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson A, Giuffre RM, and O'Malley K, \"ECG Changes in Pediatric Patients on Tricyclic Antidepressants, Desipramine, and Imipramine,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1996, 41(2):102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/12/11462/abstract-text/8705955/pubmed\" id=\"8705955\" target=\"_blank\">",
"        8705955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9470 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11462=[""].join("\n");
var outline_f11_12_11462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963008\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963010\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963056\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963055\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963057\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076334\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234150\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382967\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963011\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963018\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963013\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963014\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963044\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963047\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963058\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869456\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1963052\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9470\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9470|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/57/18325?source=related_link\">",
"      Pericyazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11463="Sarcoid arthropathy";
var content_f11_12_11463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sarcoid arthropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Winston Sequeira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Rohit Aggarwal, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11463/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/12/11463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis, a multisystem disorder of unknown etiology, is characterized pathologically by the presence of noncaseating granulomas in affected organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .) It typically affects young adults, and, although any organ may be affected, the disorder commonly presents with one or more of the following three abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral hilar adenopathy",
"     </li>",
"     <li>",
"      Pulmonary infiltrates",
"     </li>",
"     <li>",
"      Skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eye lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Musculoskeletal disease is a less common problem. However, joint manifestations may be clinically significant in patients with acute disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/1\">",
"     1",
"    </a>",
"    ]. Overall, 4 to 38 percent of patients with sarcoidosis have one or more musculoskeletal manifestations that include arthropathy, bone lesion, muscular disease, and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with sarcoidosis have an associated arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The true incidence is unclear since the diagnosis may be difficult when a patient presents with articular complaints alone; in this setting, the presence of sarcoidosis is established only after more commonly involved organs, such as the eye or lung, become affected.",
"   </p>",
"   <p>",
"    The articular manifestations of sarcoidosis and the diagnosis, differential diagnosis, and treatment of sarcoid arthropathy will be reviewed here. General issues related to sarcoidosis and its pathogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on sarcoidosis, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The muscular, skeletal, vasculitic, and other rheumatic manifestations of sarcoidosis, including discussions of diagnosis and treatment, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=see_link\">",
"     \"Sarcoid: Muscle, bone, and vascular disease manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute sarcoid arthritis may present in isolation or as part of Lofgren's syndrome. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Lofgren's syndrome'",
"    </a>",
"    below.) Among a group of patients with arthritis of less than two years&rsquo; duration, the prevalence of sarcoidosis was 4.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"     5",
"    </a>",
"    ]. The acute polyarthritis most commonly involves ankles (&gt;90 percent), often bilaterally, followed by other larger joints of lower extremity and may be mistaken for a reactive arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"     5",
"    </a>",
"    ]. The arthritis is mostly oligoarticular (87 percent), and involvement is typically symmetrical (76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"     5",
"    </a>",
"    ]. In a prospective study of 189 patients presenting with symptoms suggestive of reactive arthritis, 17 (9 percent) were eventually diagnosed with acute sarcoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/6\">",
"     6",
"    </a>",
"    ]. Ten had Lofgren's syndrome, and all 17 had bilateral ankle involvement. A prospective cohort study of patients with recent onset arthritis found that the presence of symptoms for less than two months, symmetrical ankle arthritis, and age less than 40 years had a high sensitivity (85 percent) and specificity (99 percent) for sarcoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lofgren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lofgren's syndrome is characterized by the triad of hilar adenopathy, acute polyarthritis, and erythema nodosum. Lofgren's syndrome is usually self-limiting. The erythema nodosum typically disappears in a few months, but the joint symptoms may persist up to two years. Approximately one-third of patients have a more persistent arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/7\">",
"     7",
"    </a>",
"    ]; rarely, the arthritic symptoms are recurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/7\">",
"     7",
"    </a>",
"    ]. Joint involvement in Lofgren's syndrome is similar to that in acute sarcoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/8\">",
"     8",
"    </a>",
"    ]. Hilar lymphadenopathy in these patients tends to resolve over time in up to 90 percent of patients, with only few reporting worsening of lung disease or lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"     5",
"    </a>",
"    ]. Erythema nodosum is more often seen in female compared with male patients presenting with Lofgren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/9\">",
"     9",
"    </a>",
"    ]. Reports of seasonal clusters of this syndrome suggest that an infectious or environmental agent, as yet unknown, may be pathogenetically important [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, isolated involvement of the small joints of the hands may mimic the acute onset of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Among such patients, the diagnosis of acute sarcoid arthritis is most frequently made in retrospect when other, more common features of the disease become apparent. Sarcoid arthritis can resemble rheumatic fever when the polyarthritis is migratory [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Young children presenting with both uveitis and arthritis may resemble patients with juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hilar adenopathy is uncommon in sarcoidosis in early childhood. Arthritis, however, is a prominent feature that is accompanied by uveitis and rash [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/8\">",
"     8",
"    </a>",
"    ]. When this syndrome appears in the first decade of life (usually before age four), it may represent early-onset sarcoidosis, a sporadic form of Blau syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link&amp;anchor=H9#H9\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'Blau syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients with Lofgren's syndrome have elevated ACE levels at presentation, and those with elevated ACE levels tend to have a more persistent arthritis. This presentation is associated with an increased prevalence of certain HLA-DR and DQ alleles (DQ2 and DR3) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"     \"Erythema nodosum\"",
"    </a>",
"    .) A febrile arthropathy in association with enlarged parotid glands and uveitis (eg, uveoparotid fever) is more common in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHRONIC ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different forms of chronic arthritis can occur among patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nondeforming arthritis with granulomatous synovitis",
"     </li>",
"     <li>",
"      Jaccoud's type deformity (nonerosive joint deformity)",
"     </li>",
"     <li>",
"      Joint swelling adjacent to a sarcoid bone lesion",
"     </li>",
"     <li>",
"      Dactylitis (sausage-like swelling of one or more digits)",
"     </li>",
"     <li>",
"      Acute and chronic gouty arthritis, which can be seen in association with sarcoid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients presenting with chronic arthritis are typically older than patients with acute arthritis or Lofgren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/16\">",
"     16",
"    </a>",
"    ]. The ankle, knees, hands, wrist, and metacarpophalangeal and proximal interphalangeal joints are the joints most frequently involved; rarely, the sacroiliac and temporomandibular joints may also be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/17\">",
"     17",
"    </a>",
"    ]. Presentation is usually more chronic (more than six months) and may present as oligoarticular or polyarticular involvement. Joint erosions and osseous involvement can be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of chronic arthritis is frequently associated with parenchymal pulmonary disease, and elevated serum concentrations of angiotensin converting enzyme (ACE) are found in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/18\">",
"     18",
"    </a>",
"    ]. The correlation between extremely high serum ACE levels and extrathoracic sarcoidosis, including chronic arthritis, probably reflects the high total body load of granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     JOINT EFFUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint effusions may occur among patients with sarcoidosis. One ultrasonographic study of 24 patients with acute sarcoid arthritis found that six had joint effusions of the ankle in association with tenosynovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/20\">",
"     20",
"    </a>",
"    ]. Tenosynovitis may occur in the absence of arthritis. Reported anatomic sites include the Achilles tendon and the flexor tendons of the fingers and wrist [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large joint effusions are infrequent. Synovial fluid analysis is most consistent with a mildly inflammatory effusion, which, on occasion, may be bloody [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synovial fluid in patients with arthritis is typically mildly inflammatory, with either neutrophilic or lymphocytic predominance, but may be noninflammatory in some patients with chronic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs of the hands and other joints are normal; soft tissue swelling may be identified. Ultrasonography reveals that ankle swelling may represent periarticular inflammation and not arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/27\">",
"     27",
"    </a>",
"    ]. Cystic phalangeal lesions may be present but are not well-correlated with symptoms or with arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=see_link&amp;anchor=H10#H10\">",
"     \"Sarcoid: Muscle, bone, and vascular disease manifestations\", section on 'Focal bone lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Isotope imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium-67 is concentrated within the joints with varying intensity in patients with sarcoidosis and arthritis. However, the uptake of this radioisotope does not appear to correlate with the acuteness or chronicity of the joint disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sarcoid arthropathy is based upon suggestive clinical, imaging, synovial fluid, and, in selected cases, synovial tissue biopsy. The diagnosis of sarcoidosis usually requires biopsy of the involved organ, except in case of classic Lofgren's where the diagnosis can be made based upon clinical features alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/28\">",
"     28",
"    </a>",
"    ]. In a patient with suspected Lofgren's syndrome or acute bilateral ankle arthritis, a computerized tomography (CT) scan may be helpful to identify hilar lymphadenopathy, if the chest radiograph is negative. The finding of sterile noncaseating granulomatous inflammation on synovial biopsy is supportive but is not pathognomonic of sarcoidosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Synovial biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skin testing for tuberculosis is recommended in all cases of suspected sarcoidosis. The utility of laboratory testing and of other diagnostic procedures in patients suspected of having sarcoidosis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Synovial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the characteristics of synovial tissue in acute or chronic sarcoid arthritis. Synovial cysts with typical noncaseating granulomas have been observed on arthroscopically obtained synovial biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]; however, closed synovial membrane needle biopsies are not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/31\">",
"     31",
"    </a>",
"    ]. The increasing use of needle arthroscopes which permit the performance of a synovial biopsy under direct vision may eventually provide additional useful information.",
"   </p>",
"   <p>",
"    When indicated for diagnostic purposes, several samples of synovial tissue obtained by arthroscopically directed biopsy may be submitted for the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fresh (unfixed) tissue for microbiologic studies, including mycobacterial and fungal stains and cultures",
"     </li>",
"     <li>",
"      Absolute alcohol fixed tissue for processing with water-free stains (eg, Wright-Geimsa) and examination under polarizing microscopy to exclude urate or calcium pyrophosphate dihydrate (CPPD) tophi",
"     </li>",
"     <li>",
"      Formalin fixed tissue for routine light microscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of sarcoid arthropathy includes infectious mimics of pulmonary sarcoidosis that sometimes have associated joint manifestations, particularly those due to Mycobacterium tuberculosis and Histoplasma capsulatum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the presence of typical pulmonary or other nonpulmonary features of sarcoidosis, a synovial biopsy that reveals multiple noncaseating granulomas offers additional support for the diagnosis, as noted above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Synovial biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of granulomatous synovitis is beyond the scope of this discussion. The following disorders are among the many causes of granuloma formation in the synovium, other than sarcoidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heritable &mdash; Blau syndrome",
"     </li>",
"     <li>",
"      Mycobacterial infection",
"     </li>",
"     <li>",
"      Fungal infection &mdash; eg, histo, sporotrichosis, etc.",
"     </li>",
"     <li>",
"      Foreign body &mdash; eg, plant thorn, suture, sea urchin",
"     </li>",
"     <li>",
"      Tophi &mdash; eg, urate, CPPD",
"     </li>",
"     <li>",
"      Other idiopathic granulomatous disorders &mdash; eg, Crohn's disease, granulomatosis with polyangiitis (Wegener&rsquo;s), lymphomatoid granulomatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no well-designed randomized and controlled studies of treatment of sarcoid arthropathy. Treatment suggestions are based on case reports and small uncontrolled and unblinded series with selected interventions.",
"   </p>",
"   <p>",
"    Since the acute arthritis is usually self-limiting, most patients are initially treated with nonsteroidal antiinflammatory drugs (NSAIDs) alone. If NSAIDs are contraindicated or ineffective after a two-week course at antiinflammatory doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    800 mg three or four times daily), then other agents that have been reported to be effective may be used. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      (0.6 mg two or three times a day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      (200 to",
"      <span class=\"nowrap\">",
"       400mg/day;",
"      </span>",
"      maximum of 6.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      Glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      10 to 15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who do not respond to the above therapy or in whom the doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be unacceptable,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    administered in doses of 10 to 15 mg per week may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor necrosis factor alpha (TNF alpha) is important in granuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/35\">",
"     35",
"    </a>",
"    ], and use of inhibitors of TNF alpha to treat articular sarcoid is plausible. There are emerging data regarding the use of anti-TNF agents in pulmonary sarcoidosis that are summarized elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link&amp;anchor=H26465141#H26465141\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\", section on 'Tumor necrosis factor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is not useful in the treatment of sarcoid pulmonary [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/36\">",
"     36",
"    </a>",
"    ] or eye disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    appeared to be effective in the treatment of some patients with resistant sarcoidosis in two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although several case reports showed benefit from anti-TNF therapy for treatment-resistant sarcoid arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], relapse has been observed with discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. This phenomenon has been observed with other granulomatous diseases. There have been no randomized trials with any of the available anti-TNF agents for sarcoid arthropathy, nor has there been any head-to-head comparison between the different agents.",
"   </p>",
"   <p>",
"    There are a few case reports of benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in chronic sarcoid arthropathy that was not responsive to conventional treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, given the lack of benefit for this agent in randomized trials in pulmonary sarcoidosis, we discourage its use in sarcoid arthropathy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    , in contrast, was shown to be effective for sarcoid arthropathy in both case reports and in one randomized trial, which evaluated extrapulmonary manifestation as a secondary outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/41,42,44\">",
"     41,42,44",
"    </a>",
"    ]. There have been no reports regarding the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , another anti-TNF agent, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which depletes B cells, in sarcoid arthropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Paradoxical effect of anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the possible benefit of anti-TNF agents in some patients with pulmonary or extrapulmonary sarcoidosis, the apparently paradoxical development of granulomatous pulmonary disease consistent with sarcoidosis has been reported as a rare complication of treatment with these agents for other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/45\">",
"     45",
"    </a>",
"    ]. In most patients, there was resolution of both the symptoms and the radiographic findings following withdrawal of the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H24#H24\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synovectomy may be indicated in more resistant cases. Since the diffuse synovitis observed in sarcoidosis does not appear to cause surface cartilage erosions, arthroscopic synovectomy is usually straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11463/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-quarter of patients with sarcoidosis have an associated arthropathy.",
"     </li>",
"     <li>",
"      Acute arthritis often involves the joints of the lower extremities, it may be accompanied by hilar adenopathy and erythema nodosum (Lofgren's syndrome), and it usually resolves spontaneously, although it may persist in one-third of affected patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic arthritis is frequently associated with parenchymal lung disease and other extrapulmonary manifestations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of sarcoid arthritis is based on the presence of compatible clinical features, imaging findings (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiography'",
"      </a>",
"      above), and a negative skin test for tuberculosis. An inflammatory but sterile joint aspirate (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Synovial biopsy'",
"      </a>",
"      above) is supportive.",
"     </li>",
"     <li>",
"      Synovial biopsy is sometime necessary, principally to exclude other causes of arthritis, particularly infectious diseases such as tuberculosis and histoplasmosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.) However, biopsy is not necessary in the presence of typical features of Lofgren's syndrome, unless there is a strong suspicion of an infectious etiology.",
"     </li>",
"     <li>",
"      If a synovial biopsy is performed, we recommend sending fresh, alcohol-fixed, and formalin-preserved samples for appropriate microbiologic and histologic studies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Synovial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with significant joint pain or functional impairment who have no contraindications to the use of nonsteroidal antiinflammatory drugs (NSAIDs), we suggest an antiinflammatory dose of an NSAID (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      800 mg four times daily, or equivalent NSAID) for symptomatic relief (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who do not have acceptable symptomatic relief despite regular use of antiinflammatory doses of an NSAID for two weeks, we suggest adding one of the following agents to continued NSAID therapy:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (0.6 mg two or three times daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (200 to",
"      <span class=\"nowrap\">",
"       400mg/day;",
"      </span>",
"      maximum of 6.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), or a moderate daily dose of a glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      10 to 15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients whose arthritis is refractory to the treatments above, who require high doses of glucocorticoids, or who cannot be successfully weaned from glucocorticoids, we suggest the use of weekly low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (eg, 10 to 15 mg once a week) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients for whom all of the treatments listed above are ineffective, are not tolerated, or are contraindicated, we suggest use of an anti-tumor necrosis factor alpha (anti-TNF) agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      and possibly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      will be the agents of choice. The soluble TNF alpha antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      does not appear to be effective.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/1\">",
"      Spilberg I, Siltzbach LE, McEwen C. The arthritis of sarcoidosis. Arthritis Rheum 1969; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/2\">",
"      Abril A, Cohen MD. Rheumatologic manifestations of sarcoidosis. Curr Opin Rheumatol 2004; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/3\">",
"      GENDEL BR, YOUNG JM, GREINER DJ. Sarcoidosis; a review with twenty-four additional cases. Am J Med 1952; 12:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/4\">",
"      Siltzbach LE, Duberstein JL. Arthritis in sarcoidosis. Clin Orthop Relat Res 1968; 57:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/5\">",
"      Visser H, Vos K, Zanelli E, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis 2002; 61:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/6\">",
"      Glenn&aring;s A, Kvien TK, Melby K, et al. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol 1995; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/7\">",
"      Johard U, Eklund A. Recurrent L&ouml;fgren's syndrome in three patients with sarcoidosis. Sarcoidosis 1993; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/8\">",
"      Ma&ntilde;&aacute; J, G&oacute;mez-Vaquero C, Montero A, et al. L&ouml;fgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/9\">",
"      Grunewald J, Eklund A. Sex-specific manifestations of L&ouml;fgren's syndrome. Am J Respir Crit Care Med 2007; 175:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/10\">",
"      Kaufman LD. Lofgren's syndrome (acute sarcoidosis) sine erythema nodosum mimicking acute rheumatoid arthritis. N Y State J Med 1990; 90:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/11\">",
"      Pennec Y, Youinou P, Le Goff P, et al. Comparison of the manifestations of acute sarcoid arthritis with and without erythema nodosum. Immunopathogenic significance. Scand J Rheumatol 1982; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/12\">",
"      Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila) 1998; 37:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/13\">",
"      Kremer JM. Histologic findings in siblings with acute sarcoid arthritis: association with the B8,DR3 phenotype. J Rheumatol 1986; 13:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/14\">",
"      Sukenik S, Hendler N, Yerushalmi B, et al. Jaccoud's-type arthropathy: an association with sarcoidosis. J Rheumatol 1991; 18:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/15\">",
"      Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/16\">",
"      Thelier N, Assous N, Job-Deslandre C, et al. Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments. J Rheumatol 2008; 35:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/17\">",
"      Griep EN, van Spiegel PI, van Soesbergen RM. Sarcoidosis accompanied by pulmonary tuberculosis and complicated by sacroiliitis. Arthritis Rheum 1993; 36:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/18\">",
"      Sequeira W, Stinar D. Serum angiotensin-converting enzyme levels in sarcoid arthritis. Arch Intern Med 1986; 146:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/19\">",
"      Muthuswamy PP, Lopez-Majano V, Ranginwala M, Trainor WD. Serum angiotensin-converting enzyme (SACE) activity as an indicator of total body granuloma load and prognosis in sarcoidosis. Sarcoidosis 1987; 4:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/20\">",
"      Kellner H, Sp&auml;thling S, Herzer P. Ultrasound findings in L&ouml;fgren's syndrome: is ankle swelling caused by arthritis, tenosynovitis or periarthritis? J Rheumatol 1992; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/21\">",
"      Crowder SW, Jaffey LH. Sarcoidosis presenting as Achilles tendinitis. J R Soc Med 1995; 88:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/22\">",
"      Larsen TK. Tenosynovitis as initial diagnosis of sarcoidosis. Case report. Scand J Plast Reconstr Surg Hand Surg 1996; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/23\">",
"      Katzman BM, Caligiuri DA, Klein DM, et al. Sarcoid flexor tenosynovitis of the wrist: a case report. J Hand Surg Am 1997; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/24\">",
"      Varkey B. Letter: Synovial fluid in sarcoid arthritis. Ann Intern Med 1974; 81:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/25\">",
"      Palmer DG, Schumacher HR. Synovitis with non-specific histological changes in synovium in chronic sarcoidosis. Ann Rheum Dis 1984; 43:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/26\">",
"      Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol 2003; 17:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/27\">",
"      Burman MS, Mayer L. Arthroscopic examination of the knee joint. Arch Surg 1936; 32:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/28\">",
"      Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/29\">",
"      Isdale AH, Iveson JM. Synovial cysts and sarcoid synovitis. Br J Rheumatol 1992; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/30\">",
"      Scott DG, Porto LO, Lovell CR, Thomas GO. Chronic sarcoid synovitis in the Caucasian: an arthroscopic and histological study. Ann Rheum Dis 1981; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/31\">",
"      Pettersson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol 1998; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/32\">",
"      KAPLAN H. SARCOID ARTHRITIS. A REVIEW. Arch Intern Med 1963; 112:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/33\">",
"      Fitzgerald AA, Davis P. Arthritis, hilar adenopathy, erythema nodosum complex. J Rheumatol 1982; 9:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/34\">",
"      Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/35\">",
"      Moller DR. Treatment of sarcoidosis -- from a basic science point of view. J Intern Med 2003; 253:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/36\">",
"      Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/37\">",
"      Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/38\">",
"      Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/39\">",
"      Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/40\">",
"      Ulbricht KU, Stoll M, Bierwirth J, et al. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003; 48:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/41\">",
"      Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/42\">",
"      Hobbs K. Chronic sarcoid arthritis treated with intraarticular etanercept. Arthritis Rheum 2005; 52:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/43\">",
"      Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/44\">",
"      Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/45\">",
"      Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new \"class effect\" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010; 39:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11463/abstract/46\">",
"      Limbird TJ. Arthroscopic synovectomy in sarcoid synovitis. Arthroscopy 1993; 9:599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5583 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11463=[""].join("\n");
var outline_f11_12_11463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lofgren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHRONIC ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      JOINT EFFUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Isotope imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Synovial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Paradoxical effect of anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=related_link\">",
"      Sarcoid: Muscle, bone, and vascular disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11464="Evaluation of the diabetic foot";
var content_f11_12_11464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the diabetic foot",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11464/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11464/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11464/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11464/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/12/11464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot problems are an important cause of morbidity in patients with diabetes mellitus. The lifetime risk of a foot ulcer for diabetic patients (type 1 or 2) may be as high as 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/1\">",
"     1",
"    </a>",
"    ]. A potentially preventable initiating event, most often minor trauma that causes cutaneous injury, can often be identified. Foot amputations, many of which are preventable with early recognition and therapy, may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/2\">",
"     2",
"    </a>",
"    ]. These observations illustrate the importance of frequent evaluation of the feet in patients with diabetes to identify those at risk for foot ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/3\">",
"     3",
"    </a>",
"    ]. Systematic screening examinations for neuropathic and vascular involvement of the lower extremities and careful inspection of feet may substantially reduce morbidity from foot problems.",
"   </p>",
"   <p>",
"    Evaluation of the diabetic foot is provided here. A discussion of diabetes-related foot infections (cellulitis and osteomyelitis) and the management of diabetic foot ulcers are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors are predictive of ulcers and amputation. Early recognition and management of risk factors is important for reducing morbidity of foot ulceration. Most risk factors are readily identifiable from the history or physical examination. The most important are previous foot ulceration, neuropathy (loss of protective sensation), foot deformity, and vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The significance of these risk factors was confirmed by the results of a community-based study of 1300 type 2 diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of lower extremity amputation was 3.8 per 1000 patient-years. Predictors of amputation were foot ulceration (HR 5.6, 95% CI 1.2-25), ankle brachial index &lt;0.9, elevated A1C, and neuropathy.",
"   </p>",
"   <p>",
"    Neuropathy is present in over 80 percent of patients with foot ulcers; it promotes ulcer formation by decreasing pain sensation and perception of pressure, by causing muscle imbalance that can lead to anatomic deformities, and by impairing the microcirculation and the integrity of the skin. Once ulcers form, healing may be delayed or difficult to achieve, particularly if infection penetrates to deep tissues and bone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is diminished local blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several risk classification systems designed to predict foot ulcer in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Risk categorization can be used to design preventive and monitoring strategies (",
"    <a class=\"graphic graphic_table graphicRef70817 \" href=\"UTD.htm?8/14/8428\">",
"     table 1",
"    </a>",
"    ). One system, developed by the International Working Group on the Diabetic Foot, stratifies patients as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group 0 - no evidence of neuropathy",
"     </li>",
"     <li>",
"      Group 1 - neuropathy present but no evidence of foot deformity or peripheral vascular disease",
"     </li>",
"     <li>",
"      Group 2 - neuropathy with evidence of deformity or peripheral vascular disease",
"     </li>",
"     <li>",
"      Group 3 - history of foot ulceration or lower extremity amputation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective case-control study of 225 patients with diabetes, stratification using this classification system was predictive of incident ulceration and amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/8\">",
"     8",
"    </a>",
"    ]. During 30 months (mean) of follow-up, ulcers occurred in 5, 14, 13, and 65 percent of patients in groups 0, 1, 2, and 3, respectively. Only patients in groups 2 and 3 had amputations (2 and 26 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abbreviated history combined with physical examination can usually establish the presence and severity of diabetic neuropathy and peripheral artery disease, two of the most important risk factors for developing foot ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historical facts to ascertain include duration of diabetes, glycemic control, presence of micro- or macrovascular disease, history of prior foot ulcers, lower limb bypasses or amputation, presence of claudication, and history of cigarette smoking. Two cohort studies have demonstrated an increased risk of foot ulcers in those with a longer history of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This may be related to the finding that the risk of peripheral artery disease appears to increase with the duration of type 2 diabetes. As an example, in an observational study of 48,607 men, the relative risk of peripheral artery disease in patients with type 2 diabetes compared with nondiabetics was 1.4 and 4.5 for one to five years and &gt;25 years of diabetes, respectively, even after controlling for other cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/11\">",
"     11",
"    </a>",
"    ]. Peripheral neuropathy also increases with longer diabetes duration.",
"   </p>",
"   <p>",
"    The patient should be questioned about leg discomfort. If present, further questions should be asked that allow a quantitative assessment of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the sensation felt? &mdash; Burning, numbness, or tingling (2 points); fatigue, cramping, or aching (1 point). Maximum is 2 points.",
"     </li>",
"     <li>",
"      What is the location of symptoms? &mdash; Feet (2 points); calves (1 point); elsewhere (no points). Maximum is 2 points.",
"     </li>",
"     <li>",
"      Have the symptoms ever awoken you at night? &mdash; Yes (1 point).",
"     </li>",
"     <li>",
"      What is the timing of symptoms? &mdash; Worse at night (2 points); present day and night (1 point); present only during the day (no points). Maximum is 2 points.",
"     </li>",
"     <li>",
"      How are symptoms relieved? &mdash; Walking around (2 points); standing (1 point); sitting or lying or no relief (no points). Maximum is 2 points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total symptom score can then be determined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 2 &mdash; Normal",
"     </li>",
"     <li>",
"      3 to 4 &mdash; Mild",
"     </li>",
"     <li>",
"      5 to 6 &mdash; Moderate",
"     </li>",
"     <li>",
"      7 to 9 &mdash; Severe",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include an assessment for the presence of existing ulcers, peripheral neuropathy (loss of protective sensation [LOPS]), peripheral artery disease, and foot deformities that may predispose the patient to the development of foot ulcers (",
"    <a class=\"graphic graphic_table graphicRef59069 \" href=\"UTD.htm?5/61/6108\">",
"     table 2",
"    </a>",
"    ). Several reports indicate that adequate examinations relevant to foot ulceration are often not performed in diabetic patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When 1434 clinicians in the United States were surveyed about how closely they were adhering to the nationally promoted and American Diabetes Association endorsed recommendations for routine care, only 50 percent did semiannual neurologic and foot examinations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a major California HMO that provides care for 14,539 diabetic patients, only 6 percent had a documented foot examination within the previous year [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical signs of neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy is present in over 80 percent of patients with foot ulcers; it promotes ulcer formation by decreasing pain sensation and perception of pressure by causing muscle imbalance that can lead to anatomic deformities, and by impairing the microcirculation and the integrity of the skin.",
"   </p>",
"   <p>",
"    The physical examination may reveal several abnormalities that result from diabetic neuropathy, such as claw toes and Charcot arthropathy (also called diabetic neuropathic arthropathy). Chronic motor neuropathy often affects the small intrinsic muscles of the feet so that the action of the larger muscles in the anterior tibial compartment is unopposed. This leads to subluxation of the proximal interphalangeal-metatarsal joints, resulting in a claw toe appearance. One consequence of this abnormality is increased pressure on the metatarsal heads, which are a common site of ulcer development (",
"    <a class=\"graphic graphic_picture graphicRef51991 \" href=\"UTD.htm?36/47/37631\">",
"     picture 3B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A later complication is Charcot arthropathy, which is characterized by collapse of the arch of the midfoot and abnormal bony prominences (",
"    <a class=\"graphic graphic_picture graphicRef67753 \" href=\"UTD.htm?26/18/26927\">",
"     picture 1",
"    </a>",
"    ). These changes are induced by the triad of small muscle wasting, decreased sensation, and abnormal distribution of weight when standing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The associated autonomic neuropathy can lead to several additional problems. Sweating is diminished or absent; as a result, the skin of the feet remains dry and has a tendency to become scaly and cracked, thereby allowing infection to penetrate below the skin. Lack of autonomic tone in the capillary circulation causes shunting of blood from arteries directly into veins, bypassing the tissues that need nutrition. This results in a foot that feels warm and has distended veins and bounding pulses. Despite these apparent signs of adequate perfusion, the foot is vulnerable to local \"microvascular\" gangrene, will heal very poorly and slowly, and will be less able to resist infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening tests for peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, peripheral neuropathy is most frequently assessed by determination of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vibration sensation",
"     </li>",
"     <li>",
"      Pressure sensation (monofilament)",
"     </li>",
"     <li>",
"      Superficial pain (pinprick) or temperature sensation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tests are designed to identify loss of protective sensation (LOPS), an important risk factor for ulcer formation. Screening with simple vibration testing, a monofilament examination, or superficial pain sensation appear to have a similar sensitivity and specificity for predicting diabetic neuropathy and therefore risk of foot ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/15\">",
"     15",
"    </a>",
"    ]. One study found that failure to detect pressure from monofilament at any of 12 places on the foot (",
"    <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"     figure 1",
"    </a>",
"    ) was the single most practical measurement of risk assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vibration sensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibration testing is typically conducted with a 128-Hz tuning fork applied to the bony prominence at the dorsum of the first toe, just proximal to the nail bed. The quickest method of testing is to ask the patient to report the perception of both the start of vibration sensation and the cessation of vibration on dampening. The test should be conducted twice on each great toe. The sensitivity and specificity of vibration testing for peripheral neuropathy have been estimated to be 53 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vibration sense can also be estimated quantitatively with a Biothesiometer (Bio-Medical Instrument Company). This device is essentially an electronic tuning fork that allows the vibration to be adjusted up or down depending upon the voltage applied. The vibration-perception threshold (VPT) is defined as the lowest voltage at which vibration can be sensed on the pulp of the big toe. The value in normal subjects increases with age from approximately 6 volts at age 30 years to 20 volts at age 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective trial of 469 diabetic patients with no history of foot ulceration, the VPT was found to be an excellent predictor of future foot ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/18\">",
"     18",
"    </a>",
"    ]. Less than 4 percent of patients with a VPT below 25 volts developed new ulcers versus almost 20 percent of those with a VPT above 25 volts. Furthermore, there was an excellent correlation between the VPT and the severity of findings on physical examination. A simpler alternative to the Biothesiometer is the graduated tuning fork, which can also provide a quantitative estimate of vibration sense [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pressure sensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another simple device, the monofilament pressure esthesiometer, permits quantitative assessment of the cutaneous pressure perception threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/3\">",
"     3",
"    </a>",
"    ]. The 5.07 (10-g) monofilament is placed at a right angle to the skin on the plantar surface of the foot; pressure is then increased until the filament buckles, indicating that a known amount of pressure has been applied (",
"    <a class=\"graphic graphic_picture graphicRef68612 \" href=\"UTD.htm?32/50/33583\">",
"     picture 2",
"    </a>",
"    ). The patient is asked if he or she felt the pressure induced by the monofilament.",
"   </p>",
"   <p>",
"    In a cross-sectional study of 314 diabetic patients, those with foot ulcers had a higher pressure threshold than those without ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/20\">",
"     20",
"    </a>",
"    ]. A cutaneous pressure threshold of 4.21 U or above had a sensitivity of 84 percent, a specificity of 96 percent, and a positive predictive value of 76 percent for foot ulceration. Prospective studies have shown that insensitivity to this monofilament correlates with an increased likelihood for developing plantar ulceration or lower extremity amputation in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/9,21,22\">",
"     9,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pain and temperature sense",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either pain or temperature sense can be tested; it is not necessary to evaluate both. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H74#H74\">",
"     \"The detailed neurologic examination in adults\", section on 'Pain/temperature'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical signs of peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feet should be examined for signs of peripheral artery disease such as absence of foot pulses, decrease in skin temperature, thin skin, lack of skin hair, and bluish skin color. However, these signs are neither sensitive nor specific enough to be helpful in an individual patient. More useful tests are examination of lower limb pulses and measurement of venous filling time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The absence of pedal pulses, the presence of femoral bruits, or prolongation of venous filling should prompt referral for more detailed evaluation.",
"   </p>",
"   <p>",
"    The venous filling time can be determined by identifying a prominent pedal vein with the patient in a supine position. The leg is then elevated to 45&ordm; for one minute, leading to collapse of the vein. The patient then sits up and hangs the leg over the examination table; important arterial disease is probably present if more than 20 seconds elapse before the vein bulges above the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with clinical evidence of peripheral vascular disease should have ankle-brachial pressure index (ABI) testing. This index is calculated by measuring the systolic blood pressure (by Doppler probe) in the brachial, posterior tibial, and dorsalis pedis arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/1\">",
"     1",
"    </a>",
"    ]. The highest of the four measurements in the ankles and feet is divided by the higher of the two brachial measurements. The normal index is &gt;1.0, because the pressure is higher in the ankle than in the arm. An index &lt;0.9 has 95 percent sensitivity for detecting angiogram-positive peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/25\">",
"     25",
"    </a>",
"    ]. We typically refer patients with an abnormal ABI to a vascular specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low index in the absence of a foot ulcer does not correlate with the risk of future foot ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/16\">",
"     16",
"    </a>",
"    ]; however, a low index in the presence of a foot ulcer suggests that the prognosis will be improved with reconstructive vascular surgery. In one series of patients with neuropathic foot ulcers and severe arterial insufficiency, for example, 35 of 42 extremities (83 percent) with patent bypass grafts achieved and maintained primary healing of their ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/26\">",
"     26",
"    </a>",
"    ]. A low ankle-to-brachial index also indicates more generalized arteriosclerosis and is associated with an increased risk of cardiovascular death [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Foot ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot ulcers are usually classified into two groups: acute ulcers secondary to dermal abrasion from poorly fitting shoes and chronic plantar ulcers occurring over weight-bearing areas. Chronic ulceration is probably multifactorial, due to a combination of diabetic neuropathy (with decreased pain sensation), autonomic dysfunction, and vascular insufficiency.",
"   </p>",
"   <p>",
"    Findings that may herald a developing foot ulcer include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lesions between adjacent toes due to pressure from tight shoes cramming them together",
"     </li>",
"     <li>",
"      Macerated areas between the toes (\"athlete's foot\"); these lesions are often painless and may go unnoticed until bacterial infection supervenes",
"     </li>",
"     <li>",
"      Bunions (callused areas)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Wound evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of an existing diabetic foot ulcer includes careful examination and classification of the wound. The ulcer is observed for drainage, odor, the presence (or absence) of granulation tissue, and any exposed underlying structures, such as tendons, joint capsule, or bone. The wound can be probed gently by an experienced clinician or a surgeon with a sterile, blunt probe to reveal the presence of a sinus track or communication with deeper structures, which may change the wound classification. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Wound classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Signs of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a diabetic foot infection is usually presumed if these conditions are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least two of the following: erythema, warmth, tenderness, or swelling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pus coming out of an ulcer site",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a nearby sinus tract",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osteomyelitis is likely to be present if bone can be seen at the floor of a deep ulcer, or if it can be easily detected by probing the ulcer with a sterile, blunt, stainless steel probe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/27\">",
"     27",
"    </a>",
"    ]. Other signs that suggest osteomyelitis are an ulcer size larger than 2 x 2 cm and an otherwise unexplained elevation in the erythrocyte sedimentation rate.",
"   </p>",
"   <p>",
"    A discussion of diabetes-related foot infections (infected ulcer, cellulitis, and osteomyelitis) is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs can detect structural foot deformities, soft tissue gas, foreign bodies, and may be able to detect osteomyelitis. However, radiologic changes occur late in the course of osteomyelitis and negative radiographs do not exclude it. Other imaging techniques that have been used include radionuclide bone imaging, magnetic resonance imaging, and imaging with indium-labeled leukocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\", section on 'Diagnosis of underlying osteomyelitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Wound classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic foot ulcers can be graded according to a scheme, such as that proposed by Wagner (",
"    <a class=\"graphic graphic_picture graphicRef70998 graphicRef51991 graphicRef63780 \" href=\"UTD.htm?39/41/40599\">",
"     picture 3A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; No ulcer in a high risk foot",
"     </li>",
"     <li>",
"      Grade 1 &mdash; Superficial ulcer involving the full skin thickness but not underlying tissues",
"     </li>",
"     <li>",
"      Grade 2 &mdash; Deep ulcer, penetrating down to ligaments and muscle, but no bone involvement or abscess formation",
"     </li>",
"     <li>",
"      Grade 3 &mdash; Deep ulcer with cellulitis or abscess formation, often with osteomyelitis",
"     </li>",
"     <li>",
"      Grade 4 &mdash; Localized gangrene",
"     </li>",
"     <li>",
"      Grade 5 &mdash; Extensive gangrene involving the whole foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Wound classification is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of diabetic foot lesions\", section on 'Wound classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SCREENING FOR RISK OF FOOT ULCERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 16 case-control or cohort studies found that the following diagnostic screening tests reliably identified those at risk for foot ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peak plantar pressure (requires special equipment to identify specific areas of high pressure under the foot)",
"     </li>",
"     <li>",
"      Vibration perception with a tuning fork or biothesiometer",
"     </li>",
"     <li>",
"      Cutaneous sensation with monofilament",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination findings of absent ankle reflexes and limited joint motion at both the first metatarsal-phalangeal joint and the subtalar joint also increased the risk of future foot ulcers, as did a patient history of previous amputation, ulceration or lower limb bypass procedures. Other physical examination findings, such as absence of pedal pulses and ankle brachial indices, were less reliable predictors of foot ulcers.",
"   </p>",
"   <p>",
"    In another report, conventional clinical examination had low reproducibility compared with examination using a monofilament, and the latter was recommended for screening diabetic patients for neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that all patients with diabetes be screened annually to identify those at risk for foot ulceration. We perform a history, physical examination of the foot (",
"    <a class=\"graphic graphic_table graphicRef59069 \" href=\"UTD.htm?5/61/6108\">",
"     table 2",
"    </a>",
"    ), and use a 5.07 U monofilament (",
"    <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"     figure 1",
"    </a>",
"    ) for screening purposes. As an alternative or in addition to a monofilament, vibration testing (128-Hz tuning fork or biothesiometer), ankle reflex assessment, or tests of pinprick sensation can be used to identify loss of protective sensation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Screening tests for peripheral neuropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Preventive foot care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In conjunction with screening, counseling regarding preventive foot care should be given to any patient whose feet are at risk. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"     \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"    </a>",
"    .) There are a series of recommendations that can markedly diminish ulcer formation; they are particularly important in patients with existing neuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid smoking, walking barefoot, the use of heating pads or hot water bottles, and stepping into a bath without checking the temperature.",
"     </li>",
"     <li>",
"      The toenails should be trimmed to the shape of the toe and filed to remove sharp edges.",
"     </li>",
"     <li>",
"      The feet should be inspected daily, looking between and underneath the toes and at pressure areas for skin breaks, blisters, swelling, or redness. The patient may need to use a mirror or, if vision is impaired, have someone else perform the examination.",
"     </li>",
"     <li>",
"      The patient's shoes should fit properly and not be too tight, and the socks should be cotton, loose fitting, and changed every day. Patients who have misshapen feet or have had a previous foot ulcer may benefit from the use of special customized shoes. A prospective study found that shoe variables other than the recommendation for customized shoes (eg, style, width, length, or type of shoe) had no preventive effect [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/31\">",
"       31",
"      </a>",
"      ]. The use of customized shoes, however, reduced the development of new foot ulcers from 58 to 28 percent over one year of follow-up in a second report [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/32\">",
"       32",
"      </a>",
"      ]. In a third review, the use of a viscoelastic insole in conjunction with well-fitting shoes (whether customized, standard \"comfort\" or athletic shoes) was associated with a decrease in plantar pressure; whether this results in a reduced incidence of foot ulcers remains to be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The feet should be washed daily in lukewarm water. Mild soap should be used and the feet should be dried by gentle patting. A moisturizing cream or lotion should then be applied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A particularly effective strategy is to make specific recommendations to the patient in the form of a \"contract\" and to advise the patient to request that his or her feet be examined at every visit to the doctor or nurse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the foot care measures described above, preliminary data suggest that home temperature monitoring may be effective in preventing foot ulceration in very high risk patients (for example, those with severe neuropathy and a history of prior amputations or ulcers) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Temperature monitoring involves daily or twice daily measurements of skin surface temperature with a thermometer equipped with a touch sensor. If a temperature difference (elevation) is detected between a right and left foot site (",
"    <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"     figure 1",
"    </a>",
"    ), patients are instructed to reduce activity until the temperature normalizes. Whether the benefit of monitoring temperature is specifically related to the monitoring, or the heightened attention to foot care in those performing the monitoring, is not clear. Additional efficacy and feasibility studies are required before home temperature monitoring can be recommended to reduce the risk of foot ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;We largely agree with the guidelines from the American Diabetes Association (ADA), which recommend the following with regard to foot care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11464/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a comprehensive foot examination annually on patients with diabetes to identify risk factors predictive of ulcers and amputation. Perform a visual inspection of the feet at each routine visit.",
"     </li>",
"     <li>",
"      The comprehensive foot examination can be accomplished in the primary care setting and should include inspection of the skin for integrity, especially between the toes and under the metatarsal heads. The presence of erythema, warmth, or callus formation may indicate areas of tissue damage. Bony deformities, joint mobility, and gait and balance should also be assessed.",
"     </li>",
"     <li>",
"      Test for loss of protective sensation using a Semmes-Weinstein 5.07 (10-g) monofilament at specific sites to detect loss of sensation in the foot (",
"      <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"       figure 1",
"      </a>",
"      ), plus any one of the following: vibration using a 128-Hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold with a biothesiometer.",
"     </li>",
"     <li>",
"      Screen for peripheral artery disease by asking about a history of claudication and assessing the pedal pulses. Obtain an ankle brachial index in patients over 50 years of age and consider measurement in younger patients with multiple risk factors for peripheral artery diseases, as many patients with peripheral artery disease are asymptomatic. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical signs of peripheral artery disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"       \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advice for prophylactic foot care should be given to all patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Preventive foot care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"       \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Refer high risk patients (eg, those with any positive findings from the comprehensive examination) to a foot care specialist. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"       \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot ulcers are an important cause of morbidity in patients with diabetes. Both vascular and neurologic disease increase the risk of foot ulcers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that all patients with diabetes be screened annually to identify those at risk for foot ulceration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We perform a history, comprehensive foot examination, and test for loss of protective sensation using a Semmes-Weinstein 5.07 (10-g) monofilament for screening purposes (",
"      <a class=\"graphic graphic_figure graphicRef52481 \" href=\"UTD.htm?33/55/34687\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef59069 \" href=\"UTD.htm?5/61/6108\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Screening for risk of foot ulceration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We perform ankle-brachial pressure index (ABI) testing in any patient with symptoms or physical exam findings of peripheral artery disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical signs of peripheral artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling regarding preventive foot care should be given to any patient whose feet are at risk for ulceration. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Preventive foot care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     High risk for future ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;We refer patients to a foot care specialist if they are at particularly high risk for foot ulceration due to the following risk factors (",
"    <a class=\"graphic graphic_table graphicRef70817 \" href=\"UTD.htm?8/14/8428\">",
"     table 1",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk classification'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A previous history of foot ulceration or amputation",
"     </li>",
"     <li>",
"      Loss of protective sensation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neuropathic foot deformities",
"     </li>",
"     <li>",
"      Peripheral vascular disease",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/1\">",
"      Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/2\">",
"      Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990; 13:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/3\">",
"      Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/4\">",
"      Cheer K, Shearman C, Jude EB. Managing complications of the diabetic foot. BMJ 2009; 339:b4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/5\">",
"      Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2006; 49:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/6\">",
"      Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/7\">",
"      Apelqvist J, Bakker K, van Houtum WH, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000; 16 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/8\">",
"      Peters EJ, Lavery LA, International Working Group on the Diabetic FOot. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 2001; 24:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/9\">",
"      Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/10\">",
"      Boyko EJ, Ahroni JH, Stensel V, et al. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 1999; 22:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/11\">",
"      Al-Delaimy WK, Merchant AT, Rimm EB, et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004; 116:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/12\">",
"      Young MJ, Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/13\">",
"      Kenny SJ, Smith PJ, Goldschmid MG, et al. Survey of physician practice behaviors related to diabetes mellitus in the U.S. Physician adherence to consensus recommendations. Diabetes Care 1993; 16:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/14\">",
"      Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients. A health maintenance organization experience. Diabetes Care 1996; 19:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/15\">",
"      Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/16\">",
"      McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995; 18:216.",
"     </a>",
"    </li>",
"    <li>",
"     Boulton AJ. The diabetic foot. In: Diabetes: Clinical management, Tattersall R, Gale EAM (Eds), Churchill Livingstone, Edinburgh 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/18\">",
"      Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/19\">",
"      Liniger C, Albeanu A, Bloise D, Assal JP. The tuning fork revisited. Diabet Med 1990; 7:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/20\">",
"      Sosenko JM, Kato M, Soto R, Bild DE. Comparison of quantitative sensory-threshold measures for their association with foot ulceration in diabetic patients. Diabetes Care 1990; 13:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/21\">",
"      Mayfield JA, Sugarman JR. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract 2000; 49:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/22\">",
"      Boyko EJ, Ahroni JH, Cohen V, et al. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006; 29:1202.",
"     </a>",
"    </li>",
"    <li>",
"     Ganda OP. Pathogenesis of accelerated atherosclerosis in diabetes. In: Management of diabetic foot problems, Kozak GP, Hoar CS (Eds), Saunders, Philadelphia 1984. p.17.",
"    </li>",
"    <li>",
"     Sammarco GJ. Examination of the foot and ankle. In: The foot in diabetes, Lea &amp; Febiger, Philadelphia 1991. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/25\">",
"      Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988; 17:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/26\">",
"      Rosenblum BI, Pomposelli FB Jr, Giurini JM, et al. Maximizing foot salvage by a combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. A 5-year experience. Diabetes Care 1994; 17:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/27\">",
"      Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273:721.",
"     </a>",
"    </li>",
"    <li>",
"     O'Neal, LW, Wagner, FW. The Diabetic Foot, Mosby, St Louis 1983. p.274.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/29\">",
"      Crawford F, Inkster M, Kleijnen J, Fahey T. Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM 2007; 100:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/30\">",
"      Smieja M, Hunt DL, Edelman D, et al. Clinical examination for the detection of protective sensation in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med 1999; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/31\">",
"      Litzelman DK, Marriott DJ, Vinicor F. The role of footwear in the prevention of foot lesions in patients with NIDDM. Conventional wisdom or evidence-based practice? Diabetes Care 1997; 20:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/32\">",
"      Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 1995; 18:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/33\">",
"      Lavery LA, Vela SA, Fleischli JG, et al. Reducing plantar pressure in the neuropathic foot. A comparison of footwear. Diabetes Care 1997; 20:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/34\">",
"      Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1993; 119:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/35\">",
"      Lavery LA, Higgins KR, Lanctot DR, et al. Home monitoring of foot skin temperatures to prevent ulceration. Diabetes Care 2004; 27:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/36\">",
"      Armstrong DG, Holtz-Neiderer K, Wendel C, et al. Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients. Am J Med 2007; 120:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11464/abstract/37\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1749 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11464=[""].join("\n");
var outline_f11_12_11464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical signs of neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening tests for peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vibration sensation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pressure sensation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pain and temperature sense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical signs of peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Foot ulceration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Wound evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Signs of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Wound classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SCREENING FOR RISK OF FOOT ULCERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Preventive foot care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      High risk for future ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1749|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/55/34687\" title=\"figure 1\">",
"      Test sites in diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1749|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/18/26927\" title=\"picture 1\">",
"      Charcot foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/50/33583\" title=\"picture 2\">",
"      Monofilament in diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/57/26512\" title=\"picture 3A\">",
"      Wagner 1 foot ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/47/37631\" title=\"picture 3B\">",
"      Wagner grade 2 ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/42/23200\" title=\"picture 3C\">",
"      Wagner 4 foot ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/14/8428\" title=\"table 1\">",
"      Risk classification diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/61/6108\" title=\"table 2\">",
"      Comprehensive diabetic foot exam",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=related_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11465="Chronic granulomatous disease: Treatment and prognosis";
var content_f11_12_11465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic granulomatous disease: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Sergio D Rosenzweig, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Steven M Holland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11465/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/12/11465/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/12/11465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent life-threatening bacterial and fungal infections and granuloma formation. CGD is caused by defects in phagocyte NADPH oxidase (phox). The cornerstones of CGD management are antimicrobial and immunomodulatory prophylaxis, early diagnosis of infections, and aggressive management of infectious complications.",
"   </p>",
"   <p>",
"    CGD was initially termed \"fatal granulomatous disease of childhood\" because patients rarely survived past their first decade before routine use of prophylactic antimicrobial agents. Prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    became routine in the 1980s, and prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in the 1990s. The average patient now survives at least 40 years. Patients treated with the highly active antimicrobials since diagnosis who have not yet reached 30 years are expected to have even greater longevity. Overall, survival rates are better for females than males, reflecting the greater severity of X-linked CGD.",
"   </p>",
"   <p>",
"    The treatment and prognosis of CGD will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of CGD, as well as an overview of primary disorders of phagocytic function, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other primary immunodeficiencies, diagnosis and treatment of infections in CGD must be aggressive. Reduction in mortality and morbidity in recent years is largely attributable to antimicrobial prophylaxis and aggressive recognition and treatment of infections in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cornerstones of CGD management are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antimicrobial prophylaxis",
"     </li>",
"     <li>",
"      Early diagnosis of infection",
"     </li>",
"     <li>",
"      Aggressive management of infectious complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis in CGD patients relies on a triad of therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibacterial:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX or cotrimoxazole)",
"     </li>",
"     <li>",
"      Antifungal:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"     </li>",
"     <li>",
"      Immunomodulatory: Interferon-gamma (IFN-gamma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This combination therapy dramatically reduces the rate of severe infections from 1 per patient-year to almost 1 every 10 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/1-3,5,6\">",
"     1-3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Antibacterial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials examining antibacterial prophylaxis in CGD patients. However, there are several retrospective series that suggest that TMP-SMX is effective in preventing bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. In one of these series, 11 patients were followed both on and off of antibacterial prophylaxis. TMP-SMX lowered the incidence of bacterial infections from 15.8 per 100 patient-months to 6.9 per 100 patient-months in patients with X-linked CGD (n = 4) and from 7.1 to 2.4 per 100 patient-months in patients with autosomal recessive CGD (n = 7) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/1\">",
"     1",
"    </a>",
"    ]. TMP-SMX prophylaxis did not result in an increase in fungal infections.",
"   </p>",
"   <p>",
"    Lifelong antibacterial prophylaxis with TMP-SMX (5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    up to a maximum of 320 mg, based upon the TMP component, administered orally in two divided daily doses) is suggested. Several centers use single-day doses to enhance treatment adherence. For patients allergic to sulfonamide drugs, alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    as a single agent, and beta-lactamase stable penicillins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    , cephalosporins, and fluoroquinolones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antifungal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational series and a single randomized trial demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is highly effective as antifungal prophylaxis in CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/2,10-13\">",
"     2,10-13",
"    </a>",
"    ]. In the randomized trial, 39 patients were assigned to receive either placebo or itraconazole (100 mg orally per day in patients aged 5 to 12 years; 200 mg orally per day in patients &ge;13 years or &ge;50 kg) for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/2\">",
"     2",
"    </a>",
"    ]. Thereafter, they alternated between itraconazole and placebo annually. All patients were on antibacterial prophylaxis and most received prophylactic IFN-gamma. Seven invasive fungal infections requiring systemic therapy were reported in patients while receiving placebo, compared to only one serious fungal infection while on itraconazole (this single patient was reported as non-compliant with the antifungal prophylaxis).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    oral solution administered once daily, maximum dose 200 mg) is the recommended therapy for lifelong antifungal prophylaxis. Itraconazole-resistant fungal infections do occur, but almost all have been responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The advent of the azole antifungal drugs has dramatically altered the clinical consequences of fungal infections in CGD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulatory therapy has become part of the prophylactic regimen in most centers in the United States (US), although it has not been as widely adopted in other countries.",
"   </p>",
"   <p>",
"    An international multicenter randomized trial examined prophylactic treatment with IFN-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/3\">",
"     3",
"    </a>",
"    ]. One hundred twenty-eight CGD patients (median age 15 years, range 4 to 24 years old) received IFN-gamma 50",
"    <span class=\"nowrap\">",
"     mcg/m2",
"    </span>",
"    or placebo subcutaneously three times weekly for an average of 8.9 months. Forty-six percent of patients in the placebo group developed at least one serious infection during the follow-up period, as compared to 22 percent in the IFN-gamma group. Twelve months after randomization, 77 &plusmn; 0.06 percent (mean &plusmn; SE) of patients in the IFN-gamma group had not yet developed a serious infection, whereas only 30 &plusmn; 0.11 percent of patients in the placebo group were free of serious infection. This improvement was independent of age, CGD genotype, or concomitant use of other prophylactic agents. However, there was no improvement in superoxide production by phagocytes in treated patients. In addition, no decrease in Aspergillus infections was demonstrated.",
"   </p>",
"   <p>",
"    One major limitation of the randomized trial was that other experimental drugs, which included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    at the time, were excluded. Results from earlier observational studies of prophylactic IFN-gamma therapy in which most patients were not on itraconazole are consistent with the randomized trial. Three prospective open-label phase IV studies confirmed the decreased rate of serious infections, ranging from a rate of 0.13 to 0.4 per patient-year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/6,16,17\">",
"     6,16,17",
"    </a>",
"    ]. However, a prospective study comparing treatment with TMP-SMX and itraconazole with or without IFN-gamma found no change in the rate of severe infection (0.01 severe infections per patient-year in both groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, many studies suggest a benefit to prophylactic IFN-gamma in addition to TMP-SMX. However, it is not clear how much additional benefit, if any, prophylactic IFN-gamma provides beyond that of TMP-SMX combined with itraconazole. The mechanism of IFN-gamma benefit in patients with CGD also remains unclear.",
"   </p>",
"   <p>",
"    The use of IFN-gamma in the setting of acute infection is of uncertain value. Some experts use IFN-gamma only in the setting of infection, rather than as prophylaxis, but the reasons for this are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/19\">",
"     19",
"    </a>",
"    ]. We suggest discontinuing IFN-gamma in the setting of an acute infection since antimicrobials are of much greater value in this setting, and the addition of IFN-gamma often causes increases in temperature and malaise, obscuring clinical response.",
"   </p>",
"   <p>",
"    Issues impacting the use of IFN-gamma in CGD patients around the world include the need for administration by injection, cost, and lack of general familiarity with cytokine therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/11,12,20\">",
"     11,12,20",
"    </a>",
"    ]. Additionally, it has been argued that CGD prognosis has improved significantly since the advent of routine antifungal prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , lessening the need for adjunctive costly immunomodulatory therapy.",
"   </p>",
"   <p>",
"    Despite these uncertainties, we suggest IFN-gamma (50",
"    <span class=\"nowrap\">",
"     mcg/m2",
"    </span>",
"    subcutaneously three times per week) as prophylactic therapy for CGD. For children less than 0.5 m2, 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    subcutaneously three times weekly is the suggested dose. Fever and myalgias are the most common adverse events associated with IFN-gamma. These side effects are minimized by concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and dosing of IFN-gamma before bedtime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening infections may occur at any time in patients with CGD, even in those who have been free of infections for months or years. Early diagnosis and treatment are critical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious infections, particularly those caused by fungi, may be asymptomatic or minimally symptomatic at presentation. Several interventions are suggested to monitor for and diagnose infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant increases in sedimentation rate or C-reactive protein should prompt a search for hidden infections. We suggest checking these nonspecific markers of inflammation at every encounter to aid in early detection of occult infection. Elevation is usually obvious and occurs in response to both bacterial and fungal infections, although bacterial infections tend to elicit higher levels.",
"     </li>",
"     <li>",
"      Imaging with plain radiographs, ultrasound, CT, or MRI is extremely important for the detection and determination of the extent of infections. The chest physical examination is extremely unreliable for pneumonia in patients with CGD, because of the abnormal inflammatory response in the lung. We follow the evolution of infections closely with CT (chest) or MRI (soft tissue) until resolution",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stabilization of the lesions.",
"     </li>",
"     <li>",
"      A definitive microbiologic diagnosis is essential for directing therapy because the differential diagnosis for infection includes bacteria, Nocardia, mycobacteria, and fungi. Empiric antimicrobial treatment prior to obtaining specimens for the identification of the specific pathogen is discouraged in the absence of life-threatening infection. Biopsies to identify the pathogen should be insisted upon before the initiation of therapy and not after empirical therapy has failed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute infections must be aggressive. Cultures are obtained first, if possible. Patients are then treated empirically for gram negative, gram positive, and fungal infections until the pathogen is identified. Several weeks of parenteral therapy are usually required, often followed by a few months of oral therapy. Ultimately, management of infections depends on the microbiology, but some general approaches can be outlined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric initiation of TMP-SMX (15",
"      <span class=\"nowrap\">",
"       mg/kg/day),",
"      </span>",
"      a fluoroquinolone at high dose (to cover Gram negative infection), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for two doses followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours) is appropriate for pneumonias, pending microbiology and after diagnostic specimens have been obtained. Carbapenems also cover the majority of Gram negative pathogens and Nocardia. Patients rarely develop Staphylococcal pneumonias after the initiation of prophylaxis. Most Burkholderia, Serratia, and Nocardia infections are sensitive to TMP-SMX. The use of TMP-SMX as therapy for infections that have occurred despite TMP-SMX prophylaxis is highly effective and may reflect either dose response or a failure of patients to actually take their prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Liver abscesses in immunocompetent patients typically are caused by enteric organisms and are liquid and easily drainable. In contrast, liver abscesses encountered in CGD are usually staphylococcal, consist of a dense and caseous material, and often require excisional surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/22\">",
"       22",
"      </a>",
"      ]. Glucocorticoids along with antibiotics were used successfully in the management of staphylococcal liver abscesses in CGD in one case series [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"       \"Pyogenic liver abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphadenitis is usually staphylococcal and often necrotic. These infections may respond faster to surgical excision along with antimicrobials. In view of the frequency of MRSA in the community, we start therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and then adjust antibiotics when culture results are available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\", section on 'Initial treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granulibacter bethesdensis is a Gram-negative rod that causes necrotizing lymphadenitis in CGD. It grows slowly on Legionella or tuberculosis media and appears to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chromobacterium violaceum can cause bacteremia and sepsis in CGD, and typically responds to TMP-SMX, quinolones, or carbapenems.",
"     </li>",
"     <li>",
"      Nocardia species cause severe infection, typically of the lung, in patients with CGD. Nocardia are the only pathogens that routinely cause pulmonary cavitation in patients with CGD, which is distinct from the causes of cavitary lung disease in other patient populations. We initiate therapy with TMP-SMX (15",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 gram every 8 hours) when Nocardia infection is suspected. Refractory cases may respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      at doses that are reduced to one-half of the dose used to treat rapidly growing bacteria, such as staphylococci. Nocardia lives in decaying matter and thus is often accompanied by fungi. This is manifest by frequent coinfection of Nocardia with fungi [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/25\">",
"       25",
"      </a>",
"      ]. Glucocorticoids along with antibiotics may also help in the management of Nocardia pneumonias [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In general, fungal infections are more indolent, and bacterial infections are more acute. However, acute fulminant pneumonitis with hypoxia can occur after inhalation of mulch or compost containing fungi [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/27\">",
"       27",
"      </a>",
"      ]. This presentation is likely pathognomonic of CGD and requires urgent institution of antifungals and steroids to control severe pulmonary inflammation and hypoxia. This condition represents the simultaneous evolution of infection and inflammatory response to the fungal cell wall.",
"     </li>",
"     <li>",
"      The primary site of Aspergillus nidulans infection is generally the lung, but it has a high propensity to spread to adjacent bone and to disseminate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/28\">",
"       28",
"      </a>",
"      ]. Surgical debridement is indicated for A. nidulans infections that are refractory to medical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granulocyte transfusions have been used in some CGD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/29-32\">",
"       29-32",
"      </a>",
"      ]. However, such transfusions often lead to alloimmunization, which may significantly impair the likelihood of successful bone marrow transplantation later on. We therefore view granulocyte transfusions as a last resort if medical and surgical therapy is failing.",
"     </li>",
"     <li>",
"      A handful of CGD patients with refractory infections have been successfully treated with systemic glucocorticoids in addition to antimicrobial agents [",
"      <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/33\">",
"       33",
"      </a>",
"      ]. It is critical that appropriate antimicrobial therapy is in place before glucocorticoid therapy is initiated, since treatment with glucocorticoids can mask symptoms and increase the risk of local spread of infection. This is distinct from the use of glucocorticoids for granulomatous complications in CGD. In this setting simultaneous use of aggressive antimicrobials is not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal and genitourinary involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal manifestations associated with CGD include esophageal stricture, gastric outlet obstruction, and colitis. Urologic findings include ureteral and urethral strictures and bladder granulomata. Obstructive lesions of the gastrointestinal and genitourinary typically respond to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CGD-associated colitis typically responds rapidly to treatment with glucocorticoids. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is usually initiated after biopsy-confirmation of the granulomata [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/37\">",
"     37",
"    </a>",
"    ]. This dose can be tapered gradually over a period of three to six months. However, relapses following discontinuation are common and over 40 percent of patients may require long-term low dose prednisone therapy.",
"   </p>",
"   <p>",
"    Glucocorticoid-sparing therapies include long-term treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    derivatives, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/37\">",
"     37",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/38\">",
"     38",
"    </a>",
"    ], respectively. Antimicrobials, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg twice daily) are also used, but have not been studied.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    and other inhibitors of tumor necrosis factor alpha (TNF-alpha) function are effective in inducing remission in glucocorticoid-dependent patients, but they increase the risk of severe infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, closure of enteroenteric fistulae on infliximab therapy can lead to the development or worsening of abscess due to the occlusion of drainage tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/39\">",
"     39",
"    </a>",
"    ]. Antifungal and antibacterial prophylaxis should be intensified and infections sought even more aggressively than usual if TNF-alpha blockade is used, since fungal and bacterial infections are exacerbated by TNF-alpha blockade in CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports suggest that CGD-associated colitis may respond to granulocyte- or granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful hematopoietic cell transplantation (HCT) is a definitive cure for CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. While outcomes may be better in younger patients with less CGD sequelae, HCT may be more useful in patients with recurrent serious infections despite prophylaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe, difficult to treat, inflammatory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Encouraging results were reported in one series of 27 mostly pediatric European CGD patients transplanted with unmodified marrow grafts from HLA-identical siblings (25 out of 27) or unrelated (2 out of 27) donors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/44\">",
"     44",
"    </a>",
"    ]. Absence of preexisting overt infection appeared as the single best prognostic factor. All patients free of infections at the time of the transplantation (18 out of 18) were alive and well at the time of publication. The four deaths in the study occurred among the nine patients suffering from uncontrolled infections at the time of the procedure. In addition, the four cases of severe graft versus host disease occurred in those with overt infections or acute inflammatory disease at the time of the transplant.",
"   </p>",
"   <p>",
"    Similar findings were reported in another series of 20 mostly pediatric patients in the United Kingdom, in which HCT-associated complications were restricted to those with preexisting infection or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/45\">",
"     45",
"    </a>",
"    ]. One patient died from multiorgan failure secondary to disseminated fungal infection after conditioning, but prior to HCT. A second patient died after discharge from the hospital from iatrogenic causes related to a previous disseminated fungal infection. Two patients had significant chronic graft versus host disease. Engraftment of neutrophils and adequate chimerism were observed in all transplanted patients. However, two patients required unconditioned bone marrow infusions from the original donor after neutrophil chimerism fell to insufficient levels after the initial engraftment. Colitis resolved and catch-up growth was seen in the patients with colitis (n = 10) and with growth failure (n = 7) prior to HCT.",
"   </p>",
"   <p>",
"    Conventional HCT, in which the recipient's bone marrow is ablated, has a higher risk of morbidity than a nonmyeloablative-conditioning regimen. In addition, only 5 to 10 percent normal cells are sufficient to prevent and control infections, as shown in lyonized females. Nonmyeloablative HCT was performed in 10 patients with CGD in an attempt to achieve mixed hematopoietic chimerism sufficient to prevent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients were given T-cell depleted hematopoietic stem cell grafts from HLA-identical siblings. Immune reconstitution was successful in eight patients. Three adult patients died 8 to 14 months after the initial procedure. In patients with successful engraftment, only four serious infections occurred during the follow-up period (median 17 months) and all preexisting granulomatous lesions resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'X-linked carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A shortened and less toxic conditioning protocol using bone marrow-derived stem cells was tested in three high-risk adult CGD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients were pretreated for three weeks with intravenous antibiotics and antifungals prior to transplant. These patients survived the transplant with full donor engraftment and normal neutrophil function at 12 to 27 months.",
"   </p>",
"   <p>",
"    Alternatives are being examined for patients without a matched sibling donor. One center performed HCT from matched unrelated donors in nine patients with CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/48\">",
"     48",
"    </a>",
"    ]. Seven patients were alive and well 20 to 79 months after transplantation. Two patients with restrictive lung disease now have normal lung function. A second center reported on HCT from matched unrelated donors in seven patients with CGD, all of whom had serious infections prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/49\">",
"     49",
"    </a>",
"    ]. All seven had full donor neutrophil engraftment, sustained normal levels of oxidative burst, and were alive and well at least one year post transplant at the time of the report. Three patients developed grade I acute graft-versus-host disease of the skin that responded to topic corticosteroids. A third group, acknowledging potential ethical issues, structured a HLA match for a child with X-linked CGD by promoting the birth of a female sibling via in vitro fertilization and preimplantation female sexing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/50\">",
"     50",
"    </a>",
"    ]. Insufficient cells were obtained from cord blood. Therefore, conventional HCT was performed when the donor infant (female sibling) was 12 months old. Immunologic reconstitution was successful and the patient and sister were alive and well 25 months post-HCT.",
"   </p>",
"   <p>",
"    Although transplantation is usually contraindicated in the setting of active infection, it has been used for refractory chronic infections in CGD. There are two case reports of successful treatment of invasive Aspergillus infection by HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/31,51\">",
"     31,51",
"    </a>",
"    ]. HCT for active infections should only be performed at centers with experience in this procedure, as the risk of death is high.",
"   </p>",
"   <p>",
"    The decision to pursue HCT in CGD is an evolving one. There are promising results for HLA-identical HCT in CGD patients. However, unresolved issues remain, including the proper degree of immune ablation prior to transplantation, the degree of T-cell depletion of the allograft, and the prophylaxis for graft versus host disease. For example, the benefits to patients in terms of rescue from inflammatory bowel disease will be substantial as transplant-related morbidity and mortality decline. However, survival with CGD is improving and complications are usually manageable with prophylactic therapy and aggressive treatment of infections and inflammatory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CGD is well suited for gene therapy since it results from single-gene defects that almost exclusively affect the hematopoietic system. Retroviral vectors that provide normal gp91phox, p47phox, or p67phox genes can reconstitute NADPH oxidase activity in deficient cells, establishing the proof-of-principle for gene therapy in CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral blood stem cells from five adult patients with p47phox deficient CGD were transduced ex vivo with a recombinant retrovirus containing a normal p47phox gene and then reinfused [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/52\">",
"     52",
"    </a>",
"    ]. These patients did not undergo myeloablative conditioning. Functionally corrected granulocytes were detectable in peripheral blood following this procedure. However, their peak frequency was only 0.004 to 0.05 percent of total peripheral granulocytes, a level well below the minimum number required for protective activity.",
"   </p>",
"   <p>",
"    Subsequent to this study, two adults with X-linked CGD were successfully treated with retrovirus-based gene therapy and nonablative bone marrow conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/55\">",
"     55",
"    </a>",
"    ]. Clinical response was observed after gene transfer. However, both patients developed monosomy 7, secondary to insertional activation of ecotropic viral integration site 1 (EVI1) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/56\">",
"     56",
"    </a>",
"    ], and 1 of the patients died 27 months after the procedure due to infection. In a different study, three adults with X-linked CGD underwent gene therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/57\">",
"     57",
"    </a>",
"    ]. All three patients achieved early marking (26, 5, and 4 percent, respectively) and two had sustained correction. One patient had resolution of infections, with 1.1 percent marking at 34 months post treatment, and the other had 0.03 percent marking at 11 months post gene therapy, with partial control of infections. The third patient died of an invasive fungal infection about six months post treatment after completely losing gene marking.",
"   </p>",
"   <p>",
"    Although gene therapy has not yet cured patients with CGD, the field has made significant progress with the demonstration that gene therapy can provide clinical benefit to patients. The long-term risks and effectiveness of gene therapy remain to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Liposomal reconstitution of reactive oxygen intermediates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of liposomes to restore",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    production in CGD phagocytes was proposed many years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/60\">",
"     60",
"    </a>",
"    ]. In one study, in vitro microbicidal activity was restored to CGD phagocytes by loading the cells with glucose-oxidase-containing liposomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/61\">",
"     61",
"    </a>",
"    ]. Clinical trials have not yet been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the first 92 patients with \"fatal granulomatosis of childhood\" were reported, 45 had already died, 34 of them before the age of 7 years. Survival has dramatically improved, and CGD is now a disease that is eminently survivable into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/18-20,62-64\">",
"     18-20,62-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In series with fewer than 100 patients, published survival rates at 20 years of age ranged from 73 to 87 percent, with a mean survival of approximately 18 years for patients with X-linked CGD and 36 years for autosomal recessive (AR) CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/19,63,64\">",
"     19,63,64",
"    </a>",
"    ]. Higher median survival (38 years for X-linked CGD and 50 years for AR CGD) was seen in a European survey of 429 patients, despite only 71 percent of patients receiving antibacterial prophylaxis and 53 percent receiving antifungal prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual production of reactive oxygen intermediates (ROIs) was strongly associated with increased survival, independent of the specific gene mutated, in a series of 287 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/66\">",
"     66",
"    </a>",
"    ]. Higher levels of residual ROI production were seen in patients with p47phox mutations and gp91phox missense mutations in the first 309 amino acids of the gp91phox molecule compared with other mutations that cause CGD.",
"   </p>",
"   <p>",
"    Quality of life for CGD patients has also improved dramatically. Better therapies are needed for certain manifestations of CGD, such as inflammatory bowel disease. However, antimicrobial prophylaxis with TMP-SMX,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and IFN-gamma, as well as early diagnosis and aggressive treatment of infections, have dramatically reduced the incidence of life-threatening infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/12/11465/abstract/12\">",
"     12",
"    </a>",
"    ]. Protocols for hematopoietic cell transplantation and gene therapy are improving, and these therapies offer promise for definitive correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/19/8498?source=see_link\">",
"       \"Patient information: Chronic granulomatous disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstones of CGD management are antimicrobial and immunomodulatory prophylaxis, early diagnosis of infections, and aggressive management of infectious complications. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The morbidity and mortality of CGD have improved significantly since the advent of prophylactic antimicrobial and immunomodulatory therapy. The average age of survival is undefined in the setting of newer antimicrobials, but it is at least 40 years and will continue to increase. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with CGD receive lifelong antifungal plus antibacterial prophylaxis with or without immunomodulatory therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest using TMP-SMX for antibacterial prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically administer 5",
"      <span class=\"nowrap\">",
"       mg/kg/day,",
"      </span>",
"      based upon the TMP component, administered orally in two divided daily doses. Alternative antibacterial options include beta-lactamase resistant penicillins, cephalosporins, and fluoroquinolones. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antibacterial prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antifungal prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically administer 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once daily. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antifungal prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the addition of IFN-gamma therapy to antimicrobial and antifungal prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is suggested as 50",
"      <span class=\"nowrap\">",
"       mcg/m2",
"      </span>",
"      subcutaneously three times per week; for children less than 0.5 m2, 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      subcutaneously three times weekly is suggested. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunomodulatory therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definitive microbiologic diagnosis is essential for directing therapy. Biopsies to identify the exact pathogen should be insisted upon before the initiation of therapy and not after empirical therapy has failed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of acute infections is aggressive. Once cultures have been obtained, patients are treated empirically for gram negative, gram positive, Nocardia, and fungal infections until the pathogen is identified. Several weeks of parenteral therapy are usually required, often followed by a few months of oral therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful hematopoietic cell transplantation (HCT) is a definitive cure for CGD. While outcomes may be better in younger patients with less CGD sequelae, HCT may also be useful in patients with recurrent serious infections despite prophylaxis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe, difficult to treat, inflammatory disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/1\">",
"      Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/2\">",
"      Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/3\">",
"      A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/4\">",
"      Sierre S, Lipsich J, Santos P, et al. Pulmonary fungal infection diagnosis in chronic granulomatous disease patients. Pediatr Pulmonol 2007; 42:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/5\">",
"      Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/6\">",
"      Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004; 39:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/7\">",
"      Kobayashi Y, Amano D, Ueda K, et al. Treatment of seven cases of chronic granulomatous disease with sulfamethoxazole-trimethoprim (SMX-TMP). Eur J Pediatr 1978; 127:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/8\">",
"      Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease. J Pediatr 1983; 103:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/9\">",
"      Mouy R, Fischer A, Vilmer E, et al. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/10\">",
"      Petropoulou T, Liese J, Tintelnot K, et al. [Long-term treatment of patients with itraconazole for the prevention of Aspergillus infections in patients with chronic granulomatous disease (CGD)]. Mycoses 1994; 37 Suppl 2:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/11\">",
"      Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/12\">",
"      Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 2000; 120:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/13\">",
"      Beaut&eacute; J, Obenga G, Le Mignot L, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/14\">",
"      Alsultan A, Williams MS, Lubner S, Goldman FD. Chronic granulomatous disease presenting with disseminated intracranial aspergillosis. Pediatr Blood Cancer 2006; 47:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/15\">",
"      Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/16\">",
"      Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease--European follow up study. Eur J Pediatr 1995; 154:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/17\">",
"      Bemiller LS, Roberts DH, Starko KM, Curnutte JT. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 1995; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/18\">",
"      Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 2008; 126:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/19\">",
"      Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/20\">",
"      Liese J, Kloos S, Jendrossek V, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/21\">",
"      Guide SV, Stock F, Gill VJ, et al. Reinfection, rather than persistent infection, in patients with chronic granulomatous disease. J Infect Dis 2003; 187:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/22\">",
"      Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 2002; 235:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/23\">",
"      Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis 2012; 54:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/24\">",
"      Greenberg DE, Ding L, Zelazny AM, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog 2006; 2:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/25\">",
"      Dorman SE, Guide SV, Conville PS, et al. Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002; 35:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/26\">",
"      Freeman AF, Marciano BE, Anderson VL, et al. Corticosteroids in the treatment of severe nocardia pneumonia in chronic granulomatous disease. Pediatr Infect Dis J 2011; 30:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/27\">",
"      Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007; 45:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/28\">",
"      Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/29\">",
"      Yomtovian R, Abramson J, Quie P, McCullough J. Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion 1981; 21:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/30\">",
"      von Planta M, Ozsahin H, Schroten H, et al. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease. Eur J Pediatr Surg 1997; 7:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/31\">",
"      Ozsahin H, von Planta M, M&uuml;ller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/32\">",
"      Ikincio��ullari A, Dogu F, Solaz N, et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial 2005; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/33\">",
"      Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, et al. Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann Allergy Asthma Immunol 2006; 97:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/34\">",
"      Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr 1987; 111:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/35\">",
"      Quie PG, Belani KK. Corticosteroids for chronic granulomatous disease. J Pediatr 1987; 111:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/36\">",
"      Southwick FS, van der Meer JW. Recurrent cystitis and bladder mass in two adults with chronic granulomatous disease. Ann Intern Med 1988; 109:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/37\">",
"      Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/38\">",
"      Zanditenas D, Hag&egrave;ge H, Rosa I, et al. [Inflammatory colitis and chronic granulomatous disease, a steroid-dependent case report]. Gastroenterol Clin Biol 2004; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/39\">",
"      Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-&alpha; blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 51:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/40\">",
"      Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 1998; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/41\">",
"      Wang J, Mayer L, Cunningham-Rundles C. Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol 2005; 115:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/42\">",
"      Seger RA. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010; 30:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/43\">",
"      Kang EM, Marciano BE, DeRavin S, et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 2011; 127:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/44\">",
"      Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002; 100:4344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/45\">",
"      Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/46\">",
"      Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/47\">",
"      G&uuml;ng&ouml;r T, Halter J, Klink A, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005; 79:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/48\">",
"      Schuetz C, Hoenig M, Gatz S, et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009; 44:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/49\">",
"      Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/50\">",
"      Reichenbach J, Van de Velde H, De Rycke M, et al. First successful bone marrow transplantation for X-linked chronic granulomatous disease by using preimplantation female gender typing and HLA matching. Pediatrics 2008; 122:e778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/51\">",
"      Bielorai B, Toren A, Wolach B, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/52\">",
"      Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94:12133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/53\">",
"      Weil WM, Linton GF, Whiting-Theobald N, et al. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 1997; 89:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/54\">",
"      Dinauer MC, Li LL, Bj&ouml;rgvinsd&oacute;ttir H, et al. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 1999; 94:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/55\">",
"      Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/56\">",
"      Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/57\">",
"      Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010; 115:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/58\">",
"      Ott MG, Seger R, Stein S, et al. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther 2007; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/59\">",
"      Sokolic R, Kesserwan C, Candotti F. Recent advances in gene therapy for severe congenital immunodeficiency diseases. Curr Opin Hematol 2008; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/60\">",
"      Ismail G, Boxer LA, Baehner RL. Utilization of liposomes for correction of the metabolic and bactericidal deficiencies in chronic granulomatous disease. Pediatr Res 1979; 13:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/61\">",
"      Gerber CE, Bruchelt G, Falk UB, et al. Reconstitution of bactericidal activity in chronic granulomatous disease cells by glucose-oxidase-containing liposomes. Blood 2001; 98:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/62\">",
"      Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/63\">",
"      Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008; 167:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/64\">",
"      Wolach B, Gavrieli R, de Boer M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 2008; 129:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/65\">",
"      van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/12/11465/abstract/66\">",
"      Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3923 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11465=[""].join("\n");
var outline_f11_12_11465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Antibacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antifungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal and genitourinary involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Liposomal reconstitution of reactive oxygen intermediates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/19/8498?source=related_link\">",
"      Patient information: Chronic granulomatous disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_12_11466="Acute eosinophilic pneum Low";
var content_f11_12_11466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph from a patient with acute eosinophilic pneumonia illustrates air space exudate and alveolar septal thickening resembling that seen in the organizing phase of diffuse alveolar damage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC1PrWua5pMdx4Ks0SN2Kvdamvl4/65oeWxnqeM9M1n+JdKsINVtoruzTW9Y1G3JuLzUJjFDGMbGMSLgKvcnqABXeb3Y/MSTjAyegqRfLZdrqrqAQcqDgEYIAPtXgRr8r91WX9bvd/gvI3Ukjg/E3iHQdL0XSLVNauZYLC4gi1K40mbzJkieGTo4PClgBwchRjqRUVz4l+HiItz4d1ax07VbOMC0ntLOUvJk4CSJt/eg55zkg8itC60TR9KigsL7xFerI7ptAtoEKLlioban+rJBBycN0qODw1Gnjmyv9JtrXQbW0tzBJLCkbyzDccNGNrKj5+UksG2npW8HT3bkt3vZP101vtttuOST2f4HVTajrMvhWxurXSvK1i7RIZbWZSfJduGkIz90D5sE55GazPDfhWw8P8AjS1jtnuZ7q20ySWC9knzJcSmQrK0y/e2gFQvbrySOIPGPiG6F1H4Z0OK4GqXsbETJKN0WTgBl5YKc8u20Acgmq+tW+qeF9RkvtCsdMutPESmIzyAXLyhMNGrs25lBG4Lz941nCEmuVNLmvZfl1+6/mHwxv3PRkkPnFZDsbBABP3sdSKfKiPE8bltkilWGe317GuCt9K1vSWGv6cYrrWrm1VtWtJEMrSEYOy3GflIBIwDzgYzW/oOtWviXw+NR0q6QCUPHuUEmCUAjDBgDkHnBFYypq14u6/r+l3/AAIcLanRONyDa3Ixy3cCpocuURE3MeiqMk1wl5beM721S2ttUt9Na3gYvftGrrfT7htUJkmNABnceSSeMVi+MdK+IGteHbfTodb0W2cYa4a2EqSXJHXJVcf8BXqT0pqhG+s0vv8A8v662HynoHi7UtR0K0huo9OeewRs3tyhVjbxZA3BM5brk47CuU1248HatJb3V43ibWYpSEitrWWZ4GLDjITADY569q5fSpV8OxX+hXWh6mNXS0SS0gsmLQXU4BDOSH3cnDfPyB1A6V1fw10bV9EuTdXLXWn6Z9j8iHS5Z97iUsGeZlX5UBxgKDkZPSt1SjSi3fXydr/i35aaGjSirjJoNT8XRz2dn4bg03TbRn0+zle3Md3FCirlldvlQHoMZ6fjVfUNAmh8SeG9It9L1eZDA08zalqANvhUYeVK0Ybc2QGI5HNekNJuI8xidvI3EkA1574+vksNft5NL1GePxNJbo8NjcTbbPyg/wB5t3y5yG4X5j9KmlOTlypWVn3+96hGbk7I6KbRL1rqOC28OeEYbKOLKyAOH3jlU+VcgAkk9Qa0fDOhJpazTXl02oahOAZTIP3MX+zEh6D3PJ4zV6yuVu9Pt7jzLZvMGGaGUNFvGchWPUDFR2d9bahbifTruC6g3lPMgkDqWHUZHcVjKU5Jrp1MnK2hoCQszlmLEEBj+GaqazeSWWk3VzaIZJYE8xUWMyEgEZ+Uctxngc1z99Hq0d9qE9hdeTE8iQxjyxIWDAfOc9NrFuByelb1u06QRRTv5lwkY8yZUKK/q3t/Sk6Sik7piemp5Zdad4nhutc8SyOTZTxQXdr/AGrp5n8tlzsIiRiY9o6Dafmxkd69X0OG0sNN82DzIku1+2XMt2+JCSu5mkJ+7jn5ei1HPqNvZRST397b2sScs804XAPGeTzk8fWuX1mS68d6HdaZpIuNP0e5cQ3OpXMJV54errDGcNzwNx461rJyqpKSsu/3ff8A1oiubm8h2lafYeKdct9YttPvf7DjujqXnXzsBdXO3bG8KE5WMZLYIAJA9K7iSZ/tEhkARMAo+7AP97I7c964az8OReGNKNxf+NfEBsLABIHeVIY7aPhQpGCGPOMkdxgd61IfDmmSwK0Woa1Pbyssnz6pJJHMM5G7PUc9AQKU4qWrbtstP83v/WisObjsmb7qGYZIHHG054pS2QR+HvVG0ubUEwQRG2CthY2TYrZyfl9e/wCVTFwcnPU54rJ07GfMTRSAq2AfUCqupatFp8qo0NxcXLW8k0UUEZJcJj5N3RWYkAZpjNnkcMOpqul9KswhkyrPuKZPB24yPrg04x7oW5NLd6tP5Mf9kS2cbxMZ3e6j82JiBtUbSRwc5OfpmqWqy6nZ6VMuhpbXPiG6jzEt5dgIkmBubB5ZF64A+vWrk80nkN5LgS/wkjcPyJGaxbiJ9TvTDcajOrpBskOnQLFNAXOQfOOSgIxhQORyeK2jG/RJfP8Ar8RIdJJd6d4OlvvGt601xbxZnisWMcckmRsVQo3Es2FA965zXLTWtE8B6NLqRgv0F2smr21/M0gjWXhYw452occDPPqK6h7BLp5UudSvJzbzpPBnaDaEIVHOPnzySW5yKittEtkulur+7vNYvI4/KSS9K7Av+zEoCg+/JPrW1OooO773tby2Xbff0ttq7om0vVIbXxRe+GVZVeOJbvTo1UkNbHAOGJ7PuGOuK2LjK582Mbhycr09/rWZqFlZaj5Zv7WGd4s+WzoN0eRg7WGCAQeRnFcH8QNVg0CG207w9ZILyR11C9WEPst7ZDhpmTOCxwMZ646GsY0VVkkt+v8Anf8ArUd09EekNOSqZY4xwe34VnT39woj8ixeSdyxETOFyoOM7jwCe2feuR8P+KrjWNOj/wCEO0hb20thsnfUrs20xlOSSEKnIAwc5AOcdq6XT7V7OxiiuZRcXOMzTEkmRvXJ5OOn4UOh7N+993+dnoS3bcYFv7vVJ7i+It9MFusUWnkq7PKfvPKRkcYwoU9zmofFN7dW3hq/fTRcC4EYRTaxh3jUkAsqnqQOlXWkVZVj/wCWjJvAA7A45NJvKvleD6jrRbVO3+QKVnc8d0R9TvoojZeItTlbT7gyFr5Gfe7D5Y9uQB3BD4AYdcV6poOmmxtJpWmW6vLlhJdTBt5D4yEPJwBzxx3rM8Z2dt/wjuuammmw3GoR2rP5yqUkfGPvOuD079apz+EtB1LT7aSyil0qRxHPFd2DMkycZzjOCTnvXRVmqsbttL0T7PyNXJS6WOraUdR0zUMk2V5zj1FcLoPiW50eW907xOL6SC3mK2+otaviSME/PI3OcnGMfTmtu3122ezW5u3eFpnPkWogkM4TPBaMAsCcE8gcEVDw8lpa5jJOO5qzhS3Kgg9vaqWoana2AhNyzgzyCGJVUlncjgDHT6ninPPdzR5t7B7cEgbr1lUkY+8EQk/gcGuJ8ZXF7LpdrK2oiQfaRB5cCBI5Vc7T5Y5ZpeAcE4wDVUaCnNRb/r8RanVXyf2pbz2V9YbLeVQv78JIcHrjBO1sdD7186ap4XW01q9tJ5XtJ5Hc2yMCkaoG6sx7BR2zmvVvHHix/DtzaaP59y13LGEkuJPkUDbzKJMHc2c8Adc1w8l9aa9qsF74s1y/uLS1Cw21vYR/vnGM7S7AANzyeeWrsw1OVOPOl7r7f1+ZrSvazOy+Ft3c3HhPN3ePeGGdo4pssTsHTGRn6A0VTuvHmk6ZZ2lpoumXWk2MUbO73sH8K5ULEu753ZhyxPHNFEqVSrJzjpf+umhnyqLtJf19x6bbeItOmhnaf7TayWh23kUkJP2ZsdGZcrn6GqLeKm1IrZ6BYavJezny0uzZkW9vzzKznjA5OO+MVD4Pv7SPT1g8N2Fzb6fFHNerNfXDJFE7MdwmO3KnjdgbuKis/iTZPLaweIo/7NknjaSKRXaWPaOASCNy7iPlBHI5OK4PY6y5IXt5/pv8r/f135bI6GbQ9Pls7q3khMouJEluJnY75pExtcnPGDyAMAeleb/EPSbrTpE0nQri4l07WD5s2kbi5km3cOhxu28AkZ4I54r1W3uLO8O2wv7G9YAkrbXCO/AyRtBzmucsLnWdbsrXW5LKx0FLG48+1nuL7Jlt2TD+YgXlCp7EYI6cZrOjOcZavT1tr0/Lpqh0puLu1deexWtPDuoadaK0Wu3E2vK/myXDgGCeQAKBImNxUIAo+YDjOKmvLy+0XUby/nzqWqXdlHBYrHYsIopVk5QbSTzv3Egg4X0qnpHinUvE2q6ja6BptlZwwgmO61KY7WHAG0Rk7jnJ4OBgA8mukS28UoY1Or+HbMOQryR2ckkn0jDsFLfWtnzRfLUt6P5Pom7eRnfW7F8VaXO3h+6tNR8XTWCjcr3UCRW6Sn+GMA+vIGGyeD7VR+E+hW2ieD7SaKw+yahfAzXG5nMhG4lA+7+IA84AHNa+m6XDYvJPetLql7PKGkubuJXJOMKFQDagGOw/GpfEuvWXh7TpNR1q4ZP4liUb5pjn+BMgnHcnis+Ztezjrd+n4f1stEF3ayNXI3ZPt2rmPiPq0Np4fk07MX2/UQVgDXotTHtORJvxwAwA7ZPGapWHxF0a/lijtLHW5DLIkce60Ee8sD93c3OMHIFXY9Cvte8RR69feZpEf9ny2UFjndOxcEb5xkqACSVUexNNQ9nJSnpbX59PMqMbP3i/4G0waJ4bghmtreHU5VEt7JAd3nSH/loGyc5B6jg1vAtxkc452muK+G/iK11G0/4R4yLBfaLALIkj5LwRkq0kR9AR0PJzn2rtW37GEbLvPQkZC/UVE0+d824qiaepKDxjJJPArM1vRtK1qeybUbd2vLGRZ7aeByksRDZ+Vh2z2OaTxLe3Ol6SbuzSOVlYAhm+cL32qeGP1Iq/aOzRxyNFJD5yCXY2Ny5H8WOM/SiMWkpInVanNP8ADfwxO4kvY9QvZCdzPcXbHzP9khcAAY7Y962VtrzTntE0+XTNP0K3WSS8t47f9445OYz/AA4A69frWozsijI6nHFcz4rmu0mjT+xdQ1KxUrIP7P2GQuCd27eQMYx8o6561ac6krN39f8Ag6DU21Z7Eni7UNV0/wAGT63pscQgihS5laQnz7eMkZZFxtkfacjcRg+tT6fpOl6xoml3kk+o6lDLGl3FLe3Db33LlS6qQOh+70FZGvpAktjP4xttUltprkSuhvzLb2gPKLIiIu8DhSuDz64q7qvirQrTT4xouoQS3M4MVtFZws5j2Yz+6wDhR/D17VtGM7KME7t7rb70Jx0ujS0rw1oek3st3YaPaRXLYxIVMhHHUBiQPwFbUru+Xcl3A6luT+NRpISIASxklVcArgk4z0/pWdqWu29oZFtbW91hoVL3CaUizmAAgYbBHzf7A5wCeKwtKbvuyW29zO8XXF3YXtpqD6Pea3oiWksN1ZWyrKySbg6y+UfvDAIyOnpTvCetXOsapdPf6bf6TNHaxmGymZTEYjjDDADFugPAAORzU994lWxdg+ja+7LGsw8ixMnBOMDBxuB6rnimxu95rA12KG00i3tIXhnvNVCo1yCPljYg/LGGIJOeuAK1StC0orbf8e/y2KSujoZHJJVucYODzg1GzbuM1leEzqUnhixfXWlbUX3mVnG0kF22kDHC7cYzzjGa1CqhwT90H1rGUeVtdiHpuRvKoZIy215NxRD1bA5I9h3PvTbl4oI0e5Kx7AWVmGMcc4/CsqGw1aC/1a9W8tDcXc48lpkaUwWq42RhRgDncx9zzmnXUD2Np5ltAdSRpXkvVuG3TXG8EEoPuhs4wvAxxVcivv8A1/Wg7a2H21xd3l3K9vJCltFyhMW8Tb0BUg5HCnk469OMVNpNiun2ZiZxPPJK89xPsCGaVjksQPQYUegArO0jVJkuLPT7nRrmyN0Hlt1aVXMVuhxulXjyz2wM59a3I5EmRZIXR1IP3Tz17jt9DVSjbS2ny/ruEroRjlemQRxmmnqCCPb6U914GD+faquo3NtZWU91e3EVtbQrmSWY4VcnA/EkgD3NTYnd2BpF87y2AyRke9YfjpNXuvCd/b+HordtQZCf3hCsVAP3Tg729FPHNZV98QNC0mKabxCb/Sp0z5Vtd2+2eZP7yICeOT1x0NaK+LNK+wS34GoGyRVdZEs3YOGUEFSMg9QPrVqlNNPl/AtXT0PLNM1nxb8PfDenWdylnqsZ3SmCL95cW8H3iSB8wwSclgQOADXqXhfWv7atElY27uEy7QnhT2BHODgjjNc34r1e08TXem6dpmlalcagbiM/a1i8pBCwPmLJIuSY8HDKe/T1rp/B3huDwvoradbyowe4kmLpHsX5sYUd8AAda6a/Lyc042k/6/ruOVrW6mk5xJHEMkyBmyAcDHr6Vn67fQ6Ro11f3kipDEhK7m2mRscKvqx5wAO1c/r174m1jXIbHwlctZ6Uu6O7vVVMxyqeCCc5X0AAzW7p2jtZ6jFf32p32rajEG8qe6cbY2YYdkjACqTzg9QDjNYKCjZyfy6/PsS423OZ0rT5/F8UOq6958GjsA1hpQdl+UH/AFkxGMkkH5cdK7CU7s8jA9Knkd5HZ3Yl26k9TULnC5Aziic3N9ktl2/rq+vUjYg+0KlwLYS5nMfmmLOSEzjJHbnp+NBlkGSGIZ/vN3PsT3rkdcV9B1trvQfDd7f308JU3O4m3RS4ZweSdxOPpjim6TqHi3XD56ix0K025VJrFp5CwONvzsOD64FP2N1zJ6ef+SuynHS51RGF6cegrmtWmg0nVvDiywPPDNPOkflxb2ilCja5x2AZh+Oe1QWus6udbnsJLq3uhazCCWaW1+yRyyuMqi4LHI6D8/St5baZL+a4ujGJSghjiiyVjTq3zHBYs3sOAKrldJ+92++6/wCDchqyOG+KdlreuaVb6bpGnK1hFKs09xMyfPx8qx87hjnOOuR6Vi2fg/w+0BGr6PfoiAK7w2s0JD8ZKDLbl7ZPOa9XI5Xuc/lUZDKnBIwcsc/59KI1+WPIl925UajSscVZadZWlrbXuleFL/UlkYxganchZIFT7rCOTOAccdDRXTSqF6ZK/wB73oolNSd5K/rzf5gqj2/4Bj+FdfvdP13UNOuJLS20XSIHuJrKdQs1rG2WWNGBO+UcBge/ANdZD4oSfWbezmsb2Frzd9llmiUF0ChmeRTzGuCoyf6VbtND0iGK2Eek2CmBFRf3YYjaQw+Y8sQecnnPNcR420Zo9ejs9IN/Jqnim4P2iV5T5MUaldxcAZZcdicDB9a54qlWltbT/h3+b6328zq5lJ7nV3+k+GdRmMmo2ug3Ekcu4uRGHEjf3iuCScd+uK5/XLafxV4pGhS2Hm+HobcGNlYrBHIUJSSbAB+XgCMEcYJ9Kgj0e98A+EL24hh8MMIZWlmv5DLubkBWCEfe5wFHdu1dlpmoSeI9Ee7sDc6fu4Q3CKzAkAh9mTkEEYzg1SXIrxd1sn2emqX9eZN7O+5laRf23hm2bw8NOuri5sYllhj063eaORZGztQtjZ8xyQTxnPsNZJde1G3lePw/b6dNDIpjF/frmQj73CocDHfOaS2sNdlmtzqviFls4QB9m06PyvtBzyZGbkAjIwuMetYev30vhW4QS69qWq3pkWG10iNEyC2WVpto3FAO/BIAo5FN2jZv5/8AA+d9PMhPW/UdqM09pdXWn3d7earr11bmJLHS0b7LZIxws7gkNwTySeewrb8O+H10aS6urjyZNTvIY7e4aEs0IiQYVY9+WCnqcnk1RuPC95qmovqo8QzWd5InlkaQhihlVePvPlyDjB/StG2SfQvDkdtFZi4v2M0sVukv32yWwXP3Rgjk8U5tcvLGW+62/wAtFb9WPyQ0eEvDZkjkbRbeSVOksjuzevdsdeeAK3t5jkV05wRj+lZ2jS6pLZtLrsOmQXLMRGmnyPIuzA5Zm6nPpWgSVbBGR6VhNuWknf53JcnfU8o1fRJPCHjHSJrfzLvQ7q7M8FsztGFnLY8uRuQSM5U4BboelesQzfalne2BVhtLF02kgeufTJH509Wb5lIO0gZU8g49qyvFWinxFpi6fJczW6tOkhmhG5lC5OGB4YHpg55wcVonGTSlp3f62/q5c6zq25tbEOlzS+JLzU5JVjPhu3ufKtSh2yTzR4EmSOsYbkEY5B7V0u4EgdCB2HFcXa23jDSvFFhPqOsR6p4YbetxBZ6aFkgAQ7AyoNxUcZZe/UYrrLW4t76CK6sp47m1kG6OaNsq46ZH405q2q1Xlt+KWumpnLUsY4PGfwxSDaVJO0ANwXIHPrk0ENtaR2UIilmd+AAPUngcVyevR2XiXTLO+0cXupraiU24tEVreVyAAW83CHaehHPJ61Cjf0CKvo2W/GOvafb+FNSnt9atVcRAjyHZhISceVleSWGR8pB96v8AhFIJfDunX1tpkOnCYNNHEIPLcAkjeQcsC455JPPJrgrCz8SS3McXijVprXS0ltI3S3YMsTAZ2NwFXBALPyCWwDXdjRo9LihEGo3yLFdC63NcE+fn+BwOHQjj8sVvOMYR5b63v+HyLkuVWTGeJ5Lm60+4tbG/fSXUqZNTH/LsOOQO4PQ4xgGpNIsksJrLTbazSzsFVpYFtj5aFicdiSzN1ySc0/8AtW3tvPmmEtxJtO6PhV2gfMvoox1z+tYOhebIkVpbvahwjxrDtbzrBvmYMDn5FwdoB578Ukvdfb+tf6/zuknYm8VStq1tqGmadrz2MP2YpH5TYLTI68rIOSFAIIHU8VF441G01TwwNHXF9q9+0UEFqsXmOTuUm4ZDwYwASSeM1o+DNPs7a2TUrGBIxOmIypDKRnG6Nh0QgD5RlcjI9ahl1SLRfiLDb6lFbx2+uReVa6nhi6MuD5EjdACc7QvU4Jqo6StFX5dem6/4YbaWi6HR2dnDpllb2NoXMNugjDSOXZ8dWLEknJzT2PZug9aWMSbQZUMb5IZdwOMH1qrqN7Z6bayXWp3UNpaREB5ZTgKT0HHPNYpOT7tmDv0K+orFuEsgU3NvHJLAzHBXjDkHp93r7VBp99aa1ZFdE1mxe5lBwYmDtDg53MhwQOOpHQ1BrGlQ+M/Cstlfpeadb3ZDxtkeaFB+V2Tphuuw54xn0rgjYeIr7xfeW+sSQ3H2yAadcukcO6WHeo3tJFh49+wHawPcDgGt6dKM003Zr+vn+H46XHU7rwJNbXmgy6hDJ52o3FzJHqEzSCR3ljYqAWHGwD7oAAAPTOa2mhHmSTBVWRx87AAFvqe9ZWh3FrcwSaRocUlhFpkjWzWptfLWPB42ngNnBO4euTWjp0pvdPguAQTKD2IKnJBBB7ggj8KmprJvb+tP+B5EPQmXkA59sVyHjXVVuLhfCdjpUWsalqcLFVmb/R7YqckyEc7lwGwMY4Oa6u6WTyHFuSj8AHbnGeMgVwPiLwpeSw6lJbtby6o3ywpDctGGHOZJN5YMwPUHgjgU6Kje7e35/h67mlNK92bC+BvDb/Zm1bRLDVL9IUjmvLlXZp2AwWPzd+tIPh54IQ7h4VswSMYWecL/AN878Y9qb4P1PUl0bTLTV7a5uJI4cz6w8yOsj4J4UcjH3efQV0pZHLKjqWXBODyM8jP1FKTqwk/efyf+T/AmTaM/R9E0jQ4JINB0yHToZCWdIWY7icZzuJPYcVl+Odek8PaDNPBbtNPL+4jdfnaBm4Egj/jAz0zwcetdE2FXPIwK4nXozr/irT/DrytAlsF1K7mXG6RVPywoO2f4ieMYpUkpTvPVbv0FF3d2ULPRbvwJe2c8+pXepaddMUvpY7f5gwH7tpFGTjkgYJ9Oetb914m08XemWlm/2y8vHCPbwn57UEZDS5xtHY9SPSuimlcTPcKziTlsocHPXis/UbOy1m1WLVbWO9ttwlCOxU7v725SDn8ap1PaNSqLXyt+Wn5ofPfclIKllOMjjr/Ko5MDPHTms281E6EJn1KIx6BGAy6gJfM+zDgBJVOXPPAYZ461Jo2r2Ov6al9pUwmtXYrnGCGHYjsehx71PLK3N0/r+rEPct8qQBxzwBUTHcxBJznknmpmAIyOciosbsZyRmpDdHD/ABYS0tvDEd/LZv8A2sbmNbae3y8sJX5mfAI3gAAHjuOa0/BipF4Q0kRtIVeHePMfewyScE1DpLQJ451f+0Sh1xyWtPMjO9LQAKNjfd2nngc9ck10MhY/MfmPc1vKTjTVJ+T/AA2Xl+twm1axF2POf60jANkcY6dOtLLnB2KN3YE00EsvPTHPHB+ntXPJEIzroYk9jyO/FFPuRsUySuPKUFmdmAUDuSe1FbwV0DNaLX7KTTmurJbnUHA+WOzhaTe+cbQwG3rkZ6cVj+NbjWHgSbw/oviMapETEksIWOPYSCSwIO8ZA4GCRnPFa9pqzaW6abHoWsRadZWUfz21uXiibosUeMmUk4BYdO/c1ga34wbVbyz0/wAJXU9xdRyJPqCWLA3KQ5IaJP8AbGCSR0wBnJFc1OD57xjp5vT52OyK1ViS9sLxvDMOoalo174m1ho8NZXaALbuzbWVLdMKAAMkjLdOeOOd+Fyvo15rOrazPc2WkpmDbbW7G3hcclJxgujJkKCcfU1X1D4paNBcSwLF4gtRC4jt7aDVGi2bWIJY5AGQSSDzkYrQsfE2rzx3d2+g+M4dHgdnklF4cT9OGwgYkgjoTj14rqhCpJOLW/ml8lrby/zNJRcYO63O+1/VjaaZcNpEttcasYVa0gTMzSMwymFXJ5XJBPHGTxmsLRvBk8Vrcz6xftBfaiim+jtv3srf3g1y+WywwGC4XAGMVNp174c8GF9I0mxvDqMwSa5igjMsqo2SvmzH5QFXOFyMYPc5O3Lqck1ksmhaXf3zykrFJPCbWDg8lnfnb16ZzWfvw0irJ9XbXtvol1X5nNeysizd2UU8NtDBJNZ28LqVjs38oFB/yzz12+w61zviXSdF0i9s/Es++zlFxHHdSGV2WeEna+5Cfmwp7flWjY6j4gW/aDWPDiLbqxxfWF2siKnYmNvn/r7Vk6vG/wDa2na7Aya9pJmcSSXMZeHRiFG2SMZxyfvcHGOxpQUoStzfc9/K6utfP7r2Khds7QBWX9zzEQDGAMZXscduKzfEF1Pp8NpLbmGa6luEt47ByBJdliARGeoKg7jxjHWqNvZ6rIXudY8WBoroqIF0xPsysCCQwflx9QckZ5qZPD9jLcRXS3t8+q26Okeo+eJZYt67TjcNuceozxzWajGL1d/k/wBbfPr21DRbnQGH955cfzckDB61XvNQs9ODyX95Fb28Z2yTOwCocfd929FHPIqrLpuoXEcMV3ro+zoNriytfJkuRtwTI5JKH/rn79Kp23gnwzDMJxpMU8o5Rrp2mCHIJIDcA5AOaIRh9p/cv87fk/0JdrFGxeXxhcz32n3mq2OiIv2dZbe4EMguFJ3jGMj5SvzA5B+X1FXtch1jTNEtdP8ACNtAirIi/abiYF0XO6aRt/33bnnqWYmrdxos8lzqU9lrt9YyXxV5Vggi8tWGB5iqw4cgYLc5/KrVtpwE5lvb67v9o3bZ2EcEZA5kEKAKD7sSR61q5q6atZdNf+Bf+tOgadDHgbStY0yG7lN1JDeSs8VpqzvPEAOCiKflbJUHLZxnit9bj+0L4wwC5MVrhGR4zHGQB2BHQYwMcV5/4m8c3NhdaG3hXS1m0e+uEhXVLmAlJ1LbSkEZwx25yDxnHHFdvqFzo9s8y6trenTG2ASV5rmOPucZQNxznilUg1Z2et7dWv6+8o5vVdeh8Qyaxp2gtfXyRWb27bot9mZyTmKRSuMY/jJwDitDwlLb2cOn6TCszRafZwBmkl3mGRsbVYkknjOMcDGBUt94g022trTQ9C1aws5p3YKtg6TPbRhWkd1VchGPAUsMZfIBrC8B6pZLo8mvT2V7cSTyzSzXEcbSixiUknfIQPMPy7jtBOR+FXGL5Hpp0/zf4/1vTV47G7DrU9u2szwSabBpMF81vJqDSZaNgBuZwPlIDHA3H6ntVLxdbx2enJY6VZLq15rIl3xSMC942FO+SQkHyhwWC9RgV0Nve6PcaBcX1vJYvoEqzXE06oPIYEkyM4I6k9c85681UsrY63rGl61PYSWdlZWrNZi4fEkskg27lVTgIEAAJ67uOlTCSUua1rfnbTs99+2+hN7G3BALS0gtVcusEaxKxG0EAAcDoq8cAcAcVjePbiytfBup3GqIr2lsFlBcORG5YKr/ACEMMFuoIrcwTzjAxwK5L4o28l/4esLRLFtRhvLz7O9uLoW0cgMbFd7n0IBUHgkDPappr3437kRu2bl5epovh21nmluNWn8tYIGhjJkvZvLLqAB93IUkk9ACSa818KeKIPFXiSz1TxVNYWlssBltbaZTFb7xIV/dyHHmkEAneSuW46V6ZpOnfZbCCK/vLvUbgRgO14VBGUCMuxPlAxkd+pwea4+/+HGlWmh3a6bcXUJiinkMcaLK8mQSkcSn5YwPmGAMtuycnmt6EqSvGe76/wBf5FRt3NLxh460/Q4b+K3la71KCFm8qFNwTKnZLu+6yKQQQOcjHrXnuv3Wsaf440uwvtcnF/qtvEtldW9slp5js2fmyMhlbIUtwMnjk1UubOx0nwfc/wBnyxy3Vq8dz5tlCALdPLB+cH7+F2hgflDMcjNc5ocvirxNDDZ6xp0sltdlJbTV7618x7ZZHI85WyDjP3QOBkkYroVKNJ2j87/p/X6G0IKMbns+g/2rpWpah/ampWc6RP5X2e4vUlvWbf8AM0r8YYqAQgwoHAArpl1axE7wz+dHOoV5IxGTgPyD7knIHqa80i0OE2Gm3n2m2TVDNNc3sMlvG97qLqQQ0Sr82QAGVD94HPcmr1/8UVjtdMhm0mw/t5pCkiXNwIbe12scHLfNk44GeO9YyoupK0Fd/d/W39bEOm2uYr+MviGllb3KxK76jaSNE1pBcL5SjpuuGAzhc/cU5yOayvANn4wZb3aGhsAm5Jrw7AZcggAH5wmOvHPHNK/xplsr9IX0/QY7i8k/4/Y9/lxfNhhMDyTxng8Utx8RvEUUc63Fl4UTUbp0kmeC7DvMvIUfKxXOF4OcgfWupUKsVyRgl6vf5eQ4uy5UkdibmbT9d0PTNXvrCOXVY5Li7gFsiR2xClm2MPvfMMAHr8x5rehu7E3UUC3Vqt7cRCQW6zKzuoXhgoOSMDOfTpXEWniCXWtdi8Q6WlnaaW6RQ313qDKWtTtwYw5+aFeAAcbWbuKseNdOk8O61FrWlw2umNdMlpLf3axvFaDBbzFYjKl8FSCdp3DpgVySp3koS0dvx87fLu/mzOUbnT+J71tL8Ma3qEW4TWdm8kbLglXyFDc8HBOefSuO0KfUPC91cpdeHtT1O0wsl54ghgEs06lA+4kEl0BYnPoQOMVvp4x0G40yeDW7iKG7uIZYpLVIHeCfKn5I3GVkJ4+UEn9KsfD+TWF8H6YNdgls7+JSghddjRxg/uwR/u4/lUKLhTlzR69b/h3tb019CPh0ZHa+KNFvzEILqeCSWEzot5bPbbowMl1LgAgDnI7c1Npd3HqM93DZnzAmySNo/mSWJ1yroRww7ZGRmrPiHTbTX4Y49WRpvJLGOQNteLcNrBWHIDDgjuK5Dwx4ej02HT9N1TXNR+1r5sMdkLnYk8CsHKxqvMSZVScHJ244qIRi0+/3/dsNqLjdHUa5pA1TSb3S7yNhFdwmFlZtp9ev4ZrlNHvr/SNNitF8P2FlpFvJt+3RSeRbyAkBdinLNIx7/drfm8M6K0UsZsWVJJWmJE8hKuf7pJyoxxgcY4puoaBp99rFvqE4m3whP9HSYpAxQ/IWQcZH696cZRWj1Xp/k/68+gpKzTM+fWNbF1cxWnhK8eGMFo5rm6SATfNgYBBKnvhucVZgi1u8hWTUZbfSFXhre1IuZJGz1MhG0JjsBkn2rZd92dwwSeOetRuSvPpQpq2kV+P6tr8CLnH6lqF7beMdIsb25trrTITK5lFsVntyUOd23gpnAJAwOM81Jp+r6nq0kj6bo8cVgkjxGe/n2M5UcFUXnBOOTV5vCmgE35TS4op79WjmnjJDfNzlf7vPPHXvSeHNUl1XTXe4jeK7tp3tLhHXB3pgbsehGDWnuuN0r2010+dl/W3ccpKydinLdar/AGTE8+mOt/HKpkgtnDRyJ/EFc8fg1Vtf1i9tyyabpmoZFk8iNJbkAT5wi4x846D5ema6RvujqRwSM1mvqNvba/cw3d9FbhbVJR50oQBcsWwD1wBk47VHMm/hvb1JjZ9DlNe1G1Dxf2jezNNZQefq+lnDQoPKB8sngElzxnOSKK5nUoNFn1vVtUSyt9Rg1GcZkdS32NVIzIfaQDIY9AaK9CnQTj70L/evya/HU6I8sVZux6p4e1y7OsXC30d7b6hqk6i0066jeNYraMEeaGwRuI5bGATiuomks7EXWoNHZWh2/wCkXgjWN2QHgM4wTzXnuuwXtyloLTUbzTb2WSW9sDK/l/Zoiqh437GRmOQvRdxrqtLtbt5LS/8AEGpWt1Paqwhgt4wIlJUDzGJ5klwCc4AHOK8qpTjpPv8Ap28tLa+uul3NaXILrS7LUvEls40OD+zHX7XfXV1Y7RdTLxEihsE8MzM2PrWhp17a65cXVxuc3Vm72joJiy7A3XbwOvHTjpVyO7huIxJDMsyE4Vw2Q30PevPPH2j3ml64PFPhdZbfUjEY7mSNBKqZwNwjx94jgsKSa2eltv8Ag+v+QU4urJRvr0PS3hguIJIbm0t7mCT/AFsU0YZJP94d6y7Lw7aabceboUs+kuRtMau01sVznBgZsfiCDXnHhb4ra7q3iS00+XSrCdLuQQDyVZGjYcM2MnGOWJPHFetW7XJ3rcxQK6sRvgYsjj155Bpe/FNd/wCtuoq1GdF2kYOpSavcSaok1u6GxKfZZtNRil2HH8Kuc707nJXmq+m+A9ItRLNO1xcX0gkHmFhEFD/eyqfIzHk7sd+nSusxjd2PSnKhyDgEdznOapVZRXLF29P6/r0M+fsZml6Tp+mF0hglLOxJaaUykE+megx0A7VqrGif6tEQHk7BjJ9ainV3TbG+xs9e9TEiNFDNzwOe9ZuTk7tibbF6j0x09qljAdxGNokxnBPb1/Wqep3tvp2n3N7fymG0gTfJJjcVHsO59B3rD0q3XxPNBrGsLBPpsMjx6dZLnbKg6SXAOCX77OAMc5qkm1foNRVrvYy/Efi6xvNVk0Wx1aK0hSFbqTVLMNdujBtojSOP7xycHnI9MVZFr/atnax+KLzxnMoeSd9PGkPCLjceFkeJWG0EfdLcA812MCx2yGO0iitoz83l28SxKffCgc1IJHDDBYHuN38619okrRVvuv8AfbT+rWDn0sjMaTxJqnh3URdR6Vo+qXNs8cECSNcmBiCATIpVQcHjaOD61yWh2Wo2k2l6PqGgafY2d65hj+zx25ZikYaR5FYPkZIxhsnnivQDzwTg9cVhXFrqMnim8u7W0tpIoLeO1try4YgWUzKxdkXB8x8MpOMDGBnOcTTlZOKStv8Ap/W/4lRmU/8AhX+jT6hPe6vLeapNKqIA7LBGiI25UVI1HGeuSa6+GUxMnlIscUeBHEoxGgHQKOwrk9QOq6Bq+m6jea/dajpM8q2moQTQKkVuHACzJt+6A2M7ietdVflNPt7ue8Zo4LRHlnk2ltqoCzHA5OAD0605tySu7r8Pu0/IiXN3ON1TSvDvh6O6v9ev9UvdPaWa9j0u5ufMilkYF5FVAB5mT82GyAean+FBhk8KS3NvFdwwXE7XAhnVo4oHbloIVbkRoAvPQkkis/VLm78cS6RFoCfZbKNP7UW5nYCQvlkjTy+2QC2CeQRVC1g8UaU2q3fhgrOYmS0uYbxJn824B+/GzHDZLZZuBwACcVs6d48spWk+703/AF/4c2SvC19T08DfhV3En+7XJ+K9W0vVPDl9aafq9u+pJOIbRbaRTOl2jrwidSRnBOMYJ5qHUdR8WaR4dxaWJhvkmVRqOr3kZZ1LAkrFFkk4yNo6LzyRXkWg6/Npes2NvZavNqVvYCVlXTbMCTyiWLMxdAzN8x6YIAB5xVUMPKV5p3tt8vv/AKuTGlfVn0cSZNzAq7A+XJsYEeYMbgcdDnt2qJdjOArAP/sn3ryPwp4k0T4c+AtKlm1MalHrN/JeXEmJBKqZCNsDD5mQhdwOCd3GcVuf8Jrca1qHn+Bbe3ura3tXuHv9Sjkhily5G2JB8x5BG5uMg9MGsfYS1stO702/4IpU3ewzV10nVvGupWerTXX9jf2S1rdmCP8Adq7SM2GYf6tlA3d9xI/HzRZLnxH4jh03w7Jdafps1pG8EIvGbYsbIqlV6LJ8ikhjj0A4zb8c+KLxNWisLLSpYvEVzqbXNzBflZ4hhdsCKBkDIw/PGec4r0D4QeC7/wAO6bdXniCVn1C/bebZ0XbESckjH0X06fSvRXLhqftJb2Vlf/L779vUpy5djiNY8BeM2N/eG2W61VYHj+1Fle4c7srITncZAowu0cdqq+Cvhfd67pap4n086YqOWa7l3JOwJyWIb7428DoPWvcLPUpN1y0xiPlS+WdpJdOOFf8A2vp2q5eXkghY20EdxIm3zGmOI4VPd/4ifRRyfasvr1ZLlSSfdGbnd6o81uvhr4Q1XQ3kOuzTQRDyZbiIBowyncVUdevYHNQxfA/wxFaRSRalIbdkDOZYQwkBI+ZTuGOOlelafbeXdTRXc011dxQRSebMAAVJIyqjheR0H51zPxR8cWPg60jtWiW+164USWunjkEdnk9FGCcdTjsOahYmvOfLCTf3f5Apyb0PGpdOHg7xZq+iPq0MdmlpJMtvdTb45FWTcISBxlxzjqCPxr2XwTPeW1xd+HdSsGudDeHz7Wa4PnKquqs1s5P3lAbKk+hxXjvgXwl4l1bWZfFepQWV/wD2hJPaTGZ97ROy4ZlVf4wrZUe2a9f0SeOz0yHXdSuGs9N0qzks/KkkVI3UvmJ3JP3ygA28kZ7nit8VPnhyuzf69Pnp+JpU0WpevPB+nT30N1pf2rR5IkWNV0yXyU2Ancu3Bxu4BIwTgVW1LULnTvHdhbWlybq3v1YXGmLKkkloAAVnAJ3BOSCPbI61hifxX4okBhsyNKhmCyzWt6bZJCTlvIkIJkUKRzgc8V2dro+naFa3Nl4es4bQI/zALlyTg/Mx+Y5BB64rjneDtN8z103t69f63MmujZPdymECTY7oGy+zllXuQByT6AdTXNaVqTav4r1iS8gjih0NVjtZtmxkSZcuJmzy3y52HG0dea19f17TvDkNrJqks6NcNst4YIjNLM46qijqfyFcvqNl5WozG7tmk1vVkuLqw0GCJSIRs5muTuw0jLzz0OQM1NKOl312f5/hdN7IUVfQ7NWVhlSrKeQynIPuKhlGW4A5rG+GrJP4K0+CKQPJYobadQxfyXDH5SxA9fp1AJxmt2e3uJIWW0IS4JG0suVIzyDnHXkZ7VE4qE3FvZk2ZAeB6+lZl9rmlWN9b2N5fxW95OcRRyKwDH3fG0fQms1te1+8by9D0GO1vpYZJ7O21dW33EanaXAXARgeitnPXNcfBruj6o0Bhn1jWJLeFYdSMzpFaxbnwXILY8wsQowTxznitqdDm+L8P6tvpvvoUond6vdWmlQJJJdxRtPP5cUO/c00mRlIwvO7JHB455rnfEep3fh7VDqU80NpYX5JNsy+dK8safcCL93fwN4yBgZ61ee3bQNLvtSs9H0mwjtWBEpnNxHaqCEcnau7dg9Og9cdeM+JnjOxvL200nSJzFBdxFhfjO5o2ziPgbkU4yxH5HFEU1pFX3XT16XX53NaVJSlZ/D1MvUfiX4jvr2NNK0qG3eIec1tkzHYBku5GMr14wMe5r0aO20XXJPMMkF/cXMUMspiJ2EqPlKE9OCwwO3WvK7eyuvD9vdaNeRbNSuY1i2wzqHt1IU8MRtZWBBK8n02kV7K9jpd7pkdh5Vvd2lsqwLtODGVULlWGCrD1FJtKKcdPNfL+lr8zXFQhSaUdDJ8Vf2fpujX89/ILCG4jWLfCoR1Cn5Sg77Tz0ornfEHw50/U9aW/vNQv5LWFEjS0dy+AMcFyScd+nWiuzDToU4+9KXy0OPm+Z6BqttdS3mmXcGkRatLbMwWZnAaBWHLrnjPsfw5q5Jaz3EsRS1SHzObjz0DbDjl0wcnPTAxkdadeaTHePZ3L3V9BdWjGSEWswCO/UqYjxIDjG0889RWTqA/4SDw6mrf2rNaNZ75hHaXZtovlPzLcYUspCggr2z3rxo+9az8uvn52/I6i7N4i0aDXU0Q3kA1Yt5b2sUTERsFz8xC7VGPU1shFk+SSR1RxgmJ9rYPoR0+tcVDqVroOnwa3aXDz6BGxm1GGCBXVY5E/dy27kKSoYBWDFj83rxWx4K1WPxNpM+sQsws7y6f7FArfNHCgC4cY4csCTgkYI5rScEldbfr9yt39OplKNh/huO+SWJL3T4kuYhLDJcyKomWMOfLUMuSQVK/eIOAc9q6EblGQAR+lc5ZRabB4wuY7O41ObUpo/OugJmktY8YAV/4VfHQcmt+5ZI7K4kuJza26RsXuAwTyhjqCeM+g5+lOolzaLfy/r5Et82ol5NcQhXt7Ge8UfNJ5TICiDkt8xAJ9AKbpd7Fqen2t/aB/st1GJovMG1yD0yvbis3/hH7O8ntr3UrjVbwhUkFtdTkQO20BXeDAG7HbgZPIzWzEFVVSJFRE4CqMAD2FS+Wytv/AF/WyEyK7SaWSKOGRoU3bnZV6/7JNWkj+dERC56Duc1ja7c31npszxPZ28mMRT3EpSBH5I8044U4xnjkgdTVfX7XVNV+Hd9aXEXla3dWWx47E8JIcZ2ZPIx2zyO9Pluldre3/BKSbsWNbjudbvLvQbULHpyQq17qSsGaNzysEanh2OAWzwF461uIXWMCaZp5V5aVwAX9yBxWB4O1HU9Vk1CO802G0s4ZUSxKo8UjRleA6OOW4BLA47VqaXf2mpwvPp9/a3sQbaGtXDKvsfQ/Wk01pbYc7rQ0CcEEcmgcrgdOnFZ+t6pZ6Jpcuoak8iWkW0OyRM5GTgcAZxk9aoReLvDklubiHWbaWEP5ZZEkcBsZwSF681SpzkrxTfyMzoMA8DOO1VIdPhh8QXmrxu5uLy1jtJI8/IQjEh8f3sHb9B703SruPUrm5ks7y3ubUorQRxAh1VSVd2BAOC3A7cVfXcShPA53ADr6c/n+dJ3i7BqY/jRbKbwbrseqLI9iLRnlEblGyvKlT2IbHJ49a5Xw94d/tK/TRrjxD4wvI7aAXdy8k3kwxeZGCR9p6yD5hhR05OeDXc6veSafYzXEcSSHHlqZmCQoxB+aZieIx3wC3oDXO+HPDo1TTru58UR299JNOoWCBHis02qRmFd2SrbiOQM+ldFKfLTetvx1/rrdFRulcteC7G2aa41G3Sf7JDEulWEjzljcwwkq07DgfMRgH0BPeuo3nbjPTgcnikjUIiRxokcUarGiIu1VUcBQOgAHaooSSpMi4OT+I96wnLmdwb5nc57xj4RHia70y7fUbi2bTvMe3jjUFTM2AJST0Ze3BrHv4NL0jxxZWOlajOdcci/isUcOC+wq0jHGNxG4nJGcGupN2w8YxWVu8jn7Hm8KIdtufvRHf0Dkbht9OeK4XX/BWpX3jDU9YsdljDbNF9nxP5ELRxqNwdgCQwLMwP3SAc9a6aMm1yTlZW0+b/p+nYuPusz/AIbeFNKuNbWW7tp72aC5mt45JgTawyAFhHFz8xO7ezHCk4Ap3xB8UWPhKe5tLTXYZXvbT7G6Q4Y2MA3AuhQbd7HK7ewUZ7Vs/F/XF8NeD9Ns9MvbERTjyJMSie4aMAH92g+U7j1Y4AGABzx4RcQahrCw6Db6XGCbkBVhi/49y3zHYVJJLAjcGyuQuMdu3DUniH7aXw9vR/1/mU5tta6mj4X0KLxN4rii8OPdTAtHG895IG4I+eRVABUADgnPYV9Nfapts6SQbJI5jbWmCW89EUfO3Ax7gcVw3ww0KXwXot1FdOViuZfItbVX3XDShjvQkZGBkDI7gk4AFdhqLpaQ3NpY2aanfxbZbmJ7jy0jjY5LFmOABjKqME4FY42t7WoorVLb8Lu/4GDd9CRYFgWGTesshaSSJmQHa2ATnHJA4A70sk8Vlp5vtaeGKKJS0pIJXJ5YherE9uM9KzbK9vokiub55b66njcwwWNmGCrnIXJYdRgktjoQCalbzZru3uwq3U0ab/mkHktOfu7ST8sa9c+vJzXI4a2kxblaK/vtPvVvDBDCk9k+xNVn2bth3iSUjIXA4CjJwTnmvFNF8J6jqng7XfGl5eGfU5rx/NCDzXEORuaM4++C3AzjbnPOBWj8WNbg8Z6nDoenvLK6sGDuG3Mf+Wki9QqYBCqcZzk9q3/BniSw8HySQTrqdrp7XWx4o4N0doiRn90y4JaRshiQF+6eflIPowpyp0+eK97TTy7fNHRGMqa5luYksmheFLzU9MtdaltZVs2N9KGeCUHCBFQ46gkHABY564zixrY1az8F6dpk9jPDPDGn9o3sMTPHBby52Snfk+c4xuZQdqnHU4r1q+0+21y8g1KCSSJEg2xajbRoZWDHO1WdWAXGMkDPbNQWvhjS7OyeGzk1CKRt/wDpX2pjMCwwcE/KRz0IxnnFY/Wo6OW/6/16/hrLra3Zl6Lp+tQaQdKsL6RLeM+Ut5LIZ7iNtoCxAYACDGW53DdxUeg2GuaHa3ENo+n31/vUX1vcSziFJiTlopCC2SuMqR/CMVe0nR9V057vTrjWku9IuDJIsxUx3ql+GVWHy4ChRuA6knA4q3a6NplqdLNvalm01GjtWlkZygJ5J5wzc/eIJ+lYTnurp38t/XZ/19+bmjC8JT6re65rWqalb28nlXYtYnlDIkHlZVkgTbng9XzyfStyy06KG21BCN76hNLPdSjhpS5Py567VHyqOwFaDln+/uPpnpUbDgkdRxWcpczulbb8CXK5zOo+D9OnW2aweXTriJDFJcRku1xGQQI5AThgCcjjIxXEalZTeFTZ2GqeMr3ULt7hr22t4UleeeNQVCGQvtGOSQc9K9YYnP0/Wsa+Gh+HFv8AW7q3traWZgzzeXukd8YCR+jH0GM961pV5p2bb8tP1uNS6MgTT9S1fQmOsalOt3chzGYV8l44JB/qnGfvAZGRXHeJtBFp5Z1FVFpJLaubiC28mJzErp5U5TP94Nv28n0rvINZiu4IbuyttSvLWaIPHJbwoUcHoSzOCCOQQRkelZ15retPetZ6d4curXyZcTT3jq8cse3P7vYcbicdTgc048zdrafJWKhUlHU4XxJrceparfaaYr6+uhIIrGDTsxRKV+VXEn3uScHcu3HO45rPHgu88LaSp1SSOOeaRpYreKVEaKNOZj5uMsUypVV45616hFBrEquL/U4dOt5Uy0Wk2qx3CEgZQzNuGM9SF7cEUsGn2cEU0QjknSXO9ryRrh2B6gs+ePYYHtVKcadkv8/8kvknfuVLEu1kedLpngfSbs6rb62Ly9khK27ySvLD5z8By2Cd45OGx716NZ2sdhp9vZwNvihjCBiNpf1bA7nrT0SGOHZbw28UfDBYolVc+uAMZ96S4ZlgbywGkxwOgNYVKnMlHX5v/gLzMZzc9SrcEsygFSRztbvRTJgTgnAzyT6H0FFEEmiCp42t7mbxD4XmtrC9vPsks0im1O3ypSoCMW6Lg4OSCMDv0q3bWWmeCPh7OmvyCeFVaW/YNzdSv1QZ6luF9xXVRg84bj0Fcr8QRYzaJLaX+n3GqzzqWtNOgVg7soO+UuOFRQRlj0xxz05YTc+Wn08t92/wu/zO7mukkcFc+LbjWfA92viTTr26sGlWCz0+3h+yWgXnYzyBcvh8BVXAOCTk8ib4eajrNjdan4asbmyjdUjuUtIVMsiOxHmRxNnqq4DA5IIJ9TUGtaf4X8Iabpdxqr67rurbA2+0v2jit84YrEzHIUHoRkkjORXe+F1tm8OaO1hILHSZIc22nW67W3uzM37/ADvd8ZBAPOOfSutKMVdrTppZfd/mlfubVKkeVqC0b1/r/hzR0y70vS9NfS/CsP210kYpaxyHa8zH5nllPAAOSxz2wOcVNb6D50dnL4quYNZ1C1mM8ZVClvG3G3ZH/sgAZbPf1rZGI0WJY0jiBz5aIFBJ5JIHc9SfXk0iqhzwCAORWDm221169fv/AK8zj5kth7ytIDI0gfqWfOee5NQ2dxHd2dtc2+9oLhBIhZSpKkZGQeR9KwPEq3ul+D9QltZRceW4eSNYQXkhLfNGueA2Dw2Dj0roL6JomtYYw0Q2gKoJcLgDgt3x0yaTiktP6t/w4rFXXtG07XtP+xaxaC5td6yeWzMo3DOCcEZ6nirkMccEMUUEYjgjQRqi9FUcAc/SpOwBPFRzh9p2HDDmp5na3QPIkdg67Xyy+5NZ2gaXpmgW7abpNvHbRuxnKAkl88FiT17CryAlVyAPUetQzkRTpMYy8r/u1wCfrmiLe1w8i+NroVlQOjqUdGGQwPUEHqKm06Q6fbrb6cFtbdMkRQjaMk5J46n3qorK0rKu1tvBIOcH0PoatIpJAHXsBRutSdjC8e21vdafDq17e6hYXmnuJEvrGBppQh+8joo+ZDgZz0xn1q94b8Q6X4ltFn0i8N00aAyrImyZewMi4AXPJHY1g+NfFlxpN+2k6YZre9eMYvVKk72U4hiU/ekwAT6A1ifDO/XTLq+fxHc2p8barZmUl7gsJgmdiO4wsZPA2jJ+XOe1daoydHmfTb+rbdd/lqaKN467mx4/8O6tq2sJqmnJNOumWXn2lq7qUlvN/wDDHn/nnkHd1zhcHmuZ+G18+g6tqW24tk8Isryu9zK/mwuPlijRW+ckgAbSueD6VR0Pxh8QtOiml1CPTpbCxYO8PlbWnjIBJjmyQTk4BOctkda6i78RWdr47iiTw7Pb6rdENPeSWW4Sy7MeX5pH7sxtjMq5Hc1r7Golyy1ST2fpv+nZvttopNR5Gtyx4n+IcMDJbaJaXVxbzx4XXUiaW1tpdwByuBu2ZGeRycY4o8Haj4uvp7mTWbqSdHl3WaxaesLmHJBZ0LAqxwMKenXNczB4i8Rprlpb3OkTyAziSGw09/LtI4tocF227CQ4J7bmyD143LSWCwvtM1LRoY9XtLZZRcTXEjySvJJnKrKTsLl85IBwOBgU3RjFcqir99H+PS+3Z9CXHlL/AIe1OVpr6bSruOErfq2qT3KkzSBOCi7vkHXhgCCoODmuZ8X/ABEOn6sll4W160v7J1kCW2oQtGLeXJDPLKQNyMCwUHruHsaxvEV5p1zdSaFPqGnWF/cW6S6ndtGs1uzFgQm1ThCjbDhew5zjFM8M/DLVrlhB4hney8PTxi5u+oF2/Y9N2c87SQOhFdMaFJL2lV/Lv/n5JdN97ESavZC6b4L1jWr22aJLIalZRy2l8gj22LQvsIy46ybXYFFORtQjHOe8XRdK+Hd1bxeEo7ibUZovs7NOweQoc7F+X7iluSSOQuAcnNXfErTWHw41y20G3VLWw0u5zcOBGzHyifMATA39ST3NeJ+BNW1ay8R+EJxd6rpUGoI0U13qMnmw3DMuAYwFyvOSCxwDg9jnP2sqt7vTt39evorGerVz3+OUWtwRp2XvLONkO8BvIEpywOPl85yBwPujrjvlyuAZIEUzytNvuGSIszS5wQ7fxMDxtXj2FYl7q+l6Jp2n2ukrfPYxTPJbi2iM81zKxy85U8gY6OeuflA4NcvrHxKfTtPMGji5h1Rh5dvbxbZJBgeozsVj/Cvzdcms4YectYr7/wBf609Sorsek20ls2ry6bezSG/aIFrC2wsvlnGTMxIUA8fKCSM1zfxD16LQrK5sb17NRcMCbW3xi2tsAbN2fnlJ4yBjHb15SLw/qM2h+G9Ru/EVyvirzpbh5DMssNuGO1IRklBJlidvqzZIIrO0vwXb2MbxWUNzqOryyJceUfkkWFJWVvLmyQxZxjeoGBWtOlTUlKUtF087/gv6v31hBpcyLHgPQEu7qW8ubm/s/FrM32OaUokMDbgU3cgZ4wAwPT7tewzaToejeHB/bcUMdpbIPtE7Fxl2YMSSvzct/M9ia850SOw183NnL513Fbai8Z0qSDZA92o/1srx8rGQMLkksy4z2rqviTqejGa1S8u9UkudMuFmeHSUDs7v8vluOQpIDHnnCsOpqK8pVaqim/l+H9bK/XUJJXSRi6v4p1SLX9M8S2t091Yi3SEaFB8tvJE+QJRNjaOxxjcCMcdK9FF3B9tjtkkH2iRGkEY+baF65I474z3NeZ6Fr+kReILqyvjeaiTeqtnDbQIsNw7DAKQdUC4PI6Yz3r0p7Fz4hmvWBPkWwtcDnBL7z0/Dr61hWjFNJq1l/wAMvlf17k1kk7EzYLluMYxgjpz2pjfNn26VKYZGAXa25unHXHpVW7uoLK2kmvLiKKJF3FnYDj29ScEAd65077GFmOHGfUn9KiZhk4AArKm8QWifZw9tqatOwQZtGwinPzuf4VGOSelXRfaeZBGNRsRKV3KjTqGIHfBPvWnJJdBND2A4+9z09653W7O51jxNY2cd1BJpNh5eoXcCyIdrEkIGA+YsSDxkYHNSXeviTxhp+gaZewLM8bzXUq7W2qBkJEehk4z3ABBrU0vSrDSLD7LpVpDa224uxHWRj1d3PLH3J49qafs9Xv8A1r/l/V7V4akhIG0IqoigKqqMBR6VGxBBHOCfypUdZYlkiYNHIN6OpyGB7g+lIVBJZf0GanYh6kTEjpz29c1DJ0Bxn2zUrc8c/wAqiYcdefamQ2RjJ/u5PIGeSPYen+NV725jt4WVlFxcMp8u1EqRyTn+6pbj8fauW8W6ZNqnifS5tFjabWdHdWcuwjtY1cghZWzndx91ecHPpXRQ2dw0kM+syWV1fQmTyWt4dsVuHxnYWyxPA+Y/hiplBJKTfy/L7/l5GiSRzNuvjT+07q41FdK+xsg+zael0B5XtvC/e9WOR1/ArprpMZcctjpRWinpsv6+YKSfQteHdfX/AIR6S98RXECPbeas1wmI4rrygS7W4J/eKAMBhgE9BWLot5ql7pOreIriF7y8liPl2e05Ma/NDbx4xhVJy/djxW1oGgKLW3m8RW2n3V/BJvtI0UyxafFgBIYQ4wNoGM85xmtue9htVe7vpY44FbLySEBQM9z/AFrk5oxb5VfX9dl/XodfNbY8Q1q507TZzY+JG1y4v7m3D6nJa7RN5jkN5Ks52xQrx8oGWOM8DFb3wl1HTvEGl6v4N1S1mvNPtT9rt98axts3jPKE4YMRyDjrWX4v8M3MXh+bVm8S6RdQxXktxkQPI95csOIyASNwUYwOMDJ4FcZbXsnh+7tryDWLyBoZkYNbxrG8QZRuCk8bQCR0wenFdM6knon+e67dv026HfRw1OvSbW6+493upfE3hmwa6kZfFGnQt5YtlhZL6OLk5DjKybR1LDJxWz4X17TvE+mm/wBIM5gWQxOJovLdHABKkeuCKbaeJtPbTrm7vpxaNawxTvvddzpIqlJEA5+ZmAAIHPtXBeB5Z/FvibUZL2dgi28UV5LasIZJ5UkdldtgAHyPsJ4ziinH2sJTatbqv8tv6R5sqUle6tY9B8U6Naa1o81tfF0jhIuI5UkZDDImSr5UEnHpjmqPg3QnsLQanqUEw8R6lCjapLMxDSODkBkB2qQDjApviCXUfEOsah4W08Q2FnaxwyajqLnfIVY5EEQHAYgcknI/n1lzJ507y7cFmLYHvUc8ow5b7/8AAt9+9vJGXQrso4xjHQgdqTZlx19hip1jJZflIycZxXAt4qur34kan4PvdIEVhbxlrq+iupklt41TcsuR8sfO3P161klzbFwi5HbYX5vUDOM1yWuTeMp9eNj4YykaSxhZGhQQSKRk7pGBwykAEDrnird/4u0Oxlcy6lC0cC75mZ/l29uRyfw57jNef23xpt7eRWTQ769t1nZJCp8vGMk4PIz0PPbPStqdGq7yUL+v/BNYRa1sdv4K1fXtQ1W9GqXNvfaPAsrXGoQW/kWySqyqscLkAuRg7ieB65pni7xmqtdaH4b02bXNXmf7JmNN1qjMuW3OrZO1SDxxnvXn+qavD4/ubq1n0KXTr2b5I9Q1S8lZbeEcrFEkSbQTk5JBzzmu88MXul+HfDNjolvFcQanBbFw9xbmBphvLH58bSpJO1Ax6AHkGun2Ki+Zx17bL1uv+AKcHe5X8G+HdE8LXNnY6fYf2pPBbpeXl/Id+11Y7yuThCpbAwMnnk1jX1lq3jbx1qd3MEtNYTSGQQXFsxhtGRiYSrkjcWBYqwHDK2RjFddZ6r9jvLuCytJ3FzO8VzMoQx/cBjR2YgtIegXH8Vc78NtdtNU8RXdlcWsNyl0ggju7gxpIm4kvalQcsCyErgkjnsTWjlP3qr1dt+v9eX3dhpWTkuhW8Fx3OtaRo8msBL6wsrPdJZxqPsj7yWMkhAOZGJyenOc13Gsa7Cvh+wt5bJp5mlS1gtYCYozledpOcJtG3PPWtDxVPDpXh2PSNISG1vb/AP0HTbeFAibj1OMYCqMkmuK1i5eC2tbjVdYurqys0SdPIVII7fyj89xkn99I+1iiDpuBxwKiLVZqTWl9P6Xf5Xs1e4r8zvYPE6QfZ5E1u5F5o00olTTorh2gDqyrvuZBz5aHGIo/qea848e+KH1TWprO2la7kurlo0uo5PJjtpUIRDDjBCKCfQHPU9aj1vxzrfjS+TS9D+03VpGmNPjljKTK+RtkbZkPIx4yeOT0rtPhx8OL7TLi21PWI4LPU7SaSUzSYn8xnXAV488FCc4B5713QjGhHmqvXov6+V/+AS5WWh29t4Z0O38G6PqOt6PNc6s1rDLJbWUWyeeVeMeUMbm5yxPXua39SguruBj4hkla2aXcllYAhpiQcKzDDOwz91cLxnnGana4EbyTt9pa5kUK0kgAmcDsoHRc9hgc1kX9rtubOy87dqN5ul2eaQ5QnLuxDZWJQNue/TvivL5pTfvP/gena39WMXqY3iiwuvElpPoX2Z00aOSJHjjfapZuFhDAZkZc735AHAHIJrA1TwH4V8MmO9tlmmltD5VuJpmnjmn2/LFGCcALj5z0wQvB5rvbNZGE1hbxyf2RZ8y3COVQhQWeNWbucjLDgLnvXk3ivxDc3viBbKW+TS5PK8uSMwkW1ra5LMUGMrI2QM45AB4zXTQ55Pljolr5/rr/AF2HGPM7GLqf2vUDdG31i523Vw0U2vFWjjuHZmDhMHDJyV4ABIGOMVdg02x8N6fBJo1hdXtuSETUTBmzhlztDSSD72M/MBxzjtW0sAvTFbQC10GGNYgltcTiJNPQghQSxy8jDD47bvc11tzren2U1leaRe2NvoWm23l6lpEKeXEiksfNjI4fOACRu4Oe5roqVZWSS/rpt32XT5Wv1X5NEcxovh60ntoBFqBvr+9kkP2TSfuGVVwzuzDbbKAeAR+taZ+F+pKUhj1TSrFLWMpamK2Msw353mWTgyNz649MdK62w8d+FW0yJjrVhp8ErH91JmJA3B2lioUtgjnvXQxSRzwxTwvHJDMokjlVgVdTyGUjqCK4amJrJ6q3qv8AgfIydacXoczF4G0vybdbu71OVoli3iGUWyTOnRn2Dc5zz8zGtzSLOy0xJotJsILRJX8yURJjzX/vHuT1q63JyucZwarXVvHdQPBcJ5kUgwy5IzznqOe1c3PKStJ6f10MZTk3dsq65pmn63p32LU7SGaEEGMhAHiYHIZT2INcSPDHiO11CXyzaXWnXEgknkjvTDPdyABY5WH3U2KBuAGDjjk5r0Bjhuo+lRk8DpVQqSgrReg41Gjz+58FSzW+oz+KfE+parqV0CIY7d/LjZ8grtiPPUAHGBjk11cGh6dDcTXU1lbyX1ysZuJGG8MycgKDkAA5IxTL1dVg1k6hGkF3pkNsVS1jfbcCQ53uPlIYYx8oOcA4qxpmoWWq2MV3pt1DdWsufLnibKtjqB0OR3BHFU5y5d9P60/D+rBKbZblkJclmJPcnuKgk2ZmZo4mMgVXLIDuAzgH6ZOKVmJHBzz27UxhhM44zk80kZXZUv7Gx1C1jt7yxtZoI1KRo8YwgPXb6Z74qg+kTQXds2lajNYWbOn22zI82O4jXoqBv9WSMgkcEHkVe1LUbDSYFm1S/tLGIkANczLHuJGenX9KbZX1pqdt9o068tr2AMUMtvIJFz6ZHQ005W8vw/yKuxsMCWmnW9paoNlvEIohwMgdM44FY2oWOtXcwJ1mS1gimM8K2iqg6jEcpPLoBu6Hkt7Ct5tu5QxAyduCcc+lZ9reC4uI4ZIJ7V5QxjS4hKeaV67c9eOcdcAnFNNp3QJsc93Gb2e3OEZQGDNkI2fQ+2a5p/F+3WbjT4dHulltzjzbqaO2Dvzjyg/EnTIGRniuoYbuqnapwoI7+oqKYeagSVVdAcgOARn1Ge/NF49V+Ik4p3aOY+Gsl2fCECaklyl6ZpZZluIvLfc75yf72Qev4dq6OQLk49Mc96UAoAB0Xjr0pkqkqRn8V4xUTlzScu4m76lGdtxIJOB16jqKKbKu3ABJkYYywzg+uO/0oq4zcVo7BZHYvFJED50TqegyKzdVkuGtpra0sbe9lljICXThYTyAdy4+YDOcd6pXGiCw0i4j8IxwaXenBU7iY5W4/wBaGzu+vX3rQsiwtIBNGI59g8xASQHx82CeozXFFJe8nf8Ar+up0s8e8f6aPDdroOnaNFLJL5s2pXEpuDELqRSEYbR0JDYAX+FvqawW1jwXpF/axQvqOoLIhinhuIRG1nGxyYlYnl1YEZI24PHNe8alpWm6mY/7T0+2vPLDCMzRhim4fNtPVScDkelR6Z4f0PTpreWz0awint4zDFN5AZwpzkZPXOTyeea6/axnFKabfrubUsVKkvdZ5Do/h22+IniMahpcdxpekJELe4ManzJWHJOeg+YDGf7vsK9pvLyx8G+GUhsrQwabbW0oWWA/LA6plGdfvNuYnJHQ9etT6PYWWj2b2ukWyWls7+a6J/E2MZOfYDis/wAcraXPhS+s9TvDYWV2gikuApJXPIwPcjHPGKc6kakoxt7q6fr6/eZSqOpIb8N5dJTwxaWWj6pb6jcCMXl8UmEsnnS8s0pHfPHPpRfeJNdj8aPpWi+HIb+ysGiTUJJpjFIfNGQUJwvAz0yfWua+GOgazHH/AGlqKN4ftmg+zQwWcvl3M0eAVJcA/uurAghiSecYrvNJ0yx0a0aDT45AZZTNPLLIZZZ5CMeY7tyxqJNc0m9W/wCun6d/IdVRhLR3PPdG8SavrHirxbp+p6hJ4blTEOmiR9+xjITuXPy5VFILgYGcnkitTVvC7z+HLbSU1eHRLq73ma7Zw0N5IwHJZyHlyPr16YxXUeKNMtNV0S9S72wyx2svlXiriW3O3duVuo5UZA69K8c0bw5rnifQ9E1fxf4gvJrSK9Dixm3ygwA4aUA/db/Z79MDpXTS5Ze8ny2fa+ttLf8AB2Dm5lob2v8AwmtxpsbxXfn3zIq3dzcRlocIMFguc5wOp4rY0/RRpFkNPg0eO3tZpU3200hnE8rr96T7y4O0dOa6x7y4068+zRfZmtomQSQvvM4jJC/Iehweu7k84qj4l8cw6ZEBoNsmrXscp+0Wrl4dkYyMh8YDZ28HnGeM1KnVqJRtzf116feWpz2K3hnRd+hXH2hpEmyVlnndNuc/cBBA+8pAzjjFZKanaR2TWZ1m1EFtcea8iQs64YHEajvtbO50BAwc1yfiPXL3xDcW17eW9tvgxElkrKls7sTy/O4uOAM8cCsGzuJpoZZbrU7qMWmUurBgqSWrE7Rw2G25IBK5xnniu2NDW9SSV+n9X/Q0jTlbU9bSxB0NNUtJLC9hntpnhlafbE0yHEYLnjdksQe5ABpui6RpKXmnW2qadbqZZQ8M4gKEXZw+crjy3Ygexxgd647wtcRaVaae9uN+mSXoWeGT5kt2kIBkQfwnIHt616rrnhRp7ozvPK80EiusKHY6rnkBjwTjPB65rGrek+Vy3vr/AF2Mp6PlkzlfEusandeNPFE7W07ppcFtp+nkfKIWuf8AXTpnq3BGRzjiuF163/4SOHTfC+lXOlCJ1EjQi/DzoWUHPzcFcNwiEnHOAa2rjUdZ8LeNdRuxDcNb20cbW9u6hVubFJCPl5/hA4yNwIyK5fXdck0XxfpvibRZ7O6sLxpZJYtkUXko8hkEcjj5gCOFJwccL0IroowcLcttlb1t/nr6thKNo3T0Pbvh74U0jwRpVpbCG2fWyjSTXEasZHxgER55AA2jt+tU49V1keMJoPscltpOyQrPMIz9qu85HlDO5l24HA69eK39L1MeIfBlrrNqEWSW2aZChYCORQQQpYZwCCMnrXPtcXV38QvDkEdwDJBby3EwmBxMjKuTHgfLt3cZxlvXFedHmnObqavW9/L+rf8AAOdvubOr3i6Nbahf6tZXV/L5TOEs0BMYxjy07knJJIHSsjTNKkvJ7zULto/t5txZ3uEZWhyFkaJWHKqq7VGOGJYmug1Se+iku2s7FLy5WCSKCAn5JAVyGIJGT7elYWg3enOsHhi0mnvL5ovNmEsDxSuuVP7zcARk8c9vwpU2+Rtb/p+n6/ITsYvjDUbnQL5Jr+dH0G2iIKQk/KxQ+UpGcttXOR0bAJ7VwHhKGfxFfaZp2u2zNJJcNeXksiks9mApVpRnCggDknHIz0q18Q9WbWfGVtoF1NcArcD99Ywq8RLAZUg8uquIV2N2BzXc/DfSbifTNZvL/wCzz3FxItteQsfME8ka5ZAw42MWAPYbcY4rvv7GhzS3a/4b87/cbwfKrl7wboUWpRLrOtTPfI8rzaZYTIRFZRFmCMQf9Y5THzNnjGDiusutM06c25nsLJzA2+EvbqfLYdCuRxiua0bxBLpdjrUGv2032rTbqCEmOVZXuJZ0VlT0UjcBnhfStPUNZfR/KvNasGstJeQx3VwZhK1px8ruq5GwnKnB4JHrXnVFUc9Plr5X0+T+d+5nK7ZsXYhv4xFqcEF7bZDGK5iWRcjvgjFefaFrreFL6TwreWxuLK2umaK+ecCSK2lzIhMQGXVScFlyF/CrvhLxJL44m1q60LUrax0/T5zawA2BlFxuGVlkZmBHTOxcY75rSk8F6NeTNca7aWmsXbEu01xAc7zwQvzfLEBhVj5wB1J5qYJU24VNu2uj/BdStIppsueHvEWkeIYi2kX8E7q7RGEuFkBBxkLnkHsRWlKrhv4gfcVUu9I0m7ZDc6bYOyLsQvAD5YxgYAx046Vk+E7uaOafRNWubm61uAkC4nt2jN3CnCuGxtY/NjgknHNDUXdw6dP+D/wxm0mro22HJ/OsfWNettMv7HTza3l7qV8jPa21rEWDheCWfoijuT0GTWy5O7DADPPNcHqV7rmn/EXVLrSPC1xqDyadDbW1y0wijbawY4kJwg5OVHJKg0U4qT17egoK71OhFlrU+pW9xqN9YWtvETIlrpqMzBuMZmfBOOegwc1mJ4f1LT0uodC1Gwt7UyPNaCSErLAzgGTewBDhjjsMYFZ1p/wkfhLT4oo9LXVbF3EtzdXNwltHal8s/wA7NlzuyNz4zx2Iq94X8daR4lilNhDfGVOEiSBpN785Xco2rjj5mIXnrWvLLVws4rtb8Vv/AFvYq8o6lW3XxEmtWukat4msP39s84exs1ErOuNy/N90YOQcZPcCteW1aZpo7DWbqC4RtzMUWYZK4GQwx74Hce9Z+n6Pq8ut6vrrxaPbajM6R6fFfB5Ps8IXa7OYyRvcAcDPviuhVZUjC3EsMs//AC0eFCiM3cqp5A+tNy16fJL/AC17evkTJrdGdbeHNPfE95YW+q36w+XPeXdusskqkYbdwQoOSMADjiq2kaDpXhwtHoVg1vHcDbK3mluhyBg9hnAxS+JNAbXzZMmtanpbWjmWP7G4VWfszDqSO38q0VjYv5k7Ey5Krlywx+Pc9TScnb4t+mv9f5E3BwG3A4INcdr2g6teeJrDVxqssiaa+baxViiSZGN+c4WQbmDEjkBcdTXYufmOBUM2TjDBORliM8dxilGXK7oIy5XoVVuc/u33NKp2nHOffNJNIqlB3J6D09ajijY3UuTIrHLheCGUd/wpl8+yNdqgszBAx/hzxn3oa1SIZl65banLdaZqHh42LSwM4njuiVFwrbQBntj5uetXWn1dkbfpmjI4bAZbyYqB6425/CrvA4TGBUcjfe6nBwazcrpJopS02Odv7TXbhSh1awsoWTbutLYvICT/AAs5wOKK0ZSm75cs2euODRWqlb/hl/kPnaNXXdfttGws1vf3UxAfyLGAyylc4JA4H5kVMmqaVeSRi21KBhNGHj3ExttJx0bGDnsefauaOkeKJPEXh24dXig0sukl49yN0sOeFXactuHLZHXpXY3dvaXqul3awXKMeRJGGJ5yOeuQeetcbUYpfozrlGMSs19aRGVZp1gWGYWzNOfLBkI+UKWxnODgjgkHB4q2pJ2MqsyMoZXGNpB5H1znjtXNzeGrKx8UQa5ZaVvg+zPbXVtAgl81iylH2OeoweRznGBVzwz4h0PVlt49Lmmt45lYwC+i8hXRDtbYSSPlxyM5ArZRTXNG7/r+vkYyXY3jFM1vKIJRCyoW85lDeWO7HJA4Hc8euelcvYfbNQhj0rSbq91HRLiZm1DxBdSoxmGf3luikfOCNq71wByB0NalhFHrcH27Uonks5JPMsrGXiIxrkLLKvVmY7jtPAGODW2pwsYO0BQAFUYVR6AdAPYU78mm7/r7/wAvUnYflQEWNEjjRQiRoMBFAwqgdgBgfhSEYfqQBxRkgH0Pr1pV4QAAbQPX0rMncpeJFabw5qSpaW95mAlre5crHKoILAkEEfKCRyOR1rn5dZ0qO2uLePVptahe3E6QpbiOOxh2AoquBjeB82SSePxJ4r8VWMcs+gxWI1G6uGgtZorhGFsn2jOwyMPmI4HAweeoxTPBHhtfCXh69ufEEW6e2aaR4kfMAiCYPlqR0Kjb83pXTCChC9S990u9/wCuljaKtG5j6jf3dnpU4jYW+t3AitxLdo29VJyZlY8OABkEZ564rh7rWZbC4u7JL23jRMIr7WwshzkO55LdSTggepNXvF/iO41yc3twV2WpS1WCCXciOT/CDwGxtB5xxUXhzT5PFPie1srWbT7i8iw8FtNZPcW0qDOTM6su0KeQDnJAz7+jpQpOpUXr1OyELLzNPwV4F0vxDov9oPd6nZm2druaWKRPs52kYdZF3cgZOGwevFdH410bwx4SaLX5/t1w95O86bY/ORg6knduG3ac7ySc4GAKveC7rS10lGtJrG40nQ7+e61J2Xy5JG2utu6qMKcgnAzgYAPIrkfhL47u9e8Q6lpetW1le6fqyyX1pZlY8LiQqykHowUFhnnCZHWvKqe0xKdWT2/r/g69GVOq6FXljt16GZ4djgszd6TLqNpcpd2+C1sD5bo/KMpwNoBGMY42kGvbfA2rzaloMFtqU4fW7CNYrxNx3YyQkhJAyGUZyPevK/HPg+Hwdb2t7odtJeRQbklngbc4jbGFkjC/IPl++D65AzzmL4p1PSZ7fXbG68qcbY3gHzQ30QywU9wR8446jbjHOe6C+u07J+8vz/4K/ToicVTUlzw2PZtf0X7RDK8EIWVwEd4RmZ0OQyITwpwTz0rxj4i+HL/wZ4PEMMVpMhungS8ZAft1oo8xRIvIBQ/J0HU8969z1fVPI0iw1KBBLYXnlOJo24RJFBDjI5AyD/hXmHxTunm8K6vYSr5/+hG+89oSUIVwnyZPysC4JPP0NZYSc00ntf8Ar7v67rlg5NWOu+AlzdXHw3tlvoZBFHKUhd4wnmKw3MQMnjcxAzjPWrl5DHblPEdi2ZdOQRXNvCgBmUEhlV2O0kLgbeASOtcr+zX9tPw7v7O5CTxC4Y2p80sNuNrKccjkAgY6ZNeixaAscIt5NQu0mO4r+8WNMk5wFx2PQnmssRJU6879/wAOv9dzFq5j6RqUurXt5NeyRfZHH/EvkijPzxfeyV6g9c5wajNxo3/CXxeR5jXbQCS41EthmgPLYc/eQFRk47gCr/iOfRfDKqNYv7a1kJEqLcfNM3J9OSpwcmuQ8QfEfQLz+0dJ8PF7q6htbhTJaRKsaqi8qgPVevIwMjgGnTg6mtOLs18vX+uoON2eZ6Xq8Fz4z1zxBptvK32O7kSRDECmJGIh8s5yHdvlII4ABznp654Pxp2lQ6FPd/ZfEdlbtdywTRHYJZV+VCBjftwMnJxn3rz3w3Dpmk+F0t9XiFnrlzq1jdG3hhYRpEQGiIPPJLZJOeh6V6OYNO8V6vIllqN1bmxuzqmotDIAkkYJRY3c/dUNHJleR94967MXJWs72XX8vlq/XQ2k3axZ1HwtfeIVjutZ1iO0LeRP9is7YPHFPGciRZMqzcZGGBAz3wK6LXdRh0/SdT1C4jD28MLu0XlmQP6IVHUEkD+orAl8eaZLNpsv2LVDpmoMfL1MWxS2UbsBjnkIT0JA456Vb8Y3Ev2nSvDcMSmbXTLFNK3KwWyAGYjplyDhRnvnnofLmpvlU1Zf5b/dbrqZxTclcqfC828vguGO0/s9Z1mllurawKslrI7lhGSCdxUHGST0xniumYbc9evPNYd94S0NtKuLPT7CDT3eMJDcwptkgZU2pIMEZI6+5zUAlvfDkGk291fvq8V3drbPNdfLMhZM5TaDvGVOFPI9TVStUk5Re/f7/wCr/iKSUndG8QCTjgfnXO+KtP02/vdLuNU1CS3ntgy2sTSlYXbOcun8QGDxkdTXSXTRwJJNczRQW8QzJJMwREX1YngVy8Pi+z1Ce8g0bRda1K5t1DIRZCOOVc4JWSQgBQT35PYYyaVPmvzR/r5kxTTuiOOTxbd+I40lbSbPRDbea1zFaicSyZOFTMit8wIbkADGMmptX07xENPuzpviOSe8PzxQ/ZYoY2ORuRPvFCRkKSTgnJ9r8N/crfxWN9pV1ZSzpI0Em9JoX2dVLr91sYIXHIzzxVp3WGMyyukUaY3SO2FUkgDJ7ckD8abk01ovuTv+f4MTlYxobHSPEFtItxG2rpCf3qXlw1ysTn7yEZAO0jHIwDV6NbexhS3s4I7W3kY/JbxBELH1Cjv6niuP1CDQF+JlzPMjWK6bHG81zp58mCa8ZjujuH+6cAIcZ6k9zXRR63pcMd2Dq1pNHZ/NNIJd2wHnLY7dcEcHFW4Oytdrf7xyT6F9vvMF/I9qilVpV8pGdWbo8Zww+hqnoeuaZrpm/se9ivWj2F0jzu+YAjg47H8O9VfE11dJbrpmmtAdcvMxrFxItuuCC8uGBUeh9ccU1B35Ho/MzSbZoxypMhaJlba5jOGzhgcEHFNl3hhsw3ODk9B7VW0jTn03Tba1MqSmGNUDIu0E4+YnPUlsnNWnzxu4Hr3pu19BMhWVZN5ikSTa2w7WDYPcHHQ+1NcnBHY/pUkVsA5FrDCjSMWYRqqeY56k46seOetYN14r0GLUbiy/tFLi6g4ljtUMu3kDluF4JA60oxc3aKuO3Y0biBJjH5y7/LO5BnAU+vH/AOqquqxSTabeJFn7QIWeFtoYiRRlTg9eRirw34PmReU2eULAkfiKZgk4HeltqTc4zwdqGvtezL4rkt447iCOWyIiEQZs/MgIOC3PKnngYrrZF4HGDXFaro9t461G5cD7A2lyLDFejMrTuMsCmGACr6453Y7V0TTeJnWR7jSdMlkbBAttQIM3qBuUbG7806qTldWT7ben4G84p7bj5so+QOCeBjv64orGl8Y6EryW1/dtYahEwSW0njbzI39OAc57EZ6iiqjSqPaL+4xafVHQ61N4svNMaLw5pdvpM0qFWutWnUPDnjKRpuyfc5x6VkW/gq6UyRN4w8TEtAI5LgXjBjNnLMFPGzoAM59+1dwp4B7N1oIz2yOoz2rkhUlH4dPT/g3Oly6HN6f4QsbZUGoX+sa0QDuXULxnjZj/ABeWOARzjB4ya2NT0a11fR5tKa2WK1eExxm3hUfZf9qPj5T7jrz61Y6kgH8KxvFmixeI7KLTZ7i6t18wPJJbylGVR94N2IYcY9TntWinLmUnLbr2ITvoWdL1e7l1t9I1FtImmjj3CXTp2LIFUf62JhlPTIJGcDvW+ATxjFcd4ZWPRPE9x4X0e3SWxtoVvLq8kUCUBgAkTMoAZ/unn+EE9as+M77XdP1HwxFol5ZwRXl0yXFvKgea5jG3IQEHgDOSMYyOaco3kox0uv0/AbV3odQ5EaSSyMFjjBkcnsAMn9KkjxJbRXKgtBIodJB0YEZByPY1l/Zb++N2Nelgt7CQNGLDTndi6nj95OQCQQeVUAe5rh5NF1jwTcXmt2GrwT+H7W1xi+ld3jhUZCIgGwHI2L/vetEKalpza/1pfuCin1PQLy4tI9UsrCW2hlbUYJ5GlRFL/uQpCvgbujHGemOOtc34q1S0TQtdthfzNb3Vl/oxfkJIDyik8kcdD34q5pHie0vvCR8WyaVPpXm2plMshV0aJZNowyktnOOqg49RXJ+PoimhWsrfuwvmyyxyNtJleTIeMDIZTg5HGMZrXD07zSl3t81r6dkbU4XkkzzaO8tEm+0kyx2USllBwELg/NIQB64x611nhfVLaw8Dz6jYy3q2d1qccd26WyqkbFSV+RW3MGGeRtBIAPHB5R7wmxcWiSyW8sypNB5zQg7G+8SDjI7ZyATnFeqjw5HrejwLDNpkMkZiW5gtEJg+1YfH+rK7QUHzHOcqM1rm9VpKm1o/0PWoqMXzS2Of8KRaVeaF4g07U7rWlt5v3jRaZGoMvmYCp0KhmIOAchcP0zTxb+FPDVhpF3qdhJpOvaI8qWg09F3ai8YCt5z7B8pOUJPXDkHBqHw9bG98Waho17pz6haQl2RYm+ytZyDbudfLIXZuI6k8YYclszXMcU/hy81p7Kd9Ou2ZrS5upC0lldgrmPeMlg2cBm468A9fJjXlBKF3b/M6K+Gp1qrlLrb+l/wxsfE+PUJb/Rtci1S30bS7yNJAdrkxz+SSwJAIyR8ucDOMYNcyiDW7L+0tM01f7HMZbUREpFvbzLne8atyAqhCcHALnb3qLTdYi1PwxJ4a1nUJY0u7gXlvOshligkU7QJNxz5ZIO4AnhgfWur8O6BHp51Gz8b3EXnTm3gtYI7wWbsFLf6QBwCoBAUkZOGB4rTD4h0JXW/6f156W8yatDkp8kum3mv63D4bX8b6wLGa5uIbe+jAjs5Jy8CshLfIv3fnz1GAfxrQ8QWduddSGJrq6028u5Ir37UC8f8ApMRjCI3Gxc/NgfxAHOcV5xf6b9g1Py9ZE0On20s9uZRHthMYfZui77lYc9R0I45r0zTr3ZYLptjvuJ7SUpqc07Eq435j+QZB3rgADBHPpXt1Um1Wp6pr+nf7vO9jyKkFGRw7/DzX/Dd2sXhLXbldL3RvKqyiKdnJxsVOjPjO35lBHFMTwnrniHSwms+PX+zR3TrGdjSqSzHcQwwSw24I6A8D1r0q70n+zdJ1Kee9uhYriaEwKGms1DZEZGGMpB+7uGcHB6ZrJ1x9S0/RpdUawRLa3mWK5SKBQYYX/wBbIIhkFnIRdpBCNknjNTHFTkt1fa9kn/w/9djFJPY8s17wjp+m3lvZ+KfFTta2ySnT4Q6LNKrdnc5ER3kZVs4UHr0qj4d13QPDenzyaJb3l7rkO1P7T8j9wkZkAfbwW3FTt3EY9B3rsNV8d6TbWzWegR6XmRJDcRXOmxzyCViFMmcYOEU7jjrj73OPTPh1calqOi+YrJatHIIpRZW8YS0g2qVhTcMeYMq2CDgMec1EsROzk9vPT9P+HN503ShzOxwUes6ffXuowXWumxlW4S8ieyhYrJM9s2yMSP8AcjULyCpGSenStT4O+GLO+8IIpnu7uwublL6+v3Dx/bXT7lrh+WjU7ixIwcgc547238EeG7RLSGHSbSa2gMjgXa+ezu5yXJbqSfX0GMYrornzXtZltpRDOIXELhRiJsHaduMYB7Yrnq4qPLaF1tv5f1fyOaVS+h55428URyeNB4b1I3FnplrHBfXUotnl+3R53GMbSAsQ4yTnJBGK3DKfGOsaHfpbXFpaaNdy3TSzgBp5ChQLGRwUwQxP0GK81+Ger23iLxYYfEAbXdRvgJTeWcp2SNG23DIwQCNcBsDHB6HNe5NdQyy3KJcwSvaEiaOOQMYyBnbgd8c4FZ14xpNQtqlv+Dfz8/L0KneKSW4yRvMyQv4DvWLqer2i6i2jx2VzquqxxrdLbRRYiVuqB5j8sXY56gcj0qXVfE+k6Jb6dc6hJM51GXyrKCNP3lw/cANgKBxktgCqfhTUdUtvAdlqx06TULwzTPNEhWPzP3jBWLchhgAbz2GemKzUWo8zXkumuv5W8vUyjB7lXRfCN5ZW1lD4h8R6nrAgcXE1nchWgklweuRuZFJyAeMqDgV1E0srj53Y+26uH+HEfiHTtHWLX7gSQwK6eXKxklExbcSsuTujA4GSfauvFzFKcRvlumDxVVdJu7T9CanNexQ8Q20t3ozm0uDbXNk32+CTzDGgdATiQgf6sjIYelc94durzxXfXc2uw2cNrbJA40mIs6v5sOVkkJGGRgxIHZlHpWX8X31GFbQ399JZeCZAsd9LbxeY/mlzlX2/OEK4wRkZ6g1hXXiS90bxTbXk+q2Igi00W8jSwNGtyRKNqMqjduWNsKR1YehNawpNwutW9t9P6/C6fU1pwbjoesR29vDZC0jtoFswNv2fy1MRHuhGD7kjmmlI1VgsMKrt27VjCjaOg4HQenSi1vrXUYWmsfPeAHaGmhaNumeQwB//AF0S48vGSKys76o5ndHNeOrfU5tIsbfRo42u5bgy+VHP5NxKqJkrEffOGzj5emSa0LS20vSIbULa2Gn3FyEgL7FE0shGfLL9W5B4zjiuM8bXlh/wkWraaJruzuksluo5rF9kk90FOEZjkqu3aPk2+/rVv4Wa9qGtaVLbayPPvdPEQkZ4irxqwbbuY8s3y/ewPxrb7Fl01+/+v6vY6ZUZqmpvY7Vs4JIPGc1BLy3/ANerDY27lO7I4I70xvlqEchSvbW1voTDe2sVzDuDhZBnaR3B6g1zniu803w1Lo2rxwwQpDMbeawsrYBp4pARuEaYBZWGQW46962NZ1uw0aIQySLeX5JiisY5186STHAb06qSfTNGjadLp/2i6vpln1m9KvezxcICPuxxjsi9Aep5Jq43VpPb8+//AA/9LRe6irZ69pd/I6QXJRlUswnQpt/2Wz0Yd161U1m+K67aeHYGlhvb9Gd55AUVIgvzeU3eX0HbrWnrhskspJ9SsTeptMe2ONWk+bqdzEBRxy2eOtcI2pf8I/fokNnrct4vlR2kV5cxyiC1kIPDYOC7sRkEsVUdBxVRipPRfl+f3FRhzXaO6s7O1sbZILG1htbeMcJEuPxPck+pqV8AnJPvUyBH3PbSpNCGZN8bZGQcEfUelRyZXjnGe1c71dzJ36lGdUMiy+XGZV6SmNTIo9A2MgewoqQQSSI3Ru2SQM/nRReOzFZs3YxweSQagnnjtgXcOVJ+bYpY03TtRsNQi8yyvYJkwrllPQP93dn7ue2etc7rPiGK5aLTtHuoPMl8xbt2VjJaIuB5hTg4yeD+PTNZU6cpStY6bXdi5BrslxdSmHQtVjtYm2rPIgD3S9/KjOCevBPHOaxdCtvHtjujZNHaxiika1tbmcvKWZ8qsrqMkgEjIOOma7SRMEFWLsoG0k43EDue2aSSaK0hhmu5oYFdxErO2A0h6ID3NaxqJaRitfVk3MCDS/EVz4gXVnuLXRkaxFvLZozTF5c8O+DtOBkAjnHGea2tA0ZdHku7x7qfUNTuhtkuZT85QdEUdFHXOMZ71fIeJmyh+VdxVeWxnrjr1qVmWJDJLIscS4LNIdqr7k9qUqkpKy2/r5i5mUtS1vTLPSLi+u763hhjjdgplAd2XIKKOpbIxgd6zb6KbxD4LgU6LLFZ6lAI7nTZ5tk8UZP3wcfeBAYDHTtUFjpOga54gn1pvJvLzS9QKQrFKTDFIET5mTAy2eeeM+tdbklyz8kncSTkk0StBqy18/y/4I7pbHGXfhm20TwKdI0z7YbSzha4jdnPmTbG8zZIBwST8oXGDmsfUtNU6EjSrdRmWaO5uIX25gS5i3NEoOPmD5wo6d66zUrDU2urz7JexQWUrwSsVTdMWVuVOeFU44I/Hiq+vomoaXqGuhLk3VsogKzfKGRGO6SJBwSckAnqBxXRSqONtb3f4u3/AATanPW54PPG32DUA00sU0IW4U42LhmyDxyT7DrXrvws0SI+G98Hihbe9up2nihsXVhv2FGEkUgyWAYcEEA4NedXsdwlwm+F47tvMCWkjbHnh39weM9TjtWj8OPEn/CPa1M8FoLm2l3faJopFF0jZ+VV8zhVxnKqMmu3H4Z14c0Fqj0HVlyOMXueseItKht9C/s69kkigleK0t9Sto3a5K7SW84oOCSo5xtIOD0zXO+KrvXLnS7TR92kWT3du1xNBbPEEYbuAAwLFiqAkjByT0HFbmm/EnQxbWss0N6sBd/MnnlQvBjcysUbDMCOmBx068V5z4/0nwnq90fE2malp0ejyqsjxxTvHcS3ZLHKx9QTnJJwAd3NeFPDSTs4v7rjwk5Ka9pp1V+50fw++H+ljUY4PE+nCTUjG8sUK3CNbjYw3B1Rixba4yD8pUDIzXTfEjS9O1LRzfXXh+yGqRt9i04zx75HjAJASOM9+QqnO0cnGa8qstZTRh9o8CWDx3Zm81by5mJfy9oAjfpvRirZyARx1xV3xZ4mn8XzR21wsdkn2WPz5ftUkab97ZSMZ2nPy8gZ9T0rqoYCvUSb0/rsViKj9upyldf15mXqV9Z6zBcNa3sq6lJBBBBp0p+2W20bdwjbbmLAAHzMScEE9q7jwlY3C6XrcNpp91bxrcKsV2ZBHDcbE2Oj7hxsAPzdOO1M8H+HNX+1Q6pa2thHpFuZEaSXIkG3KsscQ+6cjljzk1sWjxx6jNo1nHaXL3llgQTS4aU5+b5ycEBSRtHOea9KUowp+xhrb/gX7duvf0tw1Z80nY0NQv7WW4mh07MUVq8Iu71G2xQyPF8ux85ZQnJPTnrk1wOv6ha2Whz3V1r0EOoi1MFte2JfMjAjdHFuz8mDkEZ5NdX4mbS/CmlGPxI4v7fU43dtPluMyT3TFcqrD7qKqr14GAB6Vx00eoeG9Dsta1LwxPcw/wBoLeaRLdXAkEIKkRJKS3yxgHgcA4B61nQirXXy21+/+reYoNJXMz4ReCLrxTqNnd65pbah4bjlng/tIXTRS5C71BCsDsyNp46t7V7/AKR4e0rRLiR9G0qGymljEbmFWzIAc/Nz8xz/ABHk+tc/4SuvDfiySPUNBW8tTZSbpY7FzFBLLIuX3j/loeTljyCBzW1b6KyaWdPn17XpkErOkq3QSUIT8qGULvIH1/SubEVZSk020u2v9fkYVJ8z1LNtq2m3l01vY6lYXFyhZWgjnVpBtOG+Uc8HrWf4u1uPR9PMapNLf3qvDbJBH5jbwM/dyCeo6Vy3xA8S6V4a1fQbewt5RqujxO8cFvGEgihmATMhIwF6ksDkdP4jTPCUOv3vxHOp6vY2DLCkkpulLAIjKqKI488SnZ8znORgCoVDTneis3r18vnp94Qgl7z2NXwdoEN74L0WHxPpEP2yyma5hjaLyPJdzuOAuOm7GDxx04rnPE19pi+ObbS7bw8fKs4ZIVhggMc0kxAZblSGB2L0D5yST2r1ORwskEe4ZmYog7sQM8DvXjvxnsZZtf8APiit44JreNGcxfvZLhCwVWI+by+VzjFaYd+0qtN73t6v+mOnLmlqb3gL4cWmmQyT6vL9uWXLxxTSCViSQxLuCeM/wqcE9cmun8TeGdN8SXGnT6hLeR/2cXEUNrMYomDAcMB6AcYx+VP8KX9xqfhWxmZIrbUlhSGZWT90koUAlQDyvcDNZOnTeLdP1H/io006+02a4cTXsDeU0I5ERVBwVxtByMgnkms5upOblKXvL+tCeaTZu2tvp+iaHBZWoistLsk2qJHOyJc8lmYk9T1Nc22salq+6Twboqvbx9dQ1hzb20xyQPJC5d14zuGBzV/xTf3F3p0ml+HrSbULm9/dzXMOPs9vCfvlpD8pZhlQBnr7VsQvK8cUVxbyRMkCoQW3AY4ADA81ly2XNJXb7/m1uK9lcxZdEvtUs5LTxLqaz25bcIrBTCjkEkB853KAQAD1xk1grog0fxzcX+o4k0ExC5slW1Mm26QDLOEB2lVBCrghiQeoFd43JPApod0fchKsMcg4q1Vkr9n8iI1GtCtZ30Wp2MN9Zz/aLaZcpKuefUYPII7ggEUHcGbcRt4wB1965Txbo9/YiLV/Ct4umSxTSTag0rK0McMgHnTqjgjzMKP5AcmtybVZLbQY9TvbURyzj/RIE+Y3ZOTEFC55dQCQPu55xS5VvH7uoOF9V1MPxbpum+JruLTGtme8gkC3E5gKoICAXjaQYO4gDaP6VA/he/028huNEvra5jjnknaHUFdWbeoBG9Dg424G4HA4rodCt7uLSYRqhzfys9zcYOdruc7c99oIX8OKuOoycYx9Oa1jUlH3Vsgc2vdTMO91PUtIs7rUNZtbKXTLbDyLp29po4+7bXIDEHsMcc1R8VeJ57DS0TRNH1uTV70qlo81p5cVuSQC8rZIGAc/r0rqXjSRWSSOORGBQo65V1IwQfbFcb4Nmkg8UeINO06e8udJskRDNdXMkkkJH3Yxu/hHOMDHuaFaWttvu/r8xwSab7GxYromgWQWK70qDaFSa+Z40kuX/vO/VmPPep7W9sb1S1hf2N0Op8m4R8frV5wrSCV4YJZVIId4lYg9iCRwfeqF/pem33mG60yweSVPLaUWyLIR0xuAzQnfV7mbsUPGMIfwtqqu8UaLDvJnbbGQGHDH0PT34rz3wlqNtrep6+L3URdPDYxNZ/bIljYSRbyGwv32G7CEckEAdBXU6vogn1nT9BvphN4Vmty1tYrcFZbWaL5gTghmjIB27iwB+lX5/C2gukQk0q28yN1kW4UMs+9TkMZFIYsDzkmtU4KDi3vtZbfj5ar8WawqKmrWMT4UmF9Mu/J852DL5kzyoQ78nJQHcrc8k9QB1Oa627D+ZCI2Ccl3yM7lBUbfbqefp71UsNIbTbUx6PqVzbZeWUieKO48ySTG52Zl3Z46A4qf7PebW+0azcvnBUxWsUew98HaSc+/SueTvJyv+f8AkKrOM5uS6mZrOhaXqkiyanYQ3TqAFaQsMAfQgUVHew64kgNrqltcxRKcQ3NttaY5yA8i8LxxkD65orppKo4+7Ut/29b8zN3WiZqaBbvdvqeszX0jx6rKyLBE4aNYo2KI27HLfLuDDjBxzWnp1pbabFMtlGIzMxeeVjuklYnOXY8n+lTp8kMalFXaAgWIfKox0A7AdKBkduCO1edzOTfb+rfcbSZC8fmJgTTRc/ejO0//AFxVO/0LTdTvrW8vYDJc2ausBLsFj3dSAOM+h7VoFtsgVmVC52ruIG4+g9TWVretm2mi0/Sof7Q1m5cLFbpnYgz8zu/3VAGeD7VrT5nL3N/6v8iNTF8SeFdN0ez1HxFpkSLq9rF9pL3rvNFMyggblz154xxnHFaWkya14rtkn1mybSNGkRHFu+PtE7cZDf3VP3hgdDjntcPiGGxkmfV7K80tTMkKyTYkjkJ4XYVz15z6V0EgkDNvGD3yc1pKrOyUlr0b1+7p8x/CULGzvYNRvZ7rU2u0upfN8h7dUWEABVEZByAFABz169c1prj8/WoSpzxkc9jUi98ZOP1rB6/1/kTe427jVreSQMykLztGd2O2K5a683S9M1XVJwkumzEPJFPhXQEchAmWYDHA4I6eprqL5bdtPuhfQyXFoYm86BSQZUx8yjHPIzXh+naFqmozNdxwjT9FRpJNC0bUCWEoDlsPj5gVzlc84wORXThoKSbbsv628/yNqeu51HifSNN15tOxqmm3Mt3ZxXUj3MyQ5ZfkGI2OU64wOtcvceAri61e2tdIurTUraSAxyzyu6RwyJyqhzj5+208j1rvW0PW9b8P6xY2ei6Pol/PGttdX08yzxXQGWKxhVyqk4LFugPHNXLPwJpWoaLotxA09nI1ojXMQH7q9LoCzSxk4zu5BHoK6qeLdJW5vyfTrb8LdtdDX2iXoecT+G9Rsba2l1SwkhYo2992UTacDcWAOSfrVbSfD2sRTiO4tYoXmLxobi3a3Kgg7iSQS64PReuR616jqvgcTbJ31jUpjasksS5G6TywNkZJ4C7uR6VzV23iHRvEOhaRNqGvXdvqUjXFzNZRFOXBR974IXH+z2wfStljVKOjV/RmirSloipb6XLEVjaZtSdogbm6gVLeKAdGBLMSx7bR161p2z6bot4/maReW115ZcXSFrR8g/cLuhJyCD8mRjFdtN4V0C+ljsbvSobmzsNoiimQmMYGFI7E9c+tS3HhDRZbhDHZyRRRR7Y4Y7h/KU7ichCSA3PB7VzvFxlpK9vu/X9DH2yejOKPj7XW/s+0tkuIPtO8xFnVVK9QA7AtKWJAyep6CtDwt4a1W6n07UJbe0NrbyC6+yXUg2iTOcCMAtHIuSQT3GDip57OztPFfh+2spEa3/tBrQWt6DKTuQedLb4GYyuxgW+7k9jXoR2LI2xAu45OB1+tZ1K0Yr93FK/+bFOoorlitzzv4vtLqX9gWkFnZiC4uRLqH2lD50MMUgbIYD5Y8g7mHJHQVU8UeNruxbSota8Lafe2rYazt7ZWuUuCCUxCzYXOz7oGSc9s16hHNImPJZl5z071gzaJO195+n67fWFqCJI7SKKN0ilG7LLuHfcSR9K5lNOKi9Lev6DpVoRSUo3OD0rU/wCx/GEcq6IumvqKyXMFjC4t5o5Dn9xLuGAzAls9DgDtV7UPjT4cstUl04WOq30sI2TXFkiNEJP4lUluRnvW7418F22u+FrhJ7u4Ot29uTBrMnM6becZGMKeRtHrxTPBPhrQdP0PTbzStL+ySSwoQ1xLuYkKAzqm4qNx5Pv6Guh1aM1zzTbWn9P+n3Jlyy1OSu9Y12a/vfGR0Ca0jt4xpcEM8bGcxZDsCVHKnOQxG3JOegrbtLaeHSH1C51j+wtQv449S1e8t4vLkniPypbQ5JKNhFGRyScgc12WoapolvaXK6trFmbaSNoZo1uhvwRgqNpyGOcDockVyHhLTL/Xfh841uK9ttXS+d7GbVIPMlUIT9naRG6qoYj65NP2qlC9rJWXy+e9rX9bMm6sblnpp13TtP1DVpb+DVFiCuLecxGAk5eP5RwW+USdCdoHGKfF4N8O29xb3EWkW/2mBXVZ3LM7b+GLEn5icdT0rj/hG/iW31/VNG8RG+ijtwbjZNbZiaQnLv8AaD97cx4AyD1r1AgAZ5rOs50puClp5bWZnO8Xa5GqgLGgAVUUKoHYVHcWsF9bTWl1Ck9tOpjkikXKyKf4SKkX77/OCMcL6H/CpoVLSBBIY2Ybd69UJH3h9OtcsnbUlbnnPiHxHB4Z1DRdH8NtBqlsN3m2UEoka12nOwPn5MjOAxPI+td0uXtIZZIjDLIiySQsQzRsR90kcEj2rzv4M6jpvh/w0mkTSx2Nw1zP5t3IBBFcOGIA8xyN77VyMZGD1r0hVMqK8BWWM8b4mDj/AL6GRWtZcknF9Hv3/r7zWr00/wCCQ4PUZ/KmOOB1pzsPNSIBtxPJxxjHXPb0qpFKkWpvZhmJdPOUbCQozz839KhK5jYnJxk8EEYYOMhgeoI9PauYi8CeGUkkaHTPJkcoySpM4a1ZSSrQ5OIyCc4HBxXUsTuOVI9iKaVyT6VcZyjfldgUmji9M8U3K6zZaVrbWhu7nzhJudYprXyjtDzKDtPm5DLjbwe+aueKJdRv3uNH8Kaktlr1oUmlmkj+SJD0BLAg5yPu8j8a17/SdMv7sXN5YWs115Rh85kHmGM/wlu44GM9O1OhMUaCG3iKRAH+Hvnpz1q1KKtKK2+7+vL+nTlF6pFQWmsCSJv7cSVvK2zJNZIsc0mPv/Lhl59O1YenaP4nk8Qanres3WlWU9zax2cEVrI9x5KLn5tnEZJOD82ee1dYWOM7ajYHA68n8BRGbT6fciebSwxuQB6dc9SajUec4jwRnuR6VI3AJ6+3em5KOpC5AIOD3o9CTmfD5vL67uNdK2tpY6jbosdqshmlcoSokZvupwMbVznv0FazqCeevsax9OvodI1A6Ffo9udzSWt+8YjtrgOSwj35wJRlht77c9TitiVSrKCpUn1FaT38unp0CV7ixLgdeajlc4wamXGOtRy7cH1rB7iKVwuUJJ+929KKJe6/lRVoXM0a8VzbyX01kkyfaoYlkdB1VW6fn1x6c1zlx/wkGoeJ7p9LuTpmnWkAgdLy2LCeVs5eMg4O0YIPTsauyWNjpErapHp73V1JNma7ZwZIlfAd8seg9B9BW3LuBAGSV4x2/wDrVzRahrHXTrb56anW3bYzJtE0+9s4otYgGpsoG57n+JsfewD8p+nTpWjbbLSBobdFhhY5ZIwFBPTJx1PSoLnzZbaaOCYwSshVJQoYxsRw2Dwceho06Ce20+GG8vJL6dR+8uZI1jMh/wB1eAPpVttx1fy/rQyuy4VWWNo5UV4mGGQjII6Vg6XHf2HiC9sy93qNksFsschmBe2UtJksh6gkcsDnCgY4roEBI68isnVoNRm1LTG0m9NnMjM1w5txKtxDx+7YHpzznqM8dacHa8X1Gmbe7HBwcnHXApZFZo2CHy5GGA+OnvVa3luTO0N5AGCqGWeJT5bHOCOeh6HFXUVmYYye3T8ql+6SOhiPyKh3EYAz6+tchJ8QdBn8YyaFOqC4snZXur9zDEsgOAiYBOSc/McfjWzp3iLTbvU7myi1GyS6t2b5DdRneq43PwflUHj5sHiuPg8E6Zr/AIti8YaLOWhnuvtEsV2HjjkZcpI0Tx5zkqeTwOSM1cYrX2mn9fr0NqaSfv7HW2ei67HHO0/iVUkkmDRW9tZqbaGDBBh2nBYkHO/IOR+FdGNoWNEBCRoEUegHAqnp+oG+Mqy2b2N5AT5tqzh/LGcIwYcFWAyO/tVskEEnt2Hepk23Z/p+hlJt7i8jkc+tZEejNaa8+sWJtDcSZFwblGMhi2AeVEwOEX5QcY659a1l+8CeOOnenF2Vd3fIxj1pJtbCUiDR9Ti1bSrPUbaOVbO7gS4iaTgkNnjHqMVbDgDKvg+xrk4Yf+EP1iFonuf+EavWeH7KgLxWMrfMJSScouQw44OQMDHPWqAVVhhgwyrAdR7VdSKT93Z7f13E11RyuraffaRqtzrcAjvrCOFlitYv3N3bmRv3nlygHepLFiGwAOecUWFt4lsJ9QlOsnVtEuVSayWcgT2kZ5bLbcucHj6DpWx4kubSy8OapdamJmsIbdjKsJxI46BEP94kgD3NefaTqnjePUFsYblTfuitb6I0DTvp0UrAI95cMMrsBzgZJ9MVpHmqRsrad/6/Hz1N4XauzvvDGsLqOiwy3U9sWad7aGXzADcAH5WI7MR2/HvU/wDbeltcXNvaXiX13aY863sVM8kZzgKQowD16kdKwvD3giPTvt/9v36axHdsZ5rRYBFbGcn5pMA5fACqobptz1rrrWKO0iMVnFFbRvyRCgTJ9Tjr1rOpyJvl1/Bfj/kiJNX0OXuLXWfEt9dWusxX2gaHbIo8q2nAk1Fyxy3mL92PaPudckGquu+HdN8P6ddajp2nae2lxtGzWN1KyJuLgFY5GJCZJB29CRXZKPmGDnPUdea4j4hajL4d12xu/Lg1O/a3K6foksUhlaUPzLGBlTlcg7hkYyD1FaUpSnJRjp5K+v8AXdvQcJO50ujagjtFbWWjx2dgxfDpE0aqy42jayKCTk9PSs2/8XtDr/2C20W+1G0VUa41OCZPKhUnBcjOSqnIJ45VuOOZ5P8AhLtcmguLme38MwKu8WkRF7cu/be7DYq+qrk+9cUPAHinw742OqeDdYtH0y8nMt5a3vybv4iGAGGBYuFAHy5rNckXd2b7Xf57foaQhCd1J2PVSCyBC5KZ3AEkj9ahuporW1luLuaOC2hUyySOcKiKMkk+mKlt5vtNulwYHtmYZaGRldoz/dJUkEj2NZutalo0CPY61cW4WdAr21xHvEiEgcjBG3JAyeKiKbdkv1Oe2pesmjv7WHUNPnjuLCeLdHLEQyPz94MPyxUm3BJ7+tYuleFNE0vUpbyw0p9PmGAkCTMsSHu6xZ2rnntzW4FOT64yKTSvoD8iK5iS5WOOeOKaOJt6LKiuqtzyAQcGsqHw9otuhS1smsVZi+NPuHtgGPVtqHbuOOuO1bRQnJAGfUCoXXt396abSsmLmdzFutDma1aOy8Sa9DdGRX8+5uFuVwOqNGQAQRn371m2F9r2sx6jZwQ2+nX9tcvA80rhmjhDYEqwgE7mXlcnaM55xXVMpHse9YnifRmvdPu59KhVPEBVfstykxt2DgjBLjrgZ4IPpWkZJ+7L+vy09fuKUr7l2ytUsYfsyXF3cLlnD3kpllIJ7seuOgqVgQMZBPqap6HrcOvae91HbS2U8U721xazgB4ZkxuU4JBHIOQf4hV11YE4GAKTTT97ch3T1IHAxwQOnX9ajZBkOQcjpk1PJhRyMfhTHUnAFBOpEfY89eKZJkthfxqXB4GfxNRsuScN8tMZAqOu4O4JySCBjHoP/r0sRRZFMn3R+n+TTpFO0gEAscDjNR9znnv04p9AONGg6zqug2+m+IdStlswzG4gis0LSEMSu0kkDsdwGTntV9ok0K709bC2vptKmVoLiDzGmW0bAKTIDkheoZRx0IrecEAYb61Dgqcg4weCK3dRvfZ9Nt/60Bzb0Zl3Wv6JZTW8F9q1razXH+qWbcm7HqSMDqOpFXTtkyYZEkx1Mbhh+lTTxx3MEttdQQz20gKvHKiurAjBHP8AOuMtvAkOmJKPD+o3WmSSMoUxRo5AHBBJ5ORjkYORnmsUoPd2f3/ktPxKSTWp0U2dmB9MkUVlTapJBqK2GqwS2lwJVhjl8siG5ZlJXDeuB931opP3bXIcGdBr2nS6xot3pscvkrcFEllDbSsO4GTaegbbkDPGansL1bvR4dQMDW1sUZgJCcpGvRjxnoKqeIdOi1HS5BdzGOzgDSTo4JhdCpB8wDBKrnd1HSvMpTq9hrS+F/tK3cWryymCeS9beU2LjaDgKmBlVyc1nSpqrBpS21+XX9H5HbCHNoepJq1hLBJcwxajLaJgC4is3cSHGW2KMsQOASQOTVma/wBMt9KOrT3cY0opuWcHHmdgoBGck8AY61yzeK9Q8OaBqlmvh5YtW0qWK1s7e3JaK43sArk4HfljnkkdK6LSfCVhpl/qdw8dtL9ukEksQhYIsgOSRuYkZYbsZ6jIpSgofHddtndafdo732IaW/QzfC+sa3rCSQy2uk6bqMTMZdOvVlW5SIEbZDg4CncOo5xx1wOntrKSK6e4uJvNnZfLXy12RxocZULk55Gckk0lzpsE+p2upZlhvoPkM8TYM0XP7qTj5kyc47Eda0ByBgj0yKidRP4VYl2I/J2sc5pktubmGe3inEErxMiyFd3lllIDEd8dcVZIIccZXHr1qQEMAAM8c+1Z8z6EpHF+CdG0648NyaJrGj2U9/pji0vibddkrH5gwfALgrhjn2rs4LSO1to7a0hiht4V2wxRKFRVH8IA4AqdFJUKO54461VutU02zuGt7zUbOC4ABMUkoDDnHIGTnPbrVTqSqNv5lN8zuYNqt1od7rVzfWWp3EVzcM8C6bH9oSVSMqzr95HHKnqvcVtXl9aWFq9zqC3ltAg3SObV3EY7l9gOAPXpTn1S0Nm91am6viFzHHa27s0pIyAoIHX1PFRS3GtXi3Frb6XJpizxBBdz3SB03KQxVQDhlzxnvVXc3eSt31t+f/BB66s0URXijljkV4pFDxuDkOpGQwPcEc5p6QZ6ZI9u1ctpd7rujTppV14bX+wrHZHHf2y7/MtwgGAgORIGyxzxgniujn1nT7eK5u7k3dvp9tEJZL24t2jgAJxjJ5JHGeO9DhJPTX01/Lr5EuNthuqRXLaRqkOmzImoS2rx24kGV8wg7c/X34z9K57StcuJdHt00nQdX1W8jkEF3L+6to0lX5ZAWdzllxztyD69cal7dw31zptvpWpbheymOWSylQsyhcgBiCAuGJyOfTvUOk+IfBOlQ22iaZrOlW0dvIbeO1SYnDljkZPVi27nuc81aTUb8rb36/jb00+Y0/d5TH13Q9b8d+HNY0vVbR/DcBuo2syJllluI0Of3u0kLk4PHTjrjJ5+HSvGHhC8GpXl9arocaxWmoTSOrlot3Excnf8nA5JPPAr0qHUb651C6ji8P3qW8Z2RXU8saJP1yQMkgAisnUrLxPqVtdm603SktrRvtFpZG4859QlQZjEjEAIgYAkYycAZHfSnUktJcvL2uuvbXf128jSM38Oxzlz43vxfrdf6Ha6QhWRIxbm6lu4mICszI37oMTwCAScDk8V6FFPCNGS/vkawiSH7RcC7IU2wxk+Yegx39K8XdLvw/8AEFb+48OPLqomEslwbKSKGYsMy3OASDtwSAWAXGRya3PAM/iHx741vtS1pluPCNm8iIJIwbW7+YeWI0z/AMCLNu7DArSeH5o8+iilf/JebfmVUjDSx3ttf2+t3b2+iXtvPYJEDc3ltIsmxyeIhjoxXn2Hoay7/wAO+G28YafENQntPEJsmjiTzHndoCT8x35weuCCCRnriu0hs4LSMx2dvBbRlywjgjWNcnqQFHX1NOaCKWVZWgieVQVWUqN4U9QG6jqeK5FVs/dbS/rcwUknoc14La/ufDvmXtzDeATyLZ3KKE+0WwICOyjO1vvDHsM4JIGnfStZWV7dNb3NwLaMyCOLDyS4GSEFasMMcESwW8UcUMa4jjjXaqD0GOlVNV0+PUtPntZTLGsylPMgfZJGD1KsPunipdROV3tcltNjbdTLbQSGGWHzEEhimTa65GcMOxFcJ4h8G61rUHi5TLbTR3t1EdNs7tiqpGiBXPmL8y7s5xyPl6c132mWv2DT7ayV5Jo7eJYxJPJvkYAdWbuferSg5Y9yOB6U4V5U3eH9a3/Qalyu6PKPA+valaXQ07VIr+3uYYvKj0O5ZJpXjjUfvbacAGRsA5RzzngjFeiaVfadq1vHPpV9BcxSZKAMAxx94FPvAg5yCMjvXmHiGxtV+Pds1zcxlL1rKVVjOHjlXgKT6Pszx1Ga9I8VeEdM120vNtnZWerShni1SKIR3EM38MgdcNkHHfnvW1dx92T05lfb+r+u/rc3nCGnmjRaDByABUTRHHPI+lVPC2pjVtOhtp/O/tuxhjj1GCVCsqSYwW6AMGIJ3LkGtWMN3BHzYxjP51zycou0tznlGzKbW5PBxnvRHCGlRQDyQOPrVwjIwQcdh1qvcw/aILi1V2iaaJ4944KFgRuBHOQTng5qeZiVrnJeB53vl8QvJZrC39rTkzom0XGMKCB2KhAp9SCeua6I2+4Agc9evYdTXn2n+II7LxlpukeH/CVrc30cJs9Xks7hlOnKshGdjDAU7i+7OWyecjnvb2xt7bWoteu70w29hZzQsJSPKRXKkyA9QTtwc5z8uMY53qXjK/R7f0n16G1SCctdBGhypIHIHUnGaqalJHY2L3M0kEQXBzPIET6bjgetSya/oiXcdpNqtvBdyP5ccM4eKRn/ALoDAc9KyL2HTfEmv28d1Z3d9pQs3EfnW0kdrJIxG7fuxlgv3fqelJcyack0vQiNO++yKcPi7w08jJc69pkUqjJjWXeffBXIbp0BzTY/F/hKeRI4PEmls8pAQGXbuz06gfrW/Z+HtDs7QW9jothb26j/AFcUZUEA555559c1Dq2haPqWly6de6XYvaSIV2CIKAPYrgg+lX7Sjf7X4f18r/MbUBtnNaX8ckmnXVtdIjbXNvKsgVvQ4PH40eRuzkcg88/p/KuKufBF/wCGYLb/AIV0kMU8t27Xkl3J+9MTrtVA3AManDYIzkA885v+BvFjanqup+HtUe3j1jT2IAQEPcbTh3PYsPlz6gg84omra03dfj9xfsbwc4vY6KSA8DbgGoGgKjNaDR7d3LMXfd8xzgkAYHt7Vzmqale3WtQ6PoBjSVNz6hfTws0dooxtRQcBpGPoTilFylojBRuVvFOq3ejw2JsdLn1GW7laNYogdyqBlnwBkgf1FU411/UbmRryK10rSg5RbbJa7lTszMDhD04GevtWvbaQLbV7zUmvLi4vbgkFpW+WJCMFI1H3VOASOeQKmlyM7RkY79atSSSste+v9ad7DbSVkYcmj2IuUuDHJJLAS0JmmaQQsRgsoJ4J9fyxRWhKcBjzx1zRTbct3czuz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11466=[""].join("\n");
var outline_f11_12_11466=null;
var title_f11_12_11467="Chest pain in ER";
var content_f11_12_11467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abbreviated list of causes of chest pain in patients presenting to the emergency department",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardiac",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myocardial ischemia or infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aortic dissection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericarditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary embolus and other causes of pulmonary hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chest wall trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myocardial or pericardial contusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Traumatic valve injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aortic injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Noncardiac chest pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastrointestinal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Musculoskeletal",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11467=[""].join("\n");
var outline_f11_12_11467=null;
var title_f11_12_11468="Arsenic chelating agents";
var content_f11_12_11468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adverse effects of chelating agents used for arsenic poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chelating agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        BAL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endpoint: 24-hour urinary arsenic &lt;50 &micro;g/L or until another agent is substituted",
"       </td>",
"       <td>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Febrile reaction, diaphoresis",
"        </p>",
"        <p>",
"         Nausea, vomiting, salivation",
"        </p>",
"        <p>",
"         Lacrimation, rhinorrhea",
"        </p>",
"        <p>",
"         Headache",
"        </p>",
"        <p>",
"         Painful injection, injection site sterile abscess",
"        </p>",
"        <p>",
"         Hemolysis in G6PD-deficient patients",
"        </p>",
"        <p>",
"         Chelation of essential metals (prolonged course)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Succimer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endpoint: 24-hour urinary arsenic &lt;50 &micro;g/L",
"       </td>",
"       <td>",
"        <p>",
"         Nausea, vomiting, diarrhea",
"        </p>",
"        <p>",
"         Abdominal gas, pain",
"        </p>",
"        <p>",
"         Transient elevations in hepatic amino transferases, and alkaline phosphatase",
"        </p>",
"        <p>",
"         Rash, pruritus",
"        </p>",
"        <p>",
"         Sore throat, rhinorrhea",
"        </p>",
"        <p>",
"         Drowsiness, paresthesias",
"        </p>",
"        <p>",
"         Thrombocytosis, eosinophilia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        DMPS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endpoint: 24 hour urinary arsenic&lt;50 &micro;g/L",
"       </td>",
"       <td>",
"        <p>",
"         Allergic reactions",
"        </p>",
"        <p>",
"         Increased copper and zinc excretion",
"        </p>",
"        <p>",
"         Nausea",
"        </p>",
"        <p>",
"         Pruritus",
"        </p>",
"        <p>",
"         Vertigo",
"        </p>",
"        <p>",
"         Weakness",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Ford MD. Arsenic. In: Goldfrank's Toxicological Emergencies, Goldfrank L, Flomenbaum N, Howland MA, Hoffman R, Nelson L (Eds), Mcgraw-Hill, New York 2002. p.1183. Copyright &copy; 2002 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11468=[""].join("\n");
var outline_f11_12_11468=null;
var title_f11_12_11469="Education at initial visit";
var content_f11_12_11469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for initial visit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Concerns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What worries you most about your asthma?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you want to accomplish at this visit?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you want to be able to do that you can't do now because of your asthma?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What do you expect from treatment?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What medications have you tried?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"What other questions do you have for me today?\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            What is asthma?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            A chronic lung disease. The airways are very sensitive. They become inflamed and narrow; breathing becomes difficult.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Asthma treatments: two types of medicines are needed:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Long-term control: medications that prevent symptoms, often by reducing inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Quick relief: short-acting bronchodilator relaxes muscles around airways",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bring all medications to every appointment.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\" rowspan=\"2\">",
"            When to seek medical advice. Provide appropriate telephone number.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler and spacer/holding chamber use. Check performance.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Self-monitoring skills that are tied to an action plan:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Recognize intensity and frequency of asthma symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Review the signs of deterioration and the need to reevaluate therapy:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Waking at night with asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Increased medication use",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Decreased activity tolerance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of a simple, written self-management plan",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11469=[""].join("\n");
var outline_f11_12_11469=null;
var title_f11_12_11470="AP view comminuted midshaft femur fracture";
var content_f11_12_11470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AP view of a comminuted midshaft femur fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior (AP) radiograph shows a comminuted, angulated midshaft femur fracture prior to operative repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Mezzanotte, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_12_11470=[""].join("\n");
var outline_f11_12_11470=null;
var title_f11_12_11471="Contents: Behavior and development";
var content_f11_12_11471=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Behavior and development",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Behavior and development",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Attention deficit hyperactivity disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/18/26922\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4954\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32730\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23082\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14650\">",
"           Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Autism spectrum disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/20/15689\">",
"           Asperger disorder: Clinical features and diagnosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41801\">",
"           Asperger disorder: Management and prognosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4122\">",
"           Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16234\">",
"           Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/872\">",
"           Autism spectrum disorders in children and adolescents: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35562\">",
"           Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/41/664\">",
"           Clinical features of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38969\">",
"           Diagnosis of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/1/14361\">",
"           Screening tools for autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/17/35097\">",
"           Surveillance and screening for autism spectrum disorders in primary care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4698\">",
"           Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebral palsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colic",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10680\">",
"           Clinical features and etiology of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15177\">",
"           Evaluation and management of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1140\">",
"           Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing; speech; and language",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30114\">",
"           Case illustrating the evaluation of speech and language impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10599\">",
"           Emergent literacy including language development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19050\">",
"           Etiology of hearing impairment in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21399\">",
"           Etiology of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26343\">",
"           Evaluation and treatment of speech and language disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5098\">",
"           Overview of expressive language delay (���������late talking���������) in young children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intellectual disability (mental retardation)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/4/34889\">",
"           Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17896\">",
"           Management of children and adolescents with fragile X syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Learning disabilities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/21/1370\">",
"           Clinical features and evaluation of reading difficulty in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37480\">",
"           Definitions of specific learning disability and laws pertaining to learning disabilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17592\">",
"           Interventions for children with reading difficulty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/16/6409\">",
"           Normal reading development and etiology of reading difficulty in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/57/32665\">",
"           Specific learning disabilities in children: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37306\">",
"           Specific learning disabilities in children: Educational management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35944\">",
"           Specific learning disabilities in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44329\">",
"           Specific learning disabilities in children: Role of the primary care provider",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31097\">",
"           Childhood exposure to intimate partner violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16602\">",
"           Comprehensive health care for children in foster care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15607\">",
"           Developmental and behavioral implications for children of incarcerated parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43255\">",
"           Developmental and behavioral implications for military children with deployed parents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/51/27448\">",
"           Epidemiology of foster care placement and overview of the foster care system in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39607\">",
"           Homesickness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/28/13770\">",
"           Overview of developmental coordination disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/5/30808\">",
"           Overview of fears and specific phobias in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11209\">",
"           Promoting safety in children with disabilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/45/37592\">",
"           Toilet training",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         School issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17944\">",
"           The gifted child: Characteristics and identification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33240\">",
"           The gifted child: Educational interventions and primary care management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         School problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38185\">",
"           School readiness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28473\">",
"           Sleepwalking and other parasomnias in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surveillance and screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/29/19928\">",
"           Developmental and behavioral screening tests in primary care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26394\">",
"           Developmental-behavioral surveillance and screening in primary care",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-297FD29A10-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_12_11471=[""].join("\n");
var outline_f11_12_11471=null;
